Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer

CA3119467CActive Publication Date: 2026-10-06CORNELL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CA3119467
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-11-20
Filing Date
2019-11-20
Publication Date
2026-10-06
Estimated Expiration
2039-11-20
Patent Text Reader

Abstract

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen ("PSMA") where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein <semantics>MI<annotation encoding="application / x-tex">M^{I}< / annotation>< / semantics> is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

<DP=1>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY ²OF CANCER²CROSS-REFERENCE TO RELATED APPLICATIONS²

[0001] This application claims the benefit of and priority to U.S. Provisional ²Appl. No. ²62 / 769,989 filed on November 20, 2018, U.S. Provisional Appl. No. 62 / 788,700 ²filed on ²January, 4, 2019, and U.S. Provisional Appl. No. 62 / 792,835 filed on January ²15, 2019, each of ²which is incorporated herein by reference in its entirety for any and all ²purposes.²U.S. GOVERNMENT RIGHTS²

[0002] This invention was made with government support under UL1TR00457 ²awarded by the ²National Institutes of Health. The government has certain rights in the ²invention.²FIELD²

[0003] The present technology generally relates to macrocyclic complexes of ²alpha-emitting ²radionuclides, as well as compositions including such compounds and methods of ²use.²SUMMARY²

[0004] In an aspect, a compound of Formula I is provided:²Z3²) \²(0²oN²N ______________________________ 0²C\I!²¨ ____________ 0 \-- / ¨ OH²Z1²w5 a Z2²(I)²or a pharmaceutically acceptable salt thereof, wherein²Z1 is H or ¨X1¨W2²Z2 is OH or NH¨W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl,²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where 14) is 1, 2, 3, 4, ²5,²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9,²1²<DP=2>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²0C(0)R], -C(0)OR', -C(S)OR', -S(0)R', -SO2R], -S02(OR'), -SO2NR'2, - ²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-²NH2, -N=C=N-R', -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),-R' ²where iv is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where ²xis ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)1U, -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -1\11U-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, Cs-Cs cycloalkenyl, C2-C6 alkynyl, Cs-Cio cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²

[0005] In a related aspect, a compound of Formula IA is provided²Z3²\²co,²N---M1---N²\N 6-- / ----1\1)-e² ___________ 0 - OH²Z²w5 1²a Z2²(IA)²or a pharmaceutically acceptable salt thereof, wherein²NV is an alpha-emitting radionuclide;²Z1 is H or -V-W2²Z2 is OH or NH-W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²2²<DP=3>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl, ²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where 14) is 1, 2, 3, 4, ²5, ²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²OC(0)R', -C(0)0R% -C(S)OR', -S(0)R', -SO2R% -S02(OR'), -SO2NR'2, - ²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-²NH2, -N=C=N-R% -S02C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' ²where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where ²xis ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R% -C(0)0R% -C(S)OR', -S(0)R% -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, Cs-Cs cycloalkenyl, C2-C6 alkynyl, Cs-Cio cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²100061 In a further related aspect aspect, the present technology provides a ²compound useful in ²targeted radiotherapy of cancer and / or mammalian tissue overexpressing ²prostate specific ²membrane antigen ("PSMA") (a "targeting compound") where the compound is of ²Formula II²z3²co,²N ---M1---N²,² e , ,²___________ o - OH²Z1²a' Z2²L5²R26²(II)²or a pharmaceutically acceptable salt thereof, wherein²3²<DP=4>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²MI is an alpha-emitting radionuclide;²Z' is H or ¨L3¨R22²Z2 is OH or NH¨L4¨R24²Z3 is H or ¨L6¨R28;²a is 0 or 1;²X1 is 0, NH, or S;²L3, L4, L5, and L6 are independently at each occurence a bond or a linker ²group, and²R22, R24, K26,²and R28 each independently comprises an antibody, antibody fragment ²(e.g., an antigen-binding fragment), a binding moiety, a binding peptide, a ²binding polypeptide (such as a selective targeting oligopeptide containing up ²to ²50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety ²(such as an oligonucleotide, DNA or RNA vector, or aptamer), or a lectin.²

[0007] In a further related aspect, a modified antibody, modified antibody ²fragment, or ²modified binding peptide comprising a linkage arising from conjugation of a ²compound of ²Formula I or pharmaceutically acceptable salt thereof, with an antibody, ²antibody fragment, or ²binding peptide In a related aspect, a modified antibody, modified antibody ²fragment, or ²modified binding peptide is provided that includes a linkage arising from ²conjugation of a ²compound of Formula IA or a pharmaceutically acceptable salt thereof, with an ²antibody, ²antibody fragment, or binding peptide.²

[0008] In any embodiment and / or aspect disclosed herein (for simplicity's ²sake, hereinafter ²recited as "in any embodiment disclosed herein" or the like), it may be that ²the antibody includes ²belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, ²Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, ²Brentuximab ²vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, ²Dinutuximab, ²Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, ²Nivolumab, ²Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab ²pendetide, ²Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, Tositumomab, ²²Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, ²Catumaxomab, or Etaracizumab. In any embodiment disclosed herein, it may be ²that the ²antibody fragment includes an antigen-binding fragment of belimumab, ²Mogamulizumab, ²Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, ²Inotuzumab ²ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, ²Ipilimumab, ²Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab,²4²<DP=5>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, ²Olaratumab, ²Atezolizumab, Avelumab, Durvalumab, Capromab pendetide, Elotuzumab, Denosumab, ²Ziv-²aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, ²Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, Catumaxomab, or ²Etaracizumab. ²In any embodiment disclosed herein, it may be that the binding peptide ²includes a prostate ²specific membrane antigen ("PSMA") binding peptide, a somatostatin receptor ²agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²thereof²

[0009] In another aspect, the present technology also provides compositions ²(e.g., ²pharmaceutical compositions) and medicaments comprising any of one of the ²embodiments of ²the compounds of Formulas I, IA, or II (or a pharmaceutically acceptable salt ²thereof) disclosed ²herein and a pharmaceutically acceptable carrier or one or more excipients or ²fillers. In a similar ²aspect, the present technology also provides compositions (e.g., ²pharmaceutical compositions) ²and medicaments comprising any of one of the embodiments of the modified ²antibody, modified ²antibody fragment, or modified binding peptide of the present technology ²disclosed herein and a ²pharmaceutically acceptable carrier or one or more excipients or fillers.²

[0010] In an aspect, a method of treating a subject is provided, wherein the ²method includes ²administering a targeting compound of the present technology to the subject or ²administering a ²modified antibody, modified antibody fragment, or modified binding peptide of ²the present ²technology to the subject. In any embodiment disclosed herein, it may be that ²the subject suffers ²from cancer and / or mammalian tissue overexpressing prostate specific membrane ²antigen ²("PSMA").²

[0011] In an aspect, a compound is provided that includes a first domain ²having a blood-²protein binding moiety with low specific affinity for the blood-protein, a ²second domain having ²a tumor targeting moiety with high affinity for a tumor antigen, and a third ²domain having a ²chelator.²BRIEF DESCRIPTION OF THE DRAWINGS²

[0012] FIGs. 1A and 1B shows x-ray crystal structures of ²[La(Hmacropa)(H20)]=(C104)2 (FIG. ²1A, side view; FIG. 2B, top view). FIGs. IC and 11) shows x-ray crystal ²structures of ²[Lu(macropa)]=C104.DMF (FIG. IC, side view; FIG. ID, top view). Ellipsoids are ²drawn at the ²50% probability level. Counteranions and hydrogen atoms attached to carbons ²are omitted for ²clarity.²<DP=6>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²100131 FIGs. 2A-C shows the biodistribution of 225Ac(NO3)3 (FIG. 2A), ²[225Ac(macropa)]+ ²(FIG. 2B), and [225Ac(DOTA)]- (FIG. 2C) for select organs following ²intravenous injection in ²mice. Adult C57BL / 6 mice were sacrificed 15 min, 1 h, or 5 h post injection. ²Values for each ²time point are given as mean % ID / g 1 SD.²

[0014] FIG. 3 provides a schematic overview of the synthesis of Macropa-²(OCH2CH2)-Ph-²NCS (an embodiment of the present technology).²DETAILED DESCRIPTION²

[0015] The following terms are used throughout as defined below.²

[0016] As used herein and in the appended claims, singular articles such as ²"a" and "an" and ²"the" and similar referents in the context of describing the elements ²(especially in the context of ²the following claims) are to be construed to cover both the singular and the ²plural, unless ²otherwise indicated herein or clearly contradicted by context. Recitation of ²ranges of values ²herein are merely intended to serve as a shorthand method of referring ²individually to each ²separate value falling within the range, unless otherwise indicated herein, ²and each separate ²value is incorporated into the specification as if it were individually ²recited herein. All methods ²described herein can be performed in any suitable order unless otherwise ²indicated herein or ²otherwise clearly contradicted by context. The use of any and all examples, or ²exemplary ²language (e.g., "such as") provided herein, is intended merely to better ²illuminate the ²embodiments and does not pose a limitation on the scope of the claims unless ²otherwise stated. ²No language in the specification should be construed as indicating any non-²claimed element as ²essential.²

[0017] As used herein, "about" will be understood by persons of ordinary skill ²in the art and ²will vary to some extent depending upon the context in which it is used. If ²there are uses of the ²term which are not clear to persons of ordinary skill in the art, given the ²context in which it is ²used, "about" will mean up to plus or minus 10% of the particular term ¨ for ²example, "about 10 ²wt.%" would be understood to mean "9 wt.% to 11 wt.%." It is to be understood ²that when ²"about" precedes a term, the term is to be construed as disclosing "about" the ²term as well as the ²term without modification by "about" ¨ for example, "about 10 wt.%" discloses ²"9 wt.% to 11 ²wt.%" as well as disclosing "10 wt.%."²

[0018] Generally, reference to a certain element such as hydrogen or H is ²meant to include all ²isotopes of that element. For example, if an R group is defined to include ²hydrogen or H, it also ²includes deuterium and tritium. Compounds comprising radioisotopes such as ²tritium, C", P32²6²<DP=7>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²and S35 are thus within the scope of the present technology. Procedures for ²inserting such labels ²into the compounds of the present technology will be readily apparent to those ²skilled in the art ²based on the disclosure herein.²

[0019] In general, "substituted" refers to an organic group as defined below ²(e.g., an alkyl ²group) in which one or more bonds to a hydrogen atom contained therein are ²replaced by a bond ²to non-hydrogen or non-carbon atoms. Substituted groups also include groups in ²which one or ²more bonds to a carbon(s) or hydrogen(s) atom are replaced by one or more ²bonds, including ²double or triple bonds, to a heteroatom. Thus, a substituted group is ²substituted with one or ²more substituents, unless otherwise specified. In some embodiments, a ²substituted group is ²substituted with 1, 2, 3, 4, 5, or 6 substituents. Examples of substituent ²groups include: halogens ²(i.e., F, Cl, Br, and I); hydroxyls; alkoxy, alkenoxy, aryloxy, aralkyloxy, ²heterocyclyl, ²heterocyclylalkyl, heterocyclyloxy, and heterocyclylalkoxy groups; carbonyls ²(oxo); ²carboxylates; esters; urethanes; oximes; hydroxylamines; alkoxyamines; ²aralkoxyamines; thiols; ²sulfides; sulfoxides; sulfones; sulfonyls; pentafluorosulfanyl (i.e., SF5), ²sulfonamides; amines; ²N-oxides; hydrazines; hydrazides; hydrazones; azides; amides; ureas; amidines; ²guanidines; ²enamines; imides; isocyanates; isothiocyanates; cyanates; thiocyanates; ²imines; nitro groups; ²nitriles (i.e., CN); and the like.²

[0020] Substituted ring groups such as substituted cycloalkyl, aryl, ²heterocyclyl and heteroaryl ²groups also include rings and ring systems in which a bond to a hydrogen atom ²is replaced with ²a bond to a carbon atom. Therefore, substituted cycloalkyl, aryl, heterocyclyl ²and heteroaryl ²groups may also be substituted with substituted or unsubstituted alkyl, ²alkenyl, and alkynyl ²groups as defined below.²

[0021] As used herein, Cm-Cn, such as Ci-C12, CI-Cs, or C1-C6 when used before ²a group ²refers to that group containing m to n carbon atoms.²

[0022] Alkyl groups include straight chain and branched chain alkyl groups ²having from 1 to ²12 carbon atoms, and typically from 1 to 10 carbons or, in some embodiments, ²from 1 to 8, 1 to ²6, or 1 to 4 carbon atoms. Examples of straight chain alkyl groups include ²groups such as ²methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl ²groups. Examples of ²branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, ²sec-butyl, tert-butyl, ²neopentyl, isopentyl, and 2,2-dimethylpropyl groups. Alkyl groups may be ²substituted or ²unsubstituted. Representative substituted alkyl groups may be substituted one ²or more times ²with substituents such as those listed above, and include without limitation ²haloalkyl (e.g.,²7²<DP=8>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²trifluoromethyl), hydroxyalkyl, thioalkyl, aminoalkyl, alkylaminoalkyl, ²dialkylaminoalkyl, ²alkoxyalkyl, carboxyalkyl, and the like.²

[0023] Cycloalkyl groups include mono-, hi- or tricyclic alkyl groups having ²from 3 to 12 ²carbon atoms in the ring(s), or, in some embodiments, 3 to 10, 3 to 8, or 3 to ²4, 5, or 6 carbon ²atoms. Exemplary monocyclic cycloalkyl groups include, but not limited to, ²cyclopropyl, ²cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In ²some embodiments, ²the cycloalkyl group has 3 to 8 ring members, whereas in other embodiments the ²number of ring ²carbon atoms range from 3 to 5, 3 to 6, or 3 to 7. Bi- and tricyclic ring ²systems include both ²bridged cycloalkyl groups and fused rings, such as, but not limited to, ²bicyclo[2.1.1]hexane, ²adamantyl, decalinyl, and the like. Cycloalkyl groups may be substituted or ²unsubstituted. ²Substituted cycloalkyl groups may be substituted one or more times with, non-²hydrogen and ²non-carbon groups as defined above. However, substituted cycloalkyl groups ²also include rings ²that are substituted with straight or branched chain alkyl groups as defined ²above. ²Representative substituted cycloalkyl groups may be mono-substituted or ²substituted more than ²once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted ²cyclohexyl groups, ²which may be substituted with substituents such as those listed above.²

[0024] Cycloalkylalkyl groups are alkyl groups as defined above in which a ²hydrogen or ²carbon bond of an alkyl group is replaced with a bond to a cycloalkyl group as ²defined above. ²In some embodiments, cycloalkylalkyl groups have from 4 to 16 carbon atoms, 4 ²to 12 carbon ²atoms, and typically 4 to 10 carbon atoms. Cycloalkylalkyl groups may be ²substituted or ²unsubstituted. Substituted cycloalkylalkyl groups may be substituted at the ²alkyl, the cycloalkyl ²or both the alkyl and cycloalkyl portions of the group. Representative ²substituted ²cycloalkylalkyl groups may be mono-substituted or substituted more than once, ²such as, but not ²limited to, mono-, di- or tri-substituted with substituents such as those ²listed above.²

[0025] Alkenyl groups include straight and branched chain alkyl groups as ²defined above, ²except that at least one double bond exists between two carbon atoms. Alkenyl ²groups have ²from 2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some ²embodiments, from 2 ²to 8, 2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkenyl group ²has one, two, or ²three carbon-carbon double bonds. Examples include, but are not limited to ²vinyl,²allyl, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, ²²among others. Alkenyl groups may be substituted or unsubstituted. ²Representative substituted ²alkenyl groups may be mono-substituted or substituted more than once, such as, ²but not limited ²to, mono-, di- or tri-substituted with substituents such as those listed ²above.²8²<DP=9>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0026] Cycloalkenyl groups include cycloalkyl groups as defined above, having ²at least one ²double bond between two carbon atoms. Cycloalkenyl groups may be substituted ²or ²unsubstituted. In some embodiments the cycloalkenyl group may have one, two or ²three double ²bonds but does not include aromatic compounds. Cycloalkenyl groups have from 4 ²to 14 carbon ²atoms, or, in some embodiments, 5 to 14 carbon atoms, 5 to 10 carbon atoms, or ²even 5, 6, 7, or ²8 carbon atoms. Examples of cycloalkenyl groups include cyclohexenyl, ²cyclopentenyl, ²cyclohexadienyl, cyclobutadienyl, and cyclopentadienyl.²

[0027] Cycloalkenylalkyl groups are alkyl groups as defined above in which a ²hydrogen or ²carbon bond of the alkyl group is replaced with a bond to a cycloalkenyl group ²as defined above. ²Cycloalkenylalkyl groups may be substituted or unsubstituted. Substituted ²cycloalkenylalkyl ²groups may be substituted at the alkyl, the cycloalkenyl or both the alkyl and ²cycloalkenyl ²portions of the group. Representative substituted cycloalkenylalkyl groups may ²be substituted ²one or more times with substituents such as those listed above.²

[0028] Alkynyl groups include straight and branched chain alkyl groups as ²defined above, ²except that at least one triple bond exists between two carbon atoms. Alkynyl ²groups have from ²2 to 12 carbon atoms, and typically from 2 to 10 carbons or, in some ²embodiments, from 2 to 8, ²2 to 6, or 2 to 4 carbon atoms. In some embodiments, the alkynyl group has ²one, two, or three ²carbon-carbon triple bonds. Examples include, but are not limited to ¨²CCH, -CCCH3, -CH2CCCH3, -CCCH2CH(CH2CH3)2, among others. Alkynyl groups may ²be substituted or unsubstituted. Representative substituted alkynyl groups may ²be ²mono-substituted or substituted more than once, such as, but not limited to, ²mono-, di- or tri-²substituted with substituents such as those listed above.²

[0029] Aryl groups are cyclic aromatic hydrocarbons that do not contain ²heteroatoms. Aryl ²groups herein include monocyclic, bicyclic and tricyclic ring systems. Thus, ²aryl groups ²include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, ²fluorenyl, phenanthrenyl, ²anthracenyl, indenyl, indanyl, pentalenyl, and naphthyl groups. In some ²embodiments, aryl ²groups contain 6-14 carbons, and in others from 6 to 12 or even 6-10 carbon ²atoms in the ring ²portions of the groups. In some embodiments, the aryl groups are phenyl or ²naphthyl. Aryl ²groups may be substituted or unsubstituted. The phrase "aryl groups" includes ²groups ²containing fused rings, such as fused aromatic-aliphatic ring systems (e.g., ²indanyl, ²tetrahydronaphthyl, and the like). Representative substituted aryl groups may ²be mono-²substituted or substituted more than once. For example, monosubstituted aryl ²groups include,²9²<DP=10>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²but are not limited to, 2-, 3-, 4-, 5-, or 6-substituted phenyl or naphthyl ²groups, which may be ²substituted with substituents such as those listed above.²

[0030] Aralkyl groups are alkyl groups as defined above in which a hydrogen or ²carbon bond ²of an alkyl group is replaced with a bond to an aryl group as defined above. ²In some ²embodiments, aralkyl groups contain 7 to 16 carbon atoms, 7 to 14 carbon ²atoms, or 7 to 10 ²carbon atoms. Aralkyl groups may be substituted or unsubstituted. Substituted ²aralkyl groups ²may be substituted at the alkyl, the aryl or both the alkyl and aryl portions ²of the group. ²Representative aralkyl groups include but are not limited to benzyl and ²phenethyl groups and ²fused (cycloalkylaryl)alkyl groups such as 4-indanylethyl. Representative ²substituted aralkyl ²groups may be substituted one or more times with substituents such as those ²listed above.²

[0031] Heterocyclyl groups include aromatic (also referred to as heteroaryl) ²and non-aromatic ²ring compounds containing 3 or more ring members, of which one or more is a ²heteroatom such ²as, but not limited to, N, 0, and S. In some embodiments, the heterocyclyl ²group contains 1, 2, ²3 or 4 heteroatoms. In some embodiments, heterocyclyl groups include mono-, bi-² and tricyclic ²rings having 3 to 16 ring members, whereas other such groups have 3 to 6, 3 to ²10, 3 to 12, or 3 ²to 14 ring members. Heterocyclyl groups encompass aromatic, partially ²unsaturated and ²saturated ring systems, such as, for example, imidazolyl, imidazolinyl and ²imidazolidinyl ²groups. The phrase "heterocyclyl group" includes fused ring species including ²those comprising ²fused aromatic and non-aromatic groups, such as, for example, benzotriazolyl, ²2,3-²dihydrobenzo[1,4]dioxinyl, and benzo[1,3]dioxolyl. The phrase also includes ²bridged ²polycyclic ring systems containing a heteroatom such as, but not limited to, ²quinuclidyl. ²Heterocyclyl groups may be substituted or unsubstituted. Heterocyclyl groups ²include, but are ²not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, ²pyrazolidinyl, thiazolidinyl, ²tetrahydrothiophenyl, tetrahydrofuranyl, dioxolyl, furanyl, thiophenyl, ²pyrrolyl, pyrrolinyl, ²imidazolyl, imidazolinyl, pyrazolyl, pyrazolinyl, triazolyl, tetrazolyl, ²oxazolyl, isoxazolyl, ²thiazolyl, thiazolinyl, isothiazolyl, thiadiazolyl, oxadiazolyl, piperidyl, ²piperazinyl, morpholinyl, ²thiomorpholinyl, tetrahydropyranyl, tetrahydrothiopyranyl, oxathiane, dioxyl, ²dithianyl, pyranyl, ²pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, dihydropyridyl, ²dihydrodithiinyl, ²dihydrodithionyl, homopiperazinyl, quinuclidyl, indolyl, indolinyl, ²isoindolyl,azaindoly1 ²(pyrrolopyridyl), indazolyl, indolizinyl, benzotriazolyl, benzimidazolyl, ²benzofuranyl, ²benzothiophenyl, benzthiazolyl, benzoxadiazolyl, benzoxazinyl, benzodithiinyl, ²benzoxathiinyl, ²benzothiazinyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, ²benzo[1,3]dioxolyl, ²pyrazolopyridyl, imidazopyridyl (azabenzimidazolyl), triazolopyridyl, ²isoxazolopyridyl, purinyl,²<DP=11>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, quinolizinyl, ²quinoxalinyl, quinazolinyl, ²cinnolinyl, phthalazinyl, naphthyridinyl, pteridinyl, thianaphthyl, ²dihydrobenzothiazinyl, ²dihydrobenzofuranyl, dihydroindolyl, dihydrobenzodioxinyl, tetrahydroindolyl, ²tetrahydroindazolyl, tetrahydrobenzimidazolyl, tetrahydrobenzotriazolyl, ²tetrahydropyrrolopyridyl, tetrahydropyrazolopyridyl, tetrahydroimidazopyridyl, ²²tetrahydrotriazolopyridyl, and tetrahydroquinolinyl groups. Representative ²substituted ²heterocyclyl groups may be mono-substituted or substituted more than once, ²such as, but not ²limited to, pyridyl or morpholinyl groups, which are 2-, 3-, 4-, 5-, or 6-²substituted, or ²disubstituted with various substituents such as those listed above.²

[0032] Heteroaryl groups are aromatic ring compounds containing 5 or more ring ²members, of ²which, one or more is a heteroatom such as, but not limited to, N, 0, and S. ²Heteroaryl groups ²include, but are not limited to, groups such as pyrrolyl, pyrazolyl, ²triazolyl, tetrazolyl, oxazolyl, ²isoxazolyl, thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, ²thiophenyl, ²benzothiophenyl, furanyl, benzofuranyl, indolyl, azaindolyl ²(pyrrolopyridinyl), indazolyl, ²benzimidazolyl, imidazopyridinyl (azabenzimidazolyl), pyrazolopyridinyl, ²triazolopyridinyl, ²benzotriazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, ²imidazopyridinyl, ²isoxazolopyridinyl, thianaphthyl, purinyl, xanthinyl, adeninyl, guaninyl, ²quinolinyl, ²isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. ²Heteroaryl groups ²include fused ring compounds in which all rings are aromatic such as indolyl ²groups and include ²fused ring compounds in which only one of the rings is aromatic, such as 2,3-²dihydro indolyl ²groups. Heteroaryl groups may be substituted or unsubstituted. Thus, the ²phrase "heteroaryl ²groups" includes fused ring compounds as well as includes heteroaryl groups ²that have other ²groups bonded to one of the ring members, such as alkyl groups. Representative ²substituted ²heteroaryl groups may be substituted one or more times with various ²substituents such as those ²listed above.²

[0033] Heterocyclylalkyl groups are alkyl groups as defined above in which a ²hydrogen or ²carbon bond of an alkyl group is replaced with a bond to a heterocyclyl group ²as defined above. ²Heterocyclylalkyl groups may be substituted or unsubstituted. Substituted ²heterocyclylalkyl ²groups may be substituted at the alkyl, the heterocyclyl or both the alkyl and ²heterocyclyl ²portions of the group. Representative heterocyclyl alkyl groups include, but ²are not limited to, ²morpholin-4-yl-ethyl, furan-2-yl-methyl, imidazol-4-yl-methyl, pyridin-3-yl-²methyl, ²tetrahydrofuran-2-yl-ethyl, and indo1-2-yl-propyl. Representative substituted ²heterocyclylalkyl ²groups may be substituted one or more times with substituents such as those ²listed above.²11²<DP=12>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0034] Heteroaralkyl groups are alkyl groups as defined above in which a ²hydrogen or carbon ²bond of an alkyl group is replaced with a bond to a heteroaryl group as ²defined above. ²Heteroaralkyl groups may be substituted or unsubstituted. Substituted ²heteroaralkyl groups may ²be substituted at the alkyl, the heteroaryl or both the alkyl and heteroaryl ²portions of the group. ²Representative substituted heteroaralkyl groups may be substituted one or more ²times with ²substituents such as those listed above.²

[0035] Groups described herein having two or more points of attachment (i.e., ²divalent, ²trivalent, or polyvalent) within the compound of the present technology are ²designated by use of ²the suffix, "ene." For example, divalent alkyl groups are alkylene groups, ²divalent aryl groups ²are arylene groups, divalent heteroaryl groups are divalent heteroarylene ²groups, and so forth. ²Substituted groups having a single point of attachment to the compound of the ²present ²technology are not referred to using the "ene" designation. Thus, e.g., ²chloroethyl is not referred ²to herein as chloroethylene. Such groups may further be substituted or ²unsubstituted.²

[0036] Alkoxy groups are hydroxyl groups (-OH) in which the bond to the ²hydrogen atom is ²replaced by a bond to a carbon atom of a substituted or unsubstituted alkyl ²group as defined ²above. Examples of linear alkoxy groups include but are not limited to ²methoxy, ethoxy, ²propoxy, butoxy, pentoxy, hexoxy, and the like. Examples of branched alkoxy ²groups include ²but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, ²isohexoxy, and the like. ²Examples of cycloalkoxy groups include but are not limited to cyclopropyloxy, ²cyclobutyloxy, ²cyclopentyloxy, cyclohexyloxy, and the like. Alkoxy groups may be substituted ²or ²unsubstituted. Representative substituted alkoxy groups may be substituted one ²or more times ²with substituents such as those listed above.²

[0037] The terms "alkanoyl" and "alkanoyloxy" as used herein can refer, ²respectively, to ¨ ²C(0)¨alkyl and ¨0¨C(0)¨alkyl groups, where in some embodiments the alkanoyl or ²²alkanoyloxy groups each contain 2-5 carbon atoms. Similarly, the terms ²"aryloyl" and ²"aryloyloxy" respectively refer to ¨C(0)¨aryl and ¨0¨C(0)¨aryl groups²

[0038] The terms "aryloxy" and "arylalkoxy" refer to, respectively, a ²substituted or ²unsubstituted aryl group bonded to an oxygen atom and a substituted or ²unsubstituted aralkyl ²group bonded to the oxygen atom at the alkyl. Examples include but are not ²limited to phenoxy, ²naphthyloxy, and benzyloxy. Representative substituted aryloxy and arylalkoxy ²groups may be ²substituted one or more times with substituents such as those listed above.²

[0039] The term "carboxylic acid" as used herein refers to a compound with a ²¨C(0)0H ²group. The term "carboxylate" as used herein refers to a ¨C(0)0- group. A ²"protected²12²<DP=13>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²carboxylate" refers to a ¨C(0)0-G where G is a carboxylate protecting group. ²Carboxylate ²protecting groups are well known to one of ordinary skill in the art. An ²extensive list of ²protecting groups for the carboxylate group functionality may be found in ²Protective Groups in ²Organic Synthesis, Greene, T.W.; Wuts, P. G. M., John Wiley & Sons, New York, ²NY, (3rd ²Edition, 1999) which can be added or removed using the procedures set forth ²therein and which ²is hereby incorporated by reference in its entirety and for any and all ²purposes as if fully set ²forth herein²

[0040] The term "ester" as used herein refers to ¨COOR7 groups. It7 is a ²substituted or ²unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, ²heterocyclylalkyl or heterocyclyl ²group as defined herein.²

[0041] The term "amide" (or "amido") includes C- and N-amide groups, i.e., -²C(0)NR71R72, ²and ¨NR71C(0)1t72 groups, respectively. R7' and 1Z72 are independently ²hydrogen, or a ²substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, ²aralkyl, heterocyclylalkyl or ²heterocyclyl group as defined herein. Amido groups therefore include but are ²not limited to ²carbamoyl groups (-C(0)NH2) and formamide groups (-NHC(0)H). In some ²embodiments, the ²amide is ¨NR71C(0)-(C1-5 alkyl) and the group is termed "carbonylamino," and ²in others the ²amide is ¨NHC(0)-alkyl and the group is termed "alkanoylamino."²

[0042] The term "nitrile" or "cyano" as used herein refers to the ¨CN group.²

[0043] Urethane groups include N- and 0-urethane groups, i.e., -NICC(0)0R74 ²and -0C(0)NICR74 groups, respectively. R73 and R74 are independently a ²substituted or ²unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, ²heterocyclylalkyl, or heterocyclyl ²group as defined herein. R73 may also be H.²

[0044] The term "amine" (or "amino") as used herein refers to ¨NR75R76 groups, ²wherein R75 ²and R76 are independently hydrogen, or a substituted or unsubstituted alkyl, ²alkenyl, alkynyl, ²cycloalkyl, aryl, aralkyl, heterocyclylalkyl or heterocyclyl group as defined ²herein. In some ²embodiments, the amine is alkylamino, dialkylamino, arylamino, or ²alkylarylamino. In other ²embodiments, the amine is NH2, methylamino, dimethylamino, ethylamino, ²diethylamino, ²propylamino, isopropylamino, phenylamino, or benzylamino.²

[0045] The term "sulfonamido" includes S- and N-sulfonamide groups, i.e., -²S02N1178R79 and ²¨NR78S02R79 groups, respectively. R78 and It79 are independently hydrogen, or ²a substituted or ²unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, ²heterocyclylalkyl, or heterocyclyl ²group as defined herein. Sulfonamido groups therefore include but are not ²limited to sulfamoyl²13²<DP=14>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²groups (-SO2NH2). In some embodiments herein, the sulfonamido is -NHS02-alkyl ²and is ²referred to as the "alkylsulfonylamino" group.²

[0046] The term "thiol" refers to -SH groups, while sulfides include -SR' ²groups, sulfoxides ²include -S(0)R8' groups, sulfones include -S02R82 groups, and sulfonyls ²include -S020R83²².²R80, R81, _lc -rs 82,²and R" are each independently a substituted or unsubstituted alkyl, ²cycloalkyl, ²alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as ²defined herein. In ²some embodiments the sulfide is an alkylthio group, -S-alkyl.²

[0047] The term "urea" refers to -N1184-C(0)-NR85le" groups. R", R85, and It' ²groups are ²independently hydrogen, or a substituted or unsubstituted alkyl, alkenyl, ²alkynyl, cycloalkyl, ²aryl, aralkyl, heterocyclyl, or heterocyclylalkyl group as defined herein.²

[0048] The term "amidine" refers to -C(NR87)NR88R89 and -NR87C(NR88)R89, ²wherein R87, ²R", and R89 are each independently hydrogen, or a substituted or unsubstituted ²alkyl, cycloalkyl, ²alkenyl, alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as ²defined herein. ²

[0049] The term "guanidine" refers to -NR90c(NR91)NR92-K 93,²wherein R90, R91, R92 and R93²are each independently hydrogen, or a substituted or unsubstituted alkyl, ²cycloalkyl, alkenyl, ²alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined ²herein²

[0050] The term "enamine" refers to -C(R94)_c(R95)NR96R97 and²_NR94c(R95)_c(R96)x- 97,²wherein R94, R95, R9' and R97 are each independently hydrogen, a ²substituted or unsubstituted alkyl, cycloalkyl, alkenyl, alkynyl, aryl ²aralkyl, heterocyclyl or ²heterocyclylalkyl group as defined herein.²

[0051] The term "halogen" or "halo" as used herein refers to bromine, ²chlorine, fluorine, or ²iodine. In some embodiments, the halogen is fluorine. In other embodiments, ²the halogen is ²chlorine or bromine.²

[0052] The term "hydroxyl" as used herein can refer to -OH or its ionized ²form,²

[0053] The term "imide" refers to -C(0)NR98C(0)R99, wherein R98 and R99 are ²each ²independently hydrogen, or a substituted or unsubstituted alkyl, cycloalkyl, ²alkenyl, alkynyl, ²aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined herein.²

[0054] The term "imine" refers to -CRloo(NRio oo-²1) and -N(CR1 xioi ) groups, wherein RI' and ²R191 are each independently hydrogen or a substituted or unsubstituted alkyl, ²cycloalkyl, alkenyl, ²alkynyl, aryl aralkyl, heterocyclyl or heterocyclylalkyl group as defined ²herein, with the proviso ²that R199 and R191 are not both simultaneously hydrogen.²14²<DP=15>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0055] The term "nitro" as used herein refers to an ¨NO2 group.²

[0056] The term "trifluoromethyl" as used herein refers to ¨CF3.²

[0057] The term "trifluoromethoxy" as used herein refers to ¨0CF3.²

[0058] The term "azido" refers to ¨N3.²

[0059] The term "trialkyl ammonium" refers to a ¨N(alkyl)3 group. A ²trialkylammonium ²group is positively charged and thus typically has an associated anion, such ²as halogen anion.²N=N²c²(²

[0060] The term "trifluoromethyldiazirido" refers to ;1 CF3²

[0061] The term "isocyano" refers to ¨NC.²

[0062] The term "isothiocyano" refers to ¨NCS.²

[0063] The term "pentafluorosulfanyl" refers to ¨SF5.²

[0064] As will be understood by one skilled in the art, for any and all ²purposes, particularly in ²terms of providing a written description, all ranges disclosed herein also ²encompass any and all ²possible subranges and combinations of subranges thereof. Any listed range can ²be easily ²recognized as sufficiently describing and enabling the same range being broken ²down into at ²least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting ²example, each range ²discussed herein can be readily broken down into a lower third, middle third ²and upper third, etc. ²As will also be understood by one skilled in the art all language such as "up ²to," "at least," ²"greater than," "less than," and the like include the number recited and refer ²to ranges which can ²be subsequently broken down into subranges as discussed above. Finally, as ²will be understood ²by one skilled in the art, a range includes each individual member. Thus, for ²example, a group ²having 1-3 atoms refers to groups having 1, 2, or 3 atoms. Similarly, a group ²having 1-5 atoms ²refers to groups having 1, 2, 3, 4, or 5 atoms, and so forth.²

[0065] Pharmaceutically acceptable salts of compounds described herein are ²within the scope ²of the present technology and include acid or base addition salts which retain ²the desired ²pharmacological activity and is not biologically undesirable (e.g., the salt ²is not unduly toxic, ²allergenic, or irritating, and is bioavailable). When the compound of the ²present technology has ²a basic group, such as, for example, an amino group, pharmaceutically ²acceptable salts can be ²formed with inorganic acids (such as hydrochloric acid, hydroboric acid, ²nitric acid, sulfuric ²acid, and phosphoric acid), organic acids (e.g., alginate, formic acid, acetic ²acid, benzoic acid,²<DP=16>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²gluconic acid, fumaric acid, oxalic acid, tartaric acid, lactic acid, maleic ²acid, citric acid, ²succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, ²naphthalene sulfonic acid, ²and p-toluenesulfonic acid) or acidic amino acids (such as aspartic acid and ²glutamic acid). ²When the compound of the present technology has an acidic group, such as for ²example, a ²carboxylic acid group, it can form salts with metals, such as alkali and earth ²alkali metals (e.g., ²Na, Lit, K+, ac 2+, mg2+, zn2-H,²) ammonia or organic amines (e.g. dicyclohexylamine, ²trimethylamine, triethylamine, pyridine, picoline, ethanolamine, ²diethanolamine, ²triethanolamine) or basic amino acids (e.g., arginine, lysine and ornithine). ²Such salts can be ²prepared in situ during isolation and purification of the compounds or by ²separately reacting the ²purified compound in its free base or free acid form with a suitable acid or ²base, respectively, ²and isolating the salt thus formed.²

[0066] Those of skill in the art will appreciate that compounds of the present ²technology may ²exhibit the phenomena of tautomerism, conformational isomerism, geometric ²isomerism and / or ²stereoisomerism. As the formula drawings within the specification and claims ²can represent ²only one of the possible tautomeric, conformational isomeric, stereochemical ²or geometric ²isomeric forms, it should be understood that the present technology ²encompasses any ²tautomeric, conformational isomeric, stereochemical and / or geometric isomeric ²forms of the ²compounds having one or more of the utilities described herein, as well as ²mixtures of these ²various different forms.²

[0067] "Tautomers" refers to isomeric forms of a compound that are in ²equilibrium with each ²other. The presence and concentrations of the isomeric forms will depend on ²the environment ²the compound is found in and may be different depending upon, for example, ²whether the ²compound is a solid or is in an organic or aqueous solution. For example, in ²aqueous solution, ²quinazolinones may exhibit the following isomeric forms, which are referred to ²as tautomers of ²each other:²0 OH²NH²NMe Me²As another example, guanidines may exhibit the following isomeric forms in ²protic organic ²solution, also referred to as tautomers of each other:²16²<DP=17>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²N H)²

[0068] Because of the limits of representing compounds by structural formulas, ²it is to be ²understood that all chemical formulas of the compounds described herein ²represent all ²tautomeric forms of compounds and are within the scope of the present ²technology.²

[0069] Stereoisomers of compounds (also known as optical isomers) include all ²chiral, ²diastereomeric, and racemic forms of a structure, unless the specific ²stereochemistry is expressly ²indicated. Thus, compounds used in the present technology include enriched or ²resolved optical ²isomers at any or all asymmetric atoms as are apparent from the depictions. ²Both racemic and ²diastereomeric mixtures, as well as the individual optical isomers can be ²isolated or synthesized ²so as to be substantially free of their enantiomeric or diastereomeric ²partners, and these ²stereoisomers are all within the scope of the present technology.²

[0070] The compounds of the present technology may exist as solvates, ²especially hydrates. ²Hydrates may form during manufacture of the compounds or compositions ²comprising the ²compounds, or hydrates may form over time due to the hygroscopic nature of the ²compounds. ²Compounds of the present technology may exist as organic solvates as well, ²including DMF, ²ether, and alcohol solvates among others. The identification and preparation ²of any particular ²solvate is within the skill of the ordinary artisan of synthetic organic or ²medicinal chemistry.²

[0071] Throughout this disclosure, various publications, patents and published ²patent ²specifications are referenced by an identifying citation. Also within this ²disclosure are Arabic ²numerals referring to referenced citations, the full bibliographic details of ²which are provided ²immediately preceding the claims. The disclosures of these publications, ²patents and published ²patent specifications are hereby incorporated by reference into the present ²disclosure to more ²fully describe the present technology.²

[0072] The Present Technology ²

[0073] Although targeted radiotherapy has been practiced for some time using ²macrocyclic ²complexes of radionuclides, the macrocycles currently in use (e.g., DOTA) ²generally form ²complexes of insufficient stability with radionuclides, particularly for ²radionuclides of larger ²size, such as actinium, radium, bismuth, and lead isotopes. Such instability ²results in²17²<DP=18>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²dissociation of the radionuclide from the macrocycle, and this results in a ²lack of selectivity to ²targeted tissue, which also results in toxicity to non-targeted tissue.²

[0074] The present technology provides new macrocyclic complexes that are ²substantially ²more stable than those of the conventional art. Thus, these new complexes can ²advantageously ²target cancer cells more effectively, with substantially less toxicity to non-²targeted tissue than ²complexes of the art. Moreover, the new complexes can advantageously be ²produced at room ²temperature, in contrast to DOTA-type complexes, which generally require ²elevated ²temperatures (e.g., at least 80 C) for complexation with the radionuclide. ²The present ²technology also specifically employs alpha-emitting radionuclides instead of ²beta radionuclides. ²Alpha-emitting radionuclides are of much higher energy, and thus substantially ²more potent, ²than beta-emitting radionuclides.²

[0075] Thus, in one aspect, a compound of Formula I is provided:²Z3²\² / -N² __________ p -)²zi²a z2²w5²or a pharmaceutically acceptable salt thereof, wherein²Zi is H or -V-W2²Z2 is OH or NH-W3²Z3 is H or W';²a is 0 or 1;²X1 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl, ²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where iv is 1, 2, 3, 4, ²5, ²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²OC(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, -²18²<DP=19>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-²NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),,,-R' ²²where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where ²xis ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, Ci-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, Cs-Cs cycloalkenyl, C2-C6 alkynyl, Cs-Cio cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²Significantly, the uncomplexed form of Formula I can be complexed with a ²radionuclide, such ²as an alpha-emitting radionuclide, at room temperature (generally 18-30 C, or ²about or no more ²than 20 C, 25 C, or 30 C) at high radiochemical yields, e.g., at least or ²greater than 90%, 95%, ²97%, or 98%.²

[0076] In a related aspect, a compound of Formula IA is provided²Z3²\²CO,²N ---M1---N² Cc_ >²_______ 0 .. - 014²zi²a z2²w5 (IA)²or a pharmaceutically acceptable salt thereof, wherein²I\41 is an alpha-emitting radionuclide;²Z1 is H or -X1-W2²Z2 is OH or NH-W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²19²<DP=20>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl, ²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where 14) is 1, 2, 3, 4, ²5, ²6, 7, 8, 9, or 10, or -CH2CE12-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²OC(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, - ²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS,²-N=C=N-R', -S02C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' ²where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where ²xis ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, Cs-Cs cycloalkenyl, C2-C6 alkynyl, Cs-Cio cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²In any embodiment disclosed herein, it may be that Ml is actinium-225 ²(225Ac3+), radium-223 ²(233Ra2+), bismuth-213 (213Bi3+), lead-212 (2121-M2+ and / or 212Pb4+), terbium-²149 (149Tb3+), ²fermium-255 (255Fm3+), thorium-227 (227Th4), thorium-226 (226Th4+), astatine-²211 (211At+), ²astatine-217 (217At+), or uranium-230.²

[0077] In a further related aspect aspect, the present technology provides a ²compound useful in ²targeted radiotherapy of cancer and / or mammalian tissue overexpressing ²prostate specific ²membrane antigen ("PSMA") (a "targeting compound") where the compound is of ²Formula II²<DP=21>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²Z3²\²CQ²f¨N ----N²,²\O-10² ___________ O OH²-\ z'²ot z2²L5²R26²(II)²or a pharmaceutically acceptable salt thereof, wherein²1\4' is an alpha-emitting radionuclide;²Z' is H or -13-R22²Z2 is OH or NH¨L4¨R24²Z3 is H or ¨L6¨R28;²a is 0 or 1;²X1 is 0, NH, or S;²L3, L4, L5, and L6 are independently at each occurence a bond or a linker ²group; and²R22, R24, R26, and²R28 each independently comprises an antibody, antibody fragment²(e.g., an antigen-binding fragment), a binding moiety, a binding peptide, a²binding polypeptide (such as a selective targeting oligopeptide containing up ²to²50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety²(such as an oligonucleotide, DNA or RNA vector, or aptamer), or a lectin.²In any embodiment disclosed herein encompassed by Formula II, M" may be ²actinium-225²(225Ac3)+,, radium-223 (233Ra2+), bismuth-213 (213Bi3+), lead-212 (212pb2+ ²and / or 212Pb4+),²terbium-149 (149Tb3+), fermium-255 (255Fm3+), thorium-227 (227Th4-H,²) thorium-226 (226Th4+),²astatine-211 (211A,t)-ps,²astatine-217 (217At+), or uranium-230.²

[0078] Representative R22, R24, R26,²and R28 groups include those antibodies listed in Table A²as well as antigen-binding fragments of such antibodies and any equivalent ²embodiments, as²would be known to those of ordinary skill in the art.²Table A. Representative Antibodies²Antibody Disclosed In²(Trade Name(s)) (U.S. Patent or Patent Appl. Publ. No.)*²Belimumab²7,138,501²(Benlysta)²21²<DP=22>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²Mogamulizumab²6,989,145²(Poteligeo)²Blinatumomab²7,112,324²(Blincyto)²Ibritumomab tiuxetan²5,776,456²(Zevalin)²Obinutuzumab²6,602,684²(Gazyva)²Ofatumumabl²8,529,902²(Arzerra)²Rituximab²5,736,137²(Rituxan, MabThera)²Inotuzumab ozogamicin²8,153,768²(Besponsa)²Moxetumomab pasudotox²8,809,502²(Lumoxiti)²Brentuximab vedotin²7,829,531; 7,090,843²(Adcetris)²Daratumumab²7,829,673²(Darzalex)²Ipilimumab²6,984,720²(Yervoy)²Cetuximab²6,217,866²(Erbitux)²Necitumumab²7,598,350²(Portrazza)²Panitumumab²6,235,883²(Vectibix)²Dinutuximab2²7,432,357²(Unituxin)²Pertuzumab²7,862,817²(Perjeta, Omnitarg)²'Also designated 2F2.²2 Also designated Ch14.18.²22²<DP=23>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²Trastuzumab3²5,821,337²(Herceptin)²Trastuzumab emtansine²7,097,840²(Kadcyla)²Siltuximab²7,612,182²(Sylvant)²Cemiplimab4²9,987,500²(Libtayo)²Nivolumab²8,008,449²(Opdivo)²Pembrolizumab²8,354,509²(Keytruda)²Olaratumab²8,128,929²(Lartruvo)²Atezolizumab²8,217,149²(Tecentriq)²Avelumab 5²9,624,298²(Bavencio)²Durvalumab²8,779,108²(Imfinzi)²Capromab pendetide²5,162,504²(Prostascint)²Elotuzumab²7,709,610²(Empliciti)²Denosumab²6,740,522²(Prolia, Xgeva)²Ziv-aflibercept²7,070,959²(Zaltrap)²Bevacizumab²6,054,297²(Avastin)²Ramucirumab²7,498,414²(Cyramza)²3 Also designated HuMaB4D5-8.²4 Also designated H4H7798N.² Also designated A09-246-2.²23²<DP=24>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Tositumomab 6,565,827; ²6,287,537;,6,090,365;²(Bexxar) 6,015,542; 5,843,398; ²5,595,721²Gemtuzumab ozogamicin²5,773,001²(Mylotarg)²Alemtuzumab²6,569,430; 5,846,534²(Campath-1H)²Cixutumumab 7,968,093; 7,638,605²Girentuximab²8,466,263²(Rencarex)²Nimotuzumab²6,506,883²(Theracim, Theraloc)²Catumaxomab²9,017,676; 8,663,638; 2013 / 0309234A1²(Removab)²Etaracizumab²2004 / 0001835A1²(Abegrin, Vitaxin)²*Note: the disclosures of the each of the patents and patent publications ²listed in Table A are ²incorporated herein by reference.²

[0079] In any embodiment disclosed herein, it may be that the binding peptide ²comprises ²comprises a prostate specific membrane antigen ("PSMA") binding peptide, a ²somatostatin ²receptor agonist, a bombesin receptor agonist, a seprase binding compound, or ²a binding ²fragement thereof. Exemplary PSMA binding peptides include, but are not ²limited to, those ²according to the following structure²0²CO2P1²nn²0²P202C CO2P3²where nn is 0, 1, or 2, and PI-, P2, and P3 are each independently H, methyl, ²benzyl, 4-²methoxybenzyl, or tert-butyl. In any embodiment herein, it may be that each of ²PI-, P2, and P3 ²are H.²24²<DP=25>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²

[0080] Somatostatin, illustrated in Scheme A, is a peptide hormone that ²regulates the ²endocrine system and affects neurotransmission and cell proliferation via ²interaction with G ²protein-coupled somatostatin receptors and inhibition of the release of ²numerous secondary ²hormones. Somatostatin has two active forms produced by alternative cleavage ²of a single ²preproprotein. There are five known somatostatin receptors, all being G ²protein-coupled seven ²transmembrane receptors: SST1 (SSTR1); SST2 (SSTR2); SST3 (SSTR3); SST4 ²(SSTR4); and ²SSTS (SSTR5). Exemplary somatostatin receptor agonists include somatostatin ²itself, ²lanreotide, octreotate, octreotide, pasireotide, and vapreotide.²Scheme A.²N H²HO,,,,²0²0 Ph²N H²Ph 6õ NH O0², NNH² H 2 N 0 N H2²0 Ph 0²0²ONH 0² 0 C 02 H 0²OH HN S²N -`= / - S N N H2²N H²OH²HN²y0²N H2²

[0081] Many neuroendocrine tumors express SSTR2 and the other somatostatin ²receptors.²Long acting somatostatin agonists (e.g., Octreotide, Lanreotide) are used to ²stimulate the SSTR2²receptors, and thus to inhibit further tumor proliferation. See, Zatelli MC, ²et al., (Apr 2007).²"Control of pituitary adenoma cell proliferation by somatostatin analogs, ²dopamine agonists and²novel chimeric compounds". European Journal of Endocrinology / European ²Federation of²Endocrine Societies. 156 Suppl 1: S29-35. Octreotide is an octapeptide that ²mimics natural²<DP=26>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²somatostatin but has a significantly longer half-life in vivo. Octreotide is ²used for the treatment ²of growth hormone producing tumors (acromegaly and gigantism), when surgery is ²²contraindicated, pituitary tumors that secrete thyroid stimulating hormone ²(thyrotropinoma), ²diarrhea and flushing episodes associated with carcinoid syndrome, and ²diarrhea in people with ²vasoactive intestinal peptide-secreting tumors (VIPomas). Lanreotide is used ²in the ²management of acromegaly and symptoms caused by neuroendocrine tumors, most ²notably ²carcinoid syndrome. Pasireotide is a somatostatin analog with an increased ²affinity to SSTR5 ²compared to other somatostatin agonists and is approved for treatment of ²Cushing's disease and ²acromegaly. Vapreotide is is used in the treatment of esophageal variceal ²bleeding in patients ²with cirrhotic liver disease and AIDS-related diarrhea²

[0082] Bombesin is a peptide originally isolated from the skin of the European ²fire-bellied ²toad (Bombina bombina). In addition to stimulating gastrin release from G ²cells, bombesin ²activates at least three different G-protein-coupled receptors: BBR1, BBR2, ²and BBR3, where ²such activity includes agonism of such receptors in the brain. Bombesin is ²also a tumor marker ²for small cell carcinoma of lung, gastric cancer, pancreatic cancer, and ²neuroblastoma. ²Bombesin receptor agonists include, but are not limited to, BBR-1 agonists, ²BBR-2 agonists, ²and BBR-3 agonists.²

[0083] Seprase (or Fibroblast Activation Protein (FAP)) is an integral ²membrane serine ²peptidase. In addition to gelatinase activity, seprase has a dual function in ²tumour progression. ²Seprase promotes cell invasiveness towards the ECM and also supports tumour ²growth and ²proliferation. Seprase binding compounds include seprase inhibitors.²

[0084] In a further related aspect, a modified antibody, modified antibody ²fragment, or ²modified binding peptide comprising a linkage arising from conjugation of a ²compound of ²Formula I or pharmaceutically acceptable salt thereof, with an antibody, ²antibody fragment, or ²binding peptide In a related aspect, a modified antibody, modified antibody ²fragment, or ²modified binding peptide is provided that includes a linkage arising from ²conjugation of a ²compound of Formula IA or a pharmaceutically acceptable salt thereof, with an ²antibody, ²antibody fragment, or binding peptide. In any embodiment disclosed herein, it ²may be that the ²antibody includes belimumab, Mogamulizumab, Blinatumomab, Ibritumomab ²tiuxetan, ²Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab ²pasudotox, ²Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, ²Panitumumab, ²Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, ²Cemiplimab,²26²<DP=27>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, ²Capromab ²pendetide, Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, ²Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, ²Nimotuzumab, Catumaxomab, or Etaracizumab. In any embodiment disclosed herein, ²it may be ²that the antibody fragment includes an antigen-binding fragment of belimumab, ²Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, ²Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, ²Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, ²Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, ²Nivolumab, ²Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab ²pendetide, ²Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, Tositumomab, ²²Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, ²Catumaxomab, or Etaracizumab In any embodiment disclosed herein, it may be ²that the ²binding peptide includes a prostate specific membrane antigen ("PSMA") binding ²peptide, a ²somatostatin receptor agonist, a bombesin receptor agonist, a seprase binding ²compound, or a ²binding fragement thereof²

[0085] As an example of a modified antibody, modified antibody fragment, or ²modified ²binding peptide of the present technology, it may be that the linkage is a ²thiocyante linkage; ²wherein the thiocyanate linkage arises from conjugation of the compound with ²the antibody, ²antibody fragment, or binding peptide; and wherein the compound is²SCN²0²OH HO 0²N¨ / ²0 0)²or pharmaceutically acceptable salt thereof.²

[0086] As another example of a modified antibody, modified antibody fragment, ²or modified ²binding peptide of the present technology, it may be that the linkage is a ²thiocyante linkage; ²wherein the thiocyanate linkage arises from conjugation of the compound with ²the antibody, ²antibody fragment, or binding peptide; and wherein the compound is²27²<DP=28>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²SCN²0²OH HO²0 0²or a pharmaceutically acceptable salt thereof.²

[0087] In any embodiment herein, it may be that the structures include ²compounds of Formula ²III, a modified antibody, modified antibody fragment, or modified binding ²peptide comprising a ²linkage arising from conjugation of a compound of Formula III or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, ²compounds of Formula IV, ²a modified antibody, modified antibody fragment, or modified binding peptide ²comprising a ²linkage arising from conjugation of a compound of Formula IV or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, and ²targeting compounds ²of Formula V² / \²0 0²0 N²O\ OX1W2²N²HO ¨²O H04²(III) or a pharmaceutically acceptable salt²thereof,² / _______________ \ __ ²Qs,²0 N \²x1¨w2²HO ¨²H0¨µ²0 (IV) or a pharmaceutically acceptable salt²thereof,²28²<DP=29>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479² / \²,²0 N s`s²0 0 _________________ N²HO __________ \ __ / 4¨²²HO²0 (V) or ²a pharmaceutically acceptable salt²thereof, wherein M2 is independently at each occurence an alpha-emitting ²radionuclide.²

[0088] Targeting compounds of Formula V may be prepared by a process that ²includes ²reacting a compound of Formula III or IV with R22-W", where Table B provides ²representative ²examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, ²9, or 10). As such, ²R22 may be conjugated to macrocycle R2' by reaction of complementary chemical ²functional ²groups W' and W2 to form linker L3. For example, R22-W1 may include a modified ²target amino ²acid residue within a protein (e.g., one of the representative antibodies ²disclosed in Table A or ²an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin ²receptor agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²of any one ²thereof). W' may include a reactive chemical functional moiety, non-limiting ²examples of which ²are disclosed in the Table B, where W2 may be selected to selectively react ²with W1 in order to ²provide 1_,3 of Formula V.²29²<DP=30>²Table B.²0²tµ.) ²o² / \ ² tµ.)²o²0 0²o²c7, ²oe²N N¨²0, o 0 N²y \ ?N / )_ x i_ L3 ²_R22²\² Ho ¨ \ / )¨²²HO --²0²R21²P²µ,0²1V-R22 R21_,0-W2 X1 ² Final Conjugation Product ² (R21-xi_v_R22) ..'²o 2²N)².²H ² 0²u,²"1\1²0²R21²0 ² R22²V N²0 ² NN²,X'Ir-).²N N ² and / or²N3¨R22 R21 0 H ² 0²H²õN²R21 Y.).Lc) ² N od²n ²,-i²7 N² ,, cp² NN t.)² / o²R22²c,²,..,².6.²-4²,,,,²<DP=31>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²,q²=² 4'4²4 \²-²rq²r24 01Z . 0²II / \²4-4²\ I.²\"; *²Z$ ²0²014 0 I²I²0 0 0².--S -,²0 0²0 \ _ 0²\-²724 0²"24²--'0² ...L E4²\²\ (7,²('-'p4 r2²0 4²z²o²o²xz²o²-S-²_,o _²31²<DP=32>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²eq² . -4²4 ²= - \N²c'r e'rzI4²4². 014 41 ---." ;²(:D ²4-4²4-4²C:' 0²0²0²1--c²-:s²ct²0 ct 0² ,S 0²- C:'' 0²0 -C) 3CI² E4 \ _²\ ¨ '''r²0 Nrz4²C²0 \²\ R,²p4²0 4²Ic c²o²''²c`l²1²32²<DP=33>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²N²cq²a4 el`z² ¨cI 4--²4-4²Rd4(cla4²4-4²0 \\ \\ t²0 / ²0 ;-,². * 7 .²ct c 4Z²0²4Z 4Z² CID 0²0 0 7'24 / ². (1 / ². . _². _ (-i,².²,²,²0 4 Z 0 v) 4 Z²t.² H 4''²0²II 0²----r²4Z²CI0²0²-<²(71²r rZ4²NI²33²<DP=34>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²( .=²N²²24 N4²o=)''' 4²e² 4-4 4-4²g 0²0 '3 0²7124 / ²4 --²1 0 0²r71a,47²0 ci)²4²0²4², II²34²<DP=35>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²0²C = IN²a²CD²0²ct²SC) c²Nr24 Nc4²4²7'²¨7²=²"rx²<DP=36>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²CV1²24 24²;-²0²,=0; zµz z\z²0 0²=²4Z² / ²\-²Nr24 Nr24²4²36²<DP=37>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²PI N N²N²Z Z1 E 41 \²N² Na4 Nrz4²Z4 CI / 24² \ \ E4²4 4²4Z 4Z 0 ². . 0²=²) =²Os 0²0²0 o²0²0².__ \-_-²c:) CD)5 \-²0²\ _²'''a4 Na4²4 0 4 0 ci)²0²C C.)²4 0 b²0 0 c / ²L.)²C.) Z²4 .²= 0²o²- -. = io² 0 o Y ².._, ._². ²,µõ²37²<DP=38>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²Z²724 ,-,, 4....-,²,b, z_z, ,, z_, z_z,²\²d--724²ZZ²0²b- b-²4² L) 0 ed C 0 ed 0²>¨ ²4C) ¨1C)²0 o ²ci Z ²\ _ \ \ \²724 724 724 724 c'In'4²4 0²0 b²o²0²z²L.)²r's1²-k \ ,_,²\ _²7:4 724² / ¨Z² / \ Z²Z=<²(el²CC²38²<DP=39>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²Z Z²,-(1 4-4 4-4 4-z 4-4 "²Z ,_:3___N4 zi_,²0 0 0 0² o 'C)²Z4²-cM-²0"²-c----² / _.,.. c:D²Z4 0 0²\²NZ NZ NZ NZ²4 0²cip²C²²4²0²0²\ _²NZ²39²<DP=40>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²z Z²Z²diz / ²...C9..-Y=4²0 0 / 7: 4²4 0 4²0² IN) () / ²v) ,.(²0 0²------ tr( cirz²O²--ac,3 CY² () 4²0²01²10' Z(D 1CD4 C RI 7²,24²,- i 7, i². a4²ci) 4 =²( \ 1²c)---,²4 o² L) 4²c..)²0 vA 4²..---- j<(²0²4²0²0 4²(:)²a4²'-k²rTi / ²C 4²Z² / t ²c / Z²<DP=41>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Pi²0 cN 0 N²P4¨ xo²r¨r r0 4²ZNI---c / D 4cA Cl)²Nia4²0 I0 0 C2)²0 ' S ²*²4²\ _²0²0 0²0 (:) "C4²ZZ 0²(:)² / CD \ _²o c4²c=4²0 4 0 4 0 4²4²0²N0 4²0²...õ..s._,²0²-kr--²c'iP4²0²RI / ²Na4²gl²24²0 (²0² / 0²z²0²41²<DP=42>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²rz4²C2)²r'14²0²42²<DP=43>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Atty. Dkt. No. 093873-8703²(Cornell Ref. 8459-04-PC)²

[0089] In any embodiment herein, it may be that the structures include ²compounds of Formula²VI, a modified antibody, modified antibody fragment, or modified binding ²peptide comprising a ²linkage arising from conjugation of a compound of Formula VI or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, ²compounds of Formula²VII, a modified antibody, modified antibody fragment, or modified binding ²peptide comprising a ²linkage arising from conjugation of a compound of Formula VII or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, and ²targeting compounds ²of Formula VIII²(-0²c_²N 0 0² _______________________ OH²NH²0 \² W3 (VI) or a pharmaceutically acceptable salt thereof,² / ¨\²CR, ID²N----M3---N²N 0 0²\--- / ¨1 OH²NH²0 \² W3 (VII) or a pharmaceutically acceptable salt thereof,²OP²N 0²1\1 = / (²¨ O² NH H²0 \²L4_R24²(VIII) or a pharmaceutically acceptable salt thereof, ²wherein IVP is independently at each occurence an alpha-emitting radionuclide.²

[0090] Targeting compounds of Formula VIII may be prepared by a process that ²includes ²reacting a compound of Formula VI or VII with R24-W4, where Table C provides ²representative ²examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, ²9, or 10). As such, ²R24 may be conjugated to macrocycle R23 by reaction of complementary chemical ²functional²43²<DP=44>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Atty. Dkt. No. 093873-8703²(Cornell Ref. 8459-04-PC)²groups W3 and W4 to form linker L4. For example, 10-W4 may include a modified ²target amino ²acid residue within a protein (e.g., one of the representative antibodies ²disclosed in Table A or ²an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin ²receptor agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²of any one ²thereof). W4 may include a reactive chemical functional moiety, non-limiting ²examples of which ²are disclosed in the Table C, where W3 may be selected to selectively react ²with W4 in order to ²provide L4 of Formula VIII.²44²<DP=45>²Table C.²0²(0²oe²oe²R23 f-N²N 0²\(\1 OoJTh²OH²) / NH²0 \²L4-R24²L.²R23-W3 W4-R24 ² Final Conjugation Product²(R23-L4-R24)²0²0²R2 $0j ² N u,², R24²n²R23 \²R2²and / or²4²\ / n ² R24²R2- / -(0=\)-()N² / n²,4z²,4z²<DP=46>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²(Z \j²²e²Z4²4-4²(4-4o ZZ² g g²724²71-²ci)²46²<DP=47>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²71²\ Z -.Z. =Z "²A²r z 4²O²N'-----=²Z²C'd²M 0²Tr ^ c > 4 1 r I L C )²0²0²71-²,r Cl²N²I²i'' 4cv²Z²Ib²=,,,²-..,²4²0²0²47²<DP=48>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²(2'² / ²N²to²0 / ²N C / ) Zr,i² 11 a4²4²0²0² / ²Z²N T.²c4²e.,²,4 0²,.,_....²0²A²0²\ N²0 (²Z². 0 / 0 r_t0²i²4²0 CA 0 4²Z el² Nr24 / L. ²0=,A4²0²4 =²0²......õ0_,²y)²48²<DP=49>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0091] In any embodiment herein, it may be that the structures include ²compounds of Formula ²IX, a modified antibody, modified antibody fragment, or modified binding ²peptide comprising a ²linkage arising from conjugation of a compound of Formula IX or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, ²compounds of Formula X, ²a modified antibody, modified antibody fragment, or modified binding peptide ²comprising a ²linkage arising from conjugation of a compound of Formula X or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, and ²targeting compounds ²of Formula XI²(-0²0²\N 0 0 ___________________ ()H²W5 OH²(IX) or a pharmaceutically acceptable salt thereof,² / ¨\²(Q.²,²N 0²\N² __________________________ p OH²OH²W5 (X) or a pharmaceutically acceptable salt thereof,² / ¨\²CR,² __________________________ OH²O²L5 H²R26²(XI) or a phaimaceutically acceptable salt thereof, wherein²M4 is independently at each occurence an alpha-emitting radionuclide.²

[0092] Targeting compounds of Formula XI may be prepared by a process that ²includes ²reacting a compound of Formula IX or X with R26-W6, where Table D provides ²representative ²examples (where n is independently at each occurrence 1, 2, 3, 4, 5, 6, 7, 8, ²9, or 10). As such, ²R26 may be conjugated to macrocycle R25 by reaction of complementary chemical ²functional²49²<DP=50>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²groups W5 and W6 to form linker L5. For example, R26-W6 may include a modified ²target amino ²acid residue within a protein (e.g., one of the representative antibodies ²disclosed in Table A or ²an antigen-binding fragment thereof; a PSMA binding peptide, a somatostatin ²receptor agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²of any one ²thereof). W6 may include a reactive chemical functional moiety, non-limiting ²examples of which ²are disclosed in the Table D, where W5 may be selected to selectively react ²with W6 in order to ²provide L5 of Formula IX²<DP=51>²Table D.²0²t..) ²o ²t..) ²o² / --\ ² o² / 0 0--- ² o²oe ²oe²o² / N N²R25 1²04 , 0²- p \--- / ² OH² / \²L5 OH ² P²,²,²\R26 ² ..-²- ² ,²,,²,,,,,²'7²R25-W5 W6-R26 ² Final Conjugation Product 0,², ², ²c,²H H²NCS ² N1.rN.,R26²R25²H2N _R26²S²R25²n ² n²0 ² 00²0 ² n²1-i²NH2 ² 0 R2 6²N.. ² cp²t..)²R25 R26 0 =²n²,- ² vD²R25 ² n c:²t..)²4,.²--4²vD²<DP=52>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²C:4²4-Z²Z-Z²`e9²0²r²724²"a4²(²52²<DP=53>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²`,-²(z4²)²724 1-4CD 4 / ²4²0² ci 4²4-Z Z-Z²tc:::)²tg²g²--.²0 b"²0²' ' I²0 t I.².z -to²g²g²r=4 724²'clr24'-'²."(24²vD 4²T:4 4 I ?_0²y ,². ,² . (-².²2---²0 4 0²0²- \ -²-c0²Z²n²53²<DP=54>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0093] In any embodiment herein, it may be that the structures include ²compounds of Formula²XII, a modified antibody, modified antibody fragment, or modified binding ²peptide comprising a ²linkage arising from conjugation of a compound of Formula XII or ²pharmaceutically acceptable ²salt thereof, with an antibody, antibody fragment, or binding peptide, ²compounds of Formula²XIII, a modified antibody, modified antibody fragment, or modified binding ²peptide comprising²a linkage arising from conjugation of a compound of Formula XIII or ²pharmaceutically²acceptable salt thereof, with an antibody, antibody fragment, or binding ²peptide, and targeting²compounds of Formula XIV²\²(-0²N¨\²r / N²¨ OH²0 (XII) or a pharmaceutically acceptable salt ²thereof,²1A17²\²CQõ²e²¨ OH²0 (XIII) or a pharmaceutically acceptable salt ²thereof,²R28²L6²\²(0,s,²(N)²_ OH²0 (XIV) or a pharmaceutically acceptable salt ²thereof, ²wherein M5 is independently at each occurence an alpha-emitting radionuclide.²54²<DP=55>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0094] Targeting compounds of Formula XIV may be prepared by a process that ²includes ²reacting a compound of Formula XII or XIII with R28-W8, where Table E provides ²²representative examples (where n is independently at each occurrence 1, 2, 3, ²4, 5, 6, 7, 8, 9, or ²10). As such, R28 may be conjugated to macrocycle R2' by reaction of ²complementary chemical ²functional groups W7 and W8 to form linker L4. For example, R28-W8 may include ²a modified ²target amino acid residue within a protein (e.g., one of the representative ²antibodies disclosed in ²Table A or an antigen-binding fragment thereof, a PSMA binding peptide, a ²somatostatin ²receptor agonist, a bombesin receptor agonist, a seprase binding compound, or ²a binding ²fragement of any one thereof). W8 may include a reactive chemical functional ²moiety, non-²limiting examples of which are disclosed in the Table E, where W' may be ²selected to ²selectively react with W8 in order to provide L6 of Formula XIV.² 55²<DP=56>²Table E.²0²t..) ²o ²t..) ²o²R28²o²I ² c:²oe ²oe² L6 c:²) \²R27 1 / 0 0 --²N²N 0²\N 0 0)² OH 0²,²,²u, -OH ² ..-²0²c., 0 ² ,,,²"0²'7²,,,0²R27-W7 W8-R28 ² Final Conjugation Product ,²,²0²H H²R27²0 NCS² H2N -R28 N1rN,R28²S²n ² R27 n²00²0 ² n²0 ² 1-i²R27 ² N 0 NH2 0²cp²-. ² t..)²o²R28²vD²n 0²c7,²R27 ² t..)² n R28 4,.²--4²vD²<DP=57>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²00 N'r 4²Is 4 __ss²7=4²00²zz²czt²?=4²rz4²r24²<cv²4²E 4²57²<DP=58>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²4,²0 4²,²\ s 4²z²11²0²0 0²g g²- --.²O²cd²L L²Z Z²g g²rr-V. N²r24 r24²CV²P4 1 1²Z²0 li²58²<DP=59>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0095] A person of ordinary skill in the art will recognize that numerous ²chemical conjugation ²strategies provide ready access to targeting compounds of the present ²technology, whereby ²exposed amino acid residues on a protein (e.g., an antibody) undergo well-²known reactions with ²reactive moieties on a prosthetic molecule. For example, amide coupling is a ²well-known route, ²where ¨ as an example ¨ lysine residues on the antibody surface react with ²terminal activated ²carboxylic acid esters to generate stable amide bonds. Amide coupling is ²typically mediated by ²any of several coupling reagents (e.g., HATU, EDC, DCC, HOBT, PyBOP, etc.), ²which are ²detailed elsewhere. (See generally Eric Valeur & Mark Bradley, Amide Bond ²Formation: ²Beyond the Myth of Coupling Reagents, 38 CHEM. SOC. REV. 606 (2009).) These ²and other ²amide coupling strategies are described in a recent review by Tsuchikama. ²(Kyoji Tsuchikama ²& Zhiqiang An, Antibody-Drug Conjugates: Recent Advances in Conjugation and ²Linker ²Chemistries, 9 PROTEIN CELL 33, 36 (2018); see also, e.g., A.C. Lazar et al., ²Analysis of the ²Composition of Immunoconjugates Using Size-Exclusion Chromatography Coupled to ²Mass ²Spectrometry, 19 RAPID COMMUN. MASS SPECTROM. 1806 (2005).)²

[0096] Additionally, a person of ordinary skill in the art will recognize that ²cysteine coupling ²reactions may be employed to conjugate prosthetic molecules with thiol-²reactive termini to ²protein surfaces through exposed thiol side chains on cysteine residues on the ²protein (e.g., ²antibody) surface. (See generally Tsuchikama & An, supra, at 36-37; see also, ²e.g., Pierre ²Adumeau et al., Thiol-Reactive Bifunctional Chelators for the Creation of Site-²Selectively ²Modified Radioimmunoconjugates with Improved Stability, 29 BIOCONJUGATE CHEM. ²1364 ²(2018).) Because cysteine residues readily form disulfide linkages with nearby ²cysteine residues ²under physiological conditions, rather than existing as free thiols, some ²cysteine coupling ²strategies may rely upon selective reduction of disulfides to generate a ²higher number of reactive ²free thiols. (See id.) Cysteine coupling techniques known in the art include, ²but are not limited ²to, cys alkylation reactions, cysteine rebridging reactions, and cys-aryl ²coupling using ²organometallic palladium reagents. (See, e.g., C.R. Behrens et al., Antibody-²Drug Conjugates ²(ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrates Improved ²Homogeneity ²and Other Pharmacological Properties Over Conventional Heterogeneous ADCs, 12 ²MOL. ²PHARM. 3986 (2015); Vinogradova et al., Organometallic Palladium Reagents for ²Cysteine ²Bioconjugation, 526 NATURE 687 (2015); see also Tsuchikama, supra, at 37 ²(collecting ²examples).)²

[0097] Protein conjugation strategies using non-natural amino acid side chains ²are also well-²known in the art. For example, "click chemistries" provide access to ²conjugated proteins, by²59²<DP=60>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²rapid and selective chemical transformations under a diverse range of reaction ²conditions. Click ²chemistries are known to yield peptide conjugates with limited by-product ²formation, despite the ²presence of unprotected functional groups, in aqueous conditions. One ²important non-limiting ²example of a click reaction in the formation of conjugated peptides is the ²copper(I)-catalyzed ²azide-alkyne 1,3-dipolar cycloaddition reaction (CuAAC). (See Liyuan Liang & ²Didier Astruc, ²The Copper(I)-Catalysed Alkyne-Azide Cycloadclition (CuAAC) "Click" Reaction ²and Its ²Applications: An Overview, 255 COORD. CHEM. REV. 2933 (2011); see also, e.g., ²Herman S. Gill ²& Jan Marik, Preparation of 18F-labeled Peptides using the Copper(I)-Catalyzed ²Azide-Alkyne ²1,3-Dipolar Cycloaddition, 6 NATURE PROTOCOLS 1718 (2011).) The CuAAC click ²reaction ²may be carried out in the presence of ligands to enhance reaction rates. Such ²ligands may ²include, for example, polydentate nitrogen donors, including amines (e.g., ²tris(triazolyl)methyl ²amines) and pyridines. (See Liang & Astruc, supra, at 2934 (collecting ²examples); P.L. Golas et ²al., 39 MACROMOLECULES 6451 (2006).) Other widely-utilized click reactions ²include, but are ²not limited to, thiol-ene, oxime, Diels-Alder, Michael addition, and pyridyl ²sulfide reactions.²

[0098] Copper-free (Cu-free) click methods are also known in the art for ²delivery of ²therapeutic and / or diagnostic agents, such as radionuclides (e.g., 'F), ²chemotherapeutic agents, ²dyes, contrast agents, fluorescent labels, chemiluminescent labels, or other ²labels, to protein ²surfaces. Cu-free click methods may permit stable covalent linkage between ²target molecules ²and prosthetic groups. Cu-free click chemistry may include reacting an ²antibody or antigen-²binding fragment, which has been modified with a non-natural amino acid side ²chain that ²includes an activating moiety such as a cyclooctyne (e.g., dibenzocyclooctyne ²(DBCO)), a ²nitrone or an azide group, with a prosthetic group that presents a ²corresponding or ²complementary reactive moiety, such as an azide, nitrone or cyclooctyne (e.g., ²DBCO). (See, ²e.g., David. J. Donnelly et al., Synthesis and Biologic Evaluation of a Novel ²l8F-Labeled ²Adnectin as a PET Radioligand for Imaging PD-LI Expression, 59 J. NUCL. MED. ²529 (2018).) ²For example, where the targeting molecule comprises a cyclooctyne, the ²prosthetic group may ²include an azide, nitrone, or similar reactive moiety. Where the targeting ²molecule includes an ²azide or nitrone, the prosthetic group may present a complementary ²cyclooctyne, alkyne, or ²similar reactive moiety. Cu-free click reactions may be carried out at room ²temperature, in ²aqueous solution, in the presence of phosphate-buffered saline (PBS). The ²prosthetic group may ²be radiolabeled (e.g., with 'F) or may be conjugated to any alternative ²diagnostic and / or ²therapeutic agent (e.g., a chelating agent). (See id. at 531.)²<DP=61>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0099] The compounds of any embodiment and aspect herein of the present ²technology may ²be a tripartite compound. However, such tripartite compounds are not ²restricted to compositions ²including Formulas I, IA, or II. Thus, in an aspect, a tripartite compound is ²provided that ²includes a first domain that has relatively low but still specific affinity ²for serum albumin (e.g., ²0.5 to 50 x 10-6M), a second domain including a chelating moiety such as but ²not limited to ²those described herein, and a third domain that includes tumor targeting ²moiety (TTT) having ²relatively high affinity for a tumor antigen (e.g., 0.5 to 50 x 10-9M). The ²following exemplary ²peptide receptors, enzymes, cell adhesion molecules, tumor associated ²antigens, growth factor ²receptors and cluster of differentiation antigens are useful targets for ²constructing the TTT ²domain: somatostatin peptide receptor-2 (SSTR2), gastrin-releasing peptide ²receptor, seprase ²(FAP-alpha), incretin receptors, glucose-dependent insulinotropic polypeptide ²receptors, VIP-1, ²NPY, folate receptor, LHRH, and av133, an overexpressed peptide receptor, a ²neuronal ²transporter (e.g., noradrenaline transporter (NET)), or other tumor associated ²proteins such as ²EGFR, HER-2, VGFR, MUC-1, CEA, MUC-4, ED2,TF-antigen, endothelial specific ²markers, ²neuropeptide Y, uPAR, TAG-72, CCK analogs, VIP, bombesin, VEGFR, tumor-²specific cell ²surface proteins, GLP-1, CXCR4, Hepsin, TMPRSS2, caspaces, Alpha V beta six, ²cMET. Other ²such targets will be apparent to those of skill in the art, and compounds that ²bind these can be ²incorporated in the TTT to produce a tripartite radiotherapeutic compound.²

[0100] The following Formulas L-LIV provide exemplary general structures for ²tripartite ²compounds of the present technology.²TTT¨L501¨Rad¨L502¨A1b (L)²TTT., L5 I¨Rad¨L5 2¨Alb²X5 1 '13²N _________________________ ²(LI)²TTT²-Nx501 .*** (-**²Alb¨L502¨Rad_ 501²(LII)²61²<DP=62>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²L501¨Rad¨L502¨Alb²N²TTT²X5 I²0²=²X5 1 p²0²= L5 1¨Rad ¨L5 2¨Alb²(LIV)²where²TTT is independently at each occurence a binding domain for a somatostatin ²peptide ²receptor-2 (SSTR2), a gastrin-releasing peptide receptor, a seprase (FAP-²alpha), ²an incretin receptor, a glucose-dependent insulinotropic polypeptide receptor, ²²VIP-1, NPY, a folate receptor, LHRH, avI33, an overexpressed peptide receptor, ²a ²neuronal transporter (e.g., noradrenaline transporter (NET)), a receptor for a ²²tumor associated protein (such as EGFR, HER-2, VGFR, MUC-1, CEA, MUC-4, ²ED2,TF-antigen, endothelial specific markers, neuropeptide Y, uPAR, TAG-72, ²CCK analogs, VIP, bombesin, VEGFR, tumor-specific cell surface proteins, ²GLP-1, CXCR4, Hepsin, TMPRSS2, caspaces, Alpha V beta six, cMET, or ²combination of any two or more thereof), or a cominbation of any two or more ²thereof,²X501 is independently at each occurence absent, 0, S, or NH;.²62²<DP=63>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²L501- is independently at each occurrence absent, -C(0)-, -C(0)-NR4-, -C(0)-²NR5-C1-C12 ²alkylene-,-C1-C12 alkylene-C(0)-, -C(0)-NR6-C1-C12 alkylene-C(0)-, -arylene-, -² ²0(CH2CH20)r-CH2CH2C(0)-, -0(CH2CH20)rr-CH2CH2C(0)-NH-, - ²0(CH2CH20),CH2CH2-, an amino acid, a peptide of 2, 3, 4, 5, 6, 7, 8, 9, or 10 ²amino acids, or a combination of any two or more thereof, where r is 0, 1, 2, ²3, 4, ²5, 6, 7, 8, or 9, rr is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9, rrr is 0, 1, 2, 3, 4, ²5, 6, 7, 8, or 9, ²and where R4, R5, and R6 are each independently H, alkyl, or aryl,²Rad is independently at each occurrence a moiety capable of including a ²radionuclide, ²optionally further including a radionuclide;²L5 2 is independently at each occurrence absent, -C(0)-, -(CH2CH20),CH2CH2C(0)-², - ²(CH2CH20)ss-CH2CH2C(0)-N1f-, -(CH2CH20)sss-CH2CH2-, an amino acid, - ²CH(CO2H)-(CH2)4-, -CH(CO2H)-(CH2)4-NH-, a peptide of 2, 3, 4, 5, 6, 7, 8, 9, ²10, 11, 12, 13, 14, 15 ,16, 17, 18, 19, or 20 amino acids, or a combination of ²any ²two or more thereof, where s is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, ²14, 15 ²,16, 17, 18, or 19, ss is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, ²15,16, 17, 18, ²or 19, and sss is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ,16, ²17, 18, or 19,²Alb is independently at each occurrence an albumin-binding moiety;²p is independently at each occurrence 0, 1, 2, or 3; and²q is independently at each occurrence 1 or 2.²In any embodiment disclosed herein, the radionuclide may be 177Lu3+, 175LU3+, ²45SC3+, 66Ga3+, ²67Ga3,68Ga3, 69Ga3,71Ga3, 89-Y3+,86²Y3+, 89Zr4+, 99y3+, 99mTc+i, i3in3+, ²1151113+, 139La3+,²136ce3+, 138ce3+, 140ce3+, 142ce3+, 151Eu3+, 153Eu3+, 152Dy3+, 149Tb3+,²159Tb3+, 154Gd3+, 155Gd3+, ²156Gd3+, 157Gd3+, 158Gd3+, 160Gd3+, 188Re+1, 186Re+1, 213Bi3+, 211At+, 217At+, ²227Tb4+, 226Tb4+, ²225Ac3+, 233Ra2+, 152Dy3+, 213Bi3+, 212Bi3+, 211Bi3+, 212pb2+ ,212pb4+, ²255Fm3+, or uranium-230. For ²example, the the radionuclide may be an alpha-emitting radionuclide such as ²213Bi3+, 211m+, ²225Ac3+, 152Dy3+, 212Bi3+, 211Bi3+, 217m+, 227m4+, 226Th4+, 233Ra2+, 212pb2+ , ²or 212pb4+.²101011 In any embodiment disclosed herein, it may be the tripartite compounds ²of Formulas L-²LIV are of Formulas LV-LIX²63²<DP=64>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²CHEL²L503²L501²TTT N L5 2-Alb²0 (LV)²CHEL²L503²TTT col²X5 I ic L502-Alb²N _______________________________________________________ ²0²(LVI)² x501 p²0²1,N²Alb¨T 5 2 N¨L5 1²1-²L503²CHEL (LVII)²CHEL²L503²L5 1²L5 2-Alb²0²TTT²x501²(LVIII)²64²<DP=65>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²41 / ²CHEL²TTTx501._). ,N²L5 3²0²=²q -.L5 2- Alb²0²(LIX)²where L503 is independently at each occurrence absent, -C(0)-, alkylene-,-²C1-C12 ²alkylene-C(0)-, -C1-C12 alkylene-N10 -, -arylene-, -(CH2CH20),CH2CH2C(0)-, - ²(CH2CH20).-CH2CH2C(0)-NH-, -(CH2CH20).-CH2CH2-, an amino acid, -CH(CO2H)-²(CH2)4-, -CH(CO2H)-(CH2)4-NH-, a peptide of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, ²12, 13, 14, 15 ,16,²17, 18, 19, or 20 amino acids, or a combination of any two or more thereof, ²where z is 0, 1, 2, 3,²4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 ,16, 17, 18, or 19, zz is 0, 1,2, ²3,4, 5, 6, 7, 8, 9, 10, 11, 12, ²13, 14, 15,16, 17, 18, or 19, and zzz is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, ²12, 13, 14, 15,16, 17,²18, or 19; and²CHEL is independently at each occurrence a covalently conjugated chelator that ²optionally²includes a chelated radionuclide.²

[0102] The albumin-binding moiety plays a role in modulating the rate of blood ²plasma ²clearance of the compounds in a subject, thereby increasing circulation time ²and ²compartmentalizing the cytotoxic action of cytotoxin-containing domain and / or ²imaging ²capability of the imaging agent-containing domain in the plasma space instead ²of normal organs ²and tissues that may express antigen. Without being bound by theory, this ²component of the ²structure is believed to interact reversibly with serum proteins, such as ²albumin and / or cellular ²elements. The affinity of this albumin-binding moiety for plasma or cellular ²components of the ²blood may be configured to affect the residence time of the compounds in the ²blood pool of a ²subject. In any embodiment herein, the albumin binding-moiety may be ²configured so that it ²binds reversibly or non-reversibly with albumin when in blood plasma. In any ²embodiment ²herein, the albumin binding-moiety may be selected such that the binding ²affinity of the ²compound with human serum albumin is about 5 M to about 15 M.²<DP=66>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0103] By way of example, the albumin-binding moiety of any embodiment herein ²may ²include a short- chain fatty acid, medium-chain chain fatty acid, a long-chain ²fatty acid, myristic ²acid, a substituted or unsubstituted indole-2-carboxylic acid, a substituted ²or unsubstituted 4-²oxo-4-(5,6,7,8-tetrahydronaphthalen-2-yl)butanoic acid, a substituted or ²unsubstituted ²naphthalene acylsulfonamide, a substituted or unsubstituted ²diphenylcyclohexanol phosphate ²ester, a substituted or unsubstituted 2-(4-iodophenyl)acetic acid, a ²substituted or unsubstituted 3-²(4-iodophenyl)propionic acid, or a substituted or unsubstituted 4-(4-²iodophenyl)butanoic acid ²Certain representative examples of albumin-binding moieties that may be ²included in any ²embodiment herein include one or more of the following:²HO2C²0²I ,²0 0² / PI²N 0 0²OH²0²0², and²0²0²0 0²

[0104] In any embodiment herein, the tripartite compounds may include an ²albumin-binding ²moiety that is²66²<DP=67>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²y501²HO2C y502²aa dd²\ X5" x504²bb cc y505 y503²y504²or²y501²HO2 Ci N y502²aa dd²aVVI.P²\ X5 5 x506²bb cc y505 y503²y504², where Y501, y502,²Y503, y504, and Y505 are independently H, halo, or alkyl, X503, x504, x505, ²and X506 are each ²independently 0 or S, aa is independently at each occurence 0, 1, or 2, bb is ²independently at ²each occurence 0 or 1, cc is independently at each occurence 0 or 1, and dcl ²is independently at ²each occurence 0, 1, 2, 3, or 4. In any embodiment herein, it may be that bb ²and cc cannot be ²the same value. In any embodiment herein, it may be that Y503 is I and each of ²Y501, y502, y503,²Y504, and Y505 are each independently H.²

[0105] Representative chelators useful in any embodiment of the present ²technology include,²but are not limited to, a covalently conjugated substituted or unsubstituted ²chelator of the²following group:²1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA),²1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA),²p-SCN-Bn-DOTA (also known as 2B-DOTA-NCS),²PIP-DOTA,²diethylenetriaminepentaacetic acid (DTPA),²PIP-DTPA,²AZEP-DTPA,²ethylenediamine tetraacetic acid (EDTA),²triethylenetetraamine-N,N,N,N",N",N"-hexa-acetic acid (TTHA),²67²<DP=68>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²742-(bis-carboxymethylamino)-ethy1]-4,10-bis-carboxymethy1-1,4,7,10-tetraaza-²cyclododec-1-yl-acetic acid (DEPA),²2,2',2"-(10-(2-(bis(carboxymethyl)amino)-5-(4-isothiocyanatophenyl) penty1)-²1,4,7,10-²tetraazacyclododecane-1,4,7-triyptriacetic acid (3p-C-DEPA-NCS),²NETA,²14-carboxymethy1-7[2-(carboxyrn ethyl am in o)-ethyl j-perhydro-1 ,4,7-²triazoni n-1 -y1}-acetic ²acid (NPTA),²diacetylpyridinebis(benzoylhydrazone),²1,4,7, 10,13,16-hexaazacyclooctadecane-N,N',N",N",N"",N'""-hexaaceticacid ²(HEHA), ²octadentate terephthalamide ligands,²siderophores,²2,2'-(4-(2-(bis(carboxymethyl)amino)-5-(4-isothiocyanatophenyl)penty1)-10-(2-²(bis(carboxymethyl)amino)ethyl)-1,4,7, 1 0-tetraazacycl ododecane-1,7-²diy1)diacetic acid, ²NN'-bis[(6-carboxy-2-pyridipmethy1]-4,13-diaza-18-crown-6 (H2macropa), ²6-((16-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-7,16-²diazacyclooctadecan-7-²yl)methyl)-4-isothiocyanatopicolinic acid (macropa-NCS), ²1,4,7, 10-tetraaza-1,4,7,10-tetra(2-carbamonyl methyl)cyclododecane (TCMC), ²S-2-(4-Isothiocyanatobenzy1)-1,4,7,10-tetraaza-1,4,7,10-tetra(2-²carbamoylmethyl)cyclododecane (S-p-SCN-Bn-TCMC), ²R-2-(4-Isothiocyanatobenzy1)-1,4,7,10-tetraaza-1,4,7,10-tetra(2-²carbamoylmethyl)cyclododecane (R-p-SCN-Bn-TCMC), and ²3,9-carboxymethy1-6-(2-methoxy-5-isothiocyanatophenyl)carboxymethy1-3,6,9,15-²tetraazabicyclo-[9.3.1]pentadeca-1(15),11,13-triene. ²Certain members of this exemplary group are illustrated below.²CO2H HO2C CO2H HO2C²NCS²* NCS²CO2H HO2C CO2H HO2C²68²<DP=69>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²HO2C\²HO2C / HO2C²\ / \ / \) / CO2H²N N \.,²\ / 02H²N N² ( \ __ / NC S²C 02H²...... / "\,,² / ¨CO2H²Z-} N EI\_²CO2H N²111111N²c C 02H²N² / ,..........²,--- ) CO2H N²CO2H .02c²co2H CO2H²CO2H CO2H² AZEP-DTPA PIP-DTPA²CO21-{ HO2C² ( / \) CO2H²N N²HO2C Cil²\¨ \ N ( / 02H²N².,,,....õ.7.2:5\² CO2H (N\ N²N² ___________________________________ / NCS²HO2C) PIP-DOTA CO2H²3p-C-DEPA-NCS² CO2H CO2H² / \ )² N N²..,.,., N .CO2H²NETA²It is to be understood that a "covalently conjugated" chelator means a ²chelator (such as those²listed above) wherein one or more bonds to a hydrogen atom contained therein ²are replaced by a²bond to an atom of the remainder of the Rad and / or CHEL moiety, to L501, ²and / or to L'2, or a pi²bond between two atoms is replaced by a bond from one of the two atoms to an ²atom of the²69²<DP=70>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²remainder of the Rad and / or CREL moiety, to L501, and / or to L502, and the ²other of the two ²atoms includes a new bond, e.g. to a hydrogen (such as reaction of an ¨NCS ²group in the ²chelator to provide the covalently conjugated chelator).²

[0106] In any embodiment disclosed herein, it may be that the CHEL of the ²tripartite ²compounds is a chelator as provided in the compounds of Formula I, IA, or II. ²For example, ²tripartite compound may be a targeting compound of Formula II where R22, R24, ²R26, and R28 are ²each independently².JVVV'²L503²L501²TTT c02¨Alb²0²avvv,²1²L503²TTT (N 501²L²L5C12 Alb²N _________________________ ²0²0²Alb¨ r 502 N¨L5..o...44,1\1,,²L503²JVVV'²<DP=71>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²difIP²L5"²rcoi²N L5 2¨Alb²1\T²0²TTT,²X501 P²0²%N²TTT²x501 N L503²0 =L502 ²¨Alb²0²

[0107] In any embodiment disclosed herein, TTT may be²H ²²CO2P5 1 w501²min²0²0²p50202c 2P5 3²71²<DP=72>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²CO2135131 w501 sk²tnal²0²0²co²p50202c 2p503²,or²011111²-'r\ 501 w501²171171²,IVVV`²0² / co212.5 3²p5o2o2c²,where²w501 s =²1 C(0)¨, ¨(CH2),,,,¨, or ¨(CH2) 0¨NH2-C(0)¨;²mm is 0 or 1;²Tvw is / or 2;²oo is 1 or 2;and²P501, 1- -,s502,²and P503 are each independently H, methyl, benzyl, 4-methoxybenzyl, or tert-²butyl.²In any embodiment herein, it may be that each of P501, P502, and P503 are H.²

[0108] The tripartite compounds of the present technology include variations ²on any of the ²three domains: e.g., the domain including the chelator, the domain including ²the albumin-²binding group, or the domain including the tumor targeting moiety. The ²following are ²exemplary.²72²<DP=73>²

[0109] RPS-092²0²w²I ² o²w ²o²1--, ²cio²N ² HN²_______________________________________________________________________________²_____________ C²0 ________________________________________________________ 0 / 2N --N)MN ² H² µ0 C)2H \ / 0 _.)-²i²j-OH ² / ²0 ² / -²0²HN 0- / -²HN²0- / ² ,², ²_1=µ1N-r ² ,²0 ² ,²\-NH 0 ² u,²,²,² / -0 / ²0- / ²al / ¨²-0²HNI N -- N---1 / ²) H N---1\j²CO2H²0²A²Ho2c---NAN^co2H²H H²cp²In any embodiment disclosed herein, RPS-92 may optionally chelate 213Bi3+, ²211At+, 225Ac3+, 152Dy3+, 212Bi3+, 211Bi3+, 217At+, 227m4+, 226m4+, 233Ra2+, ² 1.)²0²1-,²VD²212pb2+ , or 212pb4+. ² -,-,--,²,..,²4,.²-,²,.,²<DP=74>²

[0110] NTI-093 is an analog of NTI-063, where TCMC is used as the chelator.²0²0 ² t..)²=²o²1--,² H 2N ,,,e,-,-----= N-'------N / 1¨ N H2 o²o²11 ² oe²o²0²(I) H2N²H2N ² N-------y N .---,...70²0²5: \²HN ² P²2²-4².6. ² 2²N) ²N)²'7²H ² ,,,0²,²N²0 ² EN1 0 I²0 z--- N²HN A N ²H 0 CO2H²----- 7------ / ²H N -õ.. / .."0² / NN²CO2H²n²--.,²0²cp²t..)²H 02C...N...L.N CO2H. ² o²o²H H²o²t..)²In any embodiment disclosed herein, NTI-93 may optionally chelate 212pb2+ or ²212pb4+. .6.²--4²VD²<DP=75>²

[0111] NTI-094 is an analog of NTI-072, where TCMC is used as the chelator.²0²t..)²I ² o²t..) ²o²= ²c7,²rA N H2 ² HN² / / / 0²___________________________________________________ 14 ² Oe²pe²,--- ² C:²i 1 H2N, ² HN-(²H2N--4x²õr¨N 1y0 ² / CO2H²\[ N ² 0²o²,² / -- / ²"N-'²H2N) . / / 4²0 N)," / -²0² / ¨ / ²HN 0¨ / ²i²HN ² o² / -0 ² ,,²,²vi ² ,²,,²HN- ² .²,,²0 µ ² ,²,I, ²u,²>\-NH 0 ² ,²,².² / -0 / ²0- / ²ANdi² / -0²HN N---- / ²) H 11-,--Nj²CO2H²0 / ²1-d²n²HO2CNANCO2H ² 1-3 ²H H²cp ²w²In any embodiment disclosed herein, NTI-94 may optionally chelate 212pb2+ or ²212pb4+. 0²1-, ²VD²7a²C:²N².6.²--4²VD²<DP=76>²

[0112] The following is a Bromo analog of NTI-063, with modification to the ²albumin binding domain².²co2H ²Ew²CO2H ² c7,'²7"¨N Na" ² g ²H 02C²\,.... N²H 02C --- / ²4111µ²HN²P²s's-- NH ² 2²M.'.²C71 ² ..]²IV² H 2'²:1²o 4H .r-, / '¨ / N u,²,²N ² 0 Br i8²N²0 / J.\ -- ²HN A²CO2H²N ²H 0²..,--²H²) H²N:--Ni²N õY."²CO2H²n²,-i²H02 C..NAN..CO2 H²cp ²t..)²H H²,.1²C7²2².6.²j²<DP=77>²

[0113] The following is a Chloro analog of NTI-063, with modification to the ²albumin binding domain²0²tµ.) ²o²õ. rco, ² a,²o²00 CO2H ² o²7---N ² N(___. / ²HO2C²H 02C-- / ²HN ² P²s----- N1H ² 2²..'²-4²-4 ² 2²N)²2'²H ² ,², ²4 ², ²0²N ² 0 CI '8²0 / ----.)-- ²N²HN A N H ²0 CO2H²..--- ,ff-----.. / ²H ²CO2H / ". N --:-N'²n ²1-i²H 02C . / \ N A N .CO2H ² cp²t..)²o²H H ² o'"²O' ²o²t..)².6.²-4²o²<DP=78>²

[0114] NTI-3 09 modifies the tumor targeting domain, to target seprase ²(Fibroblast Activation Protein / FAP)²0²t..)²CO2H ² o²r\ r²N¨N ² t..)²o²o² r--N i CO2H o²oe²HO2C²o²\--N²HO2C¨i²HN²S ² P² HN I 2²HN²0 ² 2²0 e²____________________________________________________________________ / ² N)², ,0²,²HN¨( ² ,²5',²0 µ CO2H²0² / _______________________________________________________ NH 0² / ²0 ¨ / ¨o² / -1²od²r=N HN²_________________________ ,D, ² n²r² ___________________________ \ ,²,0 ² .²w²L---N²i \²., / _______ ' 0 ² o²'a ²o²t..)²0²--4²o²<DP=79>²

[0115] The NTI-309 compound can be include TCMC as the chelator,²0²0 ² w²o²w ²o² [NH 2 1- ,²o ²o²N , ² oe²_____________________________________________________ ...-- ² -... oe²i H2N, ² o,²"-----N \²0²N \²r²r²H2N ..,.,,,) ,., (²\\'`,.,)²o ______________________________________________________ \ / ²i ¨² 1-1 N P²\²i ------------------------------------------------------ S ² .²,,²,² H N I ,²--4 H N ² .²vD ² ,² / 0 ² 0"²________________________________________________________________ / ² IV²I--I ²I ²0²u,²H N _________________________________________________________ ( ² ,²,²% ______________________________________________________________ CO2H² / ___________________________________________________ NH 0² / ²j ___________________________________________ 0²0² / -- / ²1-d²H N ² n ²7,----N\²,-i²CN '\el²....... '*=-=,²1 / ² cp²n.)²1.¨ N HN ____ \ ² o²' 0 ² o²'a²r,²0 ² o²t..)²In any embodiment disclosed herein, NTI-309 may optionally chelate 212pb2+ or ²212pb4+. .6.²--4²VD²<DP=80>²

[0116] The following is a Boronic acid analog of NTI-309.²0² / ¨co2H ² n.)²o²n.)²N ² o²HO2C / \ NY²o²o²oe²oe²NCO2H ² 0²N²H020¨ / ²HN²)¨s²P²HN ² I²µ,0²HN / ²HN²oe²o²N, ²N,0 ²'7 ²0²\Kco2H ² (3², ___________________________________________________ NH 0 ² .11² / ²0²_ / ¨²0² / ² / ²_ / -0² r¨N HN² / \²\\ \\ ' / / \ ______________ / ²\ ² IV²n²_________________ \ , I / O 0 ² 1-3²0 HN __ \<,\ ,²0²,*". 1²N²0²1-,²,---- N ² 0²i OH ² -c-:--,²is,....)., ² c,²t..,²\ ² .6.²OH ² ---1²0²<DP=81>²

[0117] The following is a Boronic acid analog of NTI-309, using TCMC as a ²chelator.²0²0 ² w²õIL, ² .²w²r "2 ² .²,N, ² 0²00² / H2N, ² Cie²0²N²if¨ i 0²0,,,-- .............................................. ²N² ____________________________________________________ )²H2N ..1²46 \ __ ²7²1.1\²HNT--- ² P²1 ² 2²HN ² / ² g²00 0²1¨, _______________________________________________________ / ² 2²Iv²2²HN ² '7²O\ co2H ² 2², ________________________________________________ NH 0 ² rl²o²o / ² / O¨ / ¨²0 / ²r= N HN __ / ²0 / ²IV²o n ²i ,,,.. ri²0, HN----,;\ ² *3²sõ,,,,x / 0²,. / ² CP²N²0²1 µ OH²c / ).' / "11 ² 0²OH ² 0²N²In any embodiment disclosed herein, this analog may optionally chelate 212pb2+ ²or 212pb4+. .6.²--4²0²<DP=82>²

[0118] Further by way of specific examples, a derivative of RPS-072 (which ²itself targets PSMA), can be constructed, where TTT has affinity for the²0²SSTR2 receptor, using a derivative of lanreotide where this compound (A) has a ²molecular weight of 3537.93 and a formula of C165H2351N28044S3. ²Similarly, a derivative of RPS-072 can be prepared, that targets GRP / bombesin ²receptor, where this compound (B) has a molecular weight of 3537.93²cio²and a foimula of C167H2481N31044S.²cio²1-d²<DP=83>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²-0²o²zi²ctN_²c.)²zi²o z_²o²o²o²o²o²i o²ON ck²l._ \ z²z²T²Cz o z²z 1) ²) ²(' 0, W z qk 5 ²0,, o _-\ iz²o i ¶ , (L)r²I 0²zi ²i²o o 0 0 zi z Il,²o²I ²z u),(0²o o z²i²2 0 ii ri)²0 0 z² 0 i 0²zJI²i 2²o z²z o². 1 z z²z²o o²83²<DP=84>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²_²zi²Itj²0_²zi² C / .....²0²0²l''²o²o iz²0²o ¨( i²zi 2--z²i o o_).--1-²(õ²I 0²cS'' ck iz²0 , 1 0²LI 'z²to ²zi²z²Cz ²z ²) ²to²i z²zi zi \²o o²iz² 0 0²o / ²______________________________________________________________ zi²0 z 0 10²i²z'l z.- / / ²0 z²0²z²z / s 1²,. z²0 0²84²<DP=85>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0119] The present technology also provides compositions (e.g., pharmaceutical ²compositions) ²and medicaments comprising any of one of the embodiments of the compounds of ²Formulas I, ²IA, II, any one of the modified antibodies, modified antibody fragments, or ²modified binding ²peptides of the present technology disclosed herein, or any one of the ²embodiments of the ²tripartite compounds disclosed herein and a pharmaceutically acceptable ²carrier or one or more ²excipients or fillers (collectively refered to as "pharmaceutically acceptable ²carrier" unless ²otherwise specified). The compositions may be used in the methods and ²treatments described ²herein. The pharmaceutical composition may include an effective amount of any ²embodiment ²of the compounds of the present technology for treating the cancer and / or ²mammalian tissue ²overexpressing PSMA or an effective amount of any embodiment of the modified ²antibody, ²modified antibody fragment, or modified binding peptide of the present ²technology for treating ²the cancer and / or mammalian tissue overexpressing PSMA or an effective amount ²of any ²embodiment of the tripartite compound of the present technology for treating ²the cancer and / or ²mammalian tissue overexpressing PSMA. In an related aspect, a method of ²treating a subject is ²provided, wherein the method includes administering a targeting compound of ²the present ²technology to the subject or administering a modified antibody, modified ²antibody fragment, or ²modified binding peptide of the present technology to the subject. In any ²embodiment disclosed ²herein, it may be that the subject suffers from cancer and / or mammalian tissue ²overexpressing ²prostate specific membrane antigen ("PSMA"). In any embodiment herein, it may ²be the ²administering includes administering an effective amount of any embodiment of ²the compounds ²of the present technology for treating the cancer and / or mammalian tissue ²overexpressing PSMA ²of the compound or an effective amount of any embodiment of the modified ²antibody, modified ²antibody fragment, or modified binding peptide of the present technology for ²treating the cancer ²and / or mammalian tissue overexpressing PSMA or an effective amount of any ²embodiment of ²the tripartite compound of the present technology for treating the cancer ²and / or mammalian ²tissue overexpressing PSMA. The subject may suffer from a mammalian tissue ²expressing a ²somatostatin receptor, a bombesin receptor, seprase, or a combination of any ²two or more ²thereof and / or mammalian tissue overexpressing PSMA. The mammalian tissue of ²any ²embodiment disclosed herein may include one or more of a growth hormone ²producing tumor, a ²neuroendocrine tumor, a pituitary tumor, a vasoactive intestinal peptide-²secreting tumor, a small ²cell carcinoma of the lung, gastric cancer tissue, pancreatic cancer tissue, a ²neuroblastoma, and a ²metastatic cancer. In any embodiment disclosed herein, the subject may suffer ²from one or more ²of a glioma, a breast cancer, an adrenal cortical cancer, a cervical ²carcinoma, a vulvar²carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ²ovarian²<DP=86>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder ²cancer, a colon ²cancer, a primary gastric adenocarcinoma, a primary colorectal adenocarcinoma, ²a renal cell ²carcinoma, and a prostate cancer. In any embodiment disclosed herein, the ²composition (e.g., ²pharmaceutical composition) and / or medicament may be formulated for parenteral ²²administration. In any embodiment disclosed herein, the composition (e.g., ²pharmaceutical ²composition) and / or medicament may be formulated for intraveneous ²administration. In any ²embodiment disclosed herein, the administering step of the method may include ²parenteral ²administration. In any embodiment disclosed herein, the administering step of ²the method may ²include intraveneous administration.²

[0120] In any of the above embodiments, the effective amount may be determined ²in relation ²to a subject. "Effective amount" refers to the amount of a compound or ²composition required to ²produce a desired effect. One non-limiting example of an effective amount ²includes amounts or ²dosages that yield acceptable toxicity and bioavailability levels for ²therapeutic (pharmaceutical) ²use including, but not limited to, the treatment of e.g., one or more of a ²glioma, a breast cancer, ²an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an ²endometrial carcinoma, ²a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell ²lung cancer, a ²small cell lung cancer, a bladder cancer, a colon cancer, a primary gastric ²adenocarcinoma, a ²primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate ²cancer. Another ²example of an effective amount includes amounts or dosages that are capable of ²reducing ²symptoms associated with e.g., one or more of a glioma, a breast cancer, an ²adrenal cortical ²cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a ²primary ovarian ²carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a ²small cell lung ²cancer, a bladder cancer, a colon cancer, a primary gastric adenocarcinoma, a ²primary colorectal ²adenocarcinoma, a renal cell carcinoma, and a prostate cancer, such as, for ²example, reduction in ²proliferation and / or metastasis of prostate cancer, breast cancer, or bladder ²cancer.. The ²effective amount may be from about 0.01m to about 1 mg of the compound per ²gram of the ²composition, and preferably from about 0.1 ittg to about 500 [tg of the ²compound per gram of the ²composition. As used herein, a "subject" or "patient" is a mammal, such as a ²cat, dog, rodent or ²primate. Typically the subject is a human, and, preferably, a human suffering ²from or suspected ²of suffering from one or more of a glioma, a breast cancer, an adrenal ²cortical cancer, a cervical ²carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian ²carcinoma, a ²metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung ²cancer, a bladder ²cancer, a colon cancer (such as colon adenocarcinoma), a primary gastric ²adenocarcinoma, a²86²<DP=87>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate ²cancer. The term ²"subject" and "patient" can be used interchangeably.²

[0121] In any of the embodiments of the present technology described herein, ²the ²pharmaceutical composition may be packaged in unit dosage form. The unit ²dosage form is ²effective in treating one or more of a glioma, a breast cancer, an adrenal ²cortical cancer, a ²cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ²ovarian ²carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a ²small cell lung ²cancer, a bladder cancer, a colon cancer (such as colon adenocarcinoma), a ²primary gastric ²adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, ²and a prostate ²cancer. Generally, a unit dosage including a compound of the present ²technology will vary ²depending on patient considerations. Such considerations include, for example, ²age, protocol, ²condition, sex, extent of disease, contraindications, concomitant therapies ²and the like. An ²exemplary unit dosage based on these considerations may also be adjusted or ²modified by a ²physician skilled in the art. For example, a unit dosage for a patient ²comprising a compound of ²the present technology may vary from 1 x i0 g / kg to 1 g / kg, preferably, 1 >< ²10 'g / kg to 1.0 ²g / kg. Dosage of a compound of the present technology may also vary from 0.01 ²mg / kg to 100 ²mg / kg or, preferably, from 0.1 mg / kg to 10 mg / kg. Suitable unit dosage forms, ²include, but are ²not limited to powders, tablets, pills, capsules, lozenges. suppositories. ²patches. nasal sprays, ²injectibles, implantable sustained-release formulations, rnucoadherent films, ²topical varnishes, ²lipid complexes, etc.²

[0122] The pharmaceutical compositions may be prepared by mixing one or more ²of the ²compounds of Formulas I, IA, II, or any one of the modified antibodies, ²modified antibody ²fragments, or modified binding peptides of the present technology, or any ²embodiment of the ²tripartite compound of the present technology, pharmaceutically acceptable ²salts thereof, ²stereoisomers thereof, tautomers thereof, or solvates thereof, with ²pharmaceutically acceptable ²carriers, excipients, binders, diluents or the like to prevent and treat ²disorders associated with ²cancer and / or a mammalian tissue overexpressing PSMA. The compounds and ²compositions ²described herein may be used to prepare formulations and medicaments that ²treat e.g., prostate ²cancer, breast cancer, or bladder cancer. Such compositions may be in the form ²of, for example, ²granules, powders, tablets, capsules, syrup, suppositories, injections, ²emulsions, elixirs, ²suspensions or solutions. The instant compositions may be formulated for ²various routes of ²administration, for example, by oral, parenteral, topical, rectal, nasal, ²vaginal administration, or ²via implanted reservoir. Parenteral or systemic administration includes, but ²is not limited to,²87²<DP=88>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²subcutaneous, intravenous, intraperitoneal, and intramuscular, injections. The ²following dosage ²forms are given by way of example and should not be construed as limiting the ²instant present ²technology.²

[0123] For oral, buccal, and sublingual administration, powders, suspensions, ²granules, tablets, ²pills, capsules, gelcaps, and caplets are acceptable as solid dosage forms. ²These can be ²prepared, for example, by mixing one or more compounds of the instant present ²technology, or ²pharmaceutically acceptable salts or tautomers thereof, with at least one ²additive such as a starch ²or other additive. Suitable additives are sucrose, lactose, cellulose sugar, ²mannitol, maltitol, ²dextran, starch, agar, alginates, chitins, chitosans, pectins, tragacanth gum, ²gum arabic, gelatins, ²collagens, casein, albumin, synthetic or semi-synthetic polymers or ²glycerides. Optionally, oral ²dosage forms can contain other ingredients to aid in administration, such as ²an inactive diluent, ²or lubricants such as magnesium stearate, or preservatives such as paraben or ²sorbic acid, or ²anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating ²agent, binders, ²thickeners, buffers, sweeteners, flavoring agents or perfuming agents. Tablets ²and pills may be ²further treated with suitable coating materials known in the art.²

[0124] Liquid dosage forms for oral administration may be in the form of ²pharmaceutically ²acceptable emulsions, syrups, elixirs, suspensions, and solutions, which may ²contain an inactive ²diluent, such as water. Pharmaceutical formulations and medicaments may be ²prepared as liquid ²suspensions or solutions using a sterile liquid, such as, but not limited to, ²an oil, water, an ²alcohol, and combinations of these. Pharmaceutically suitable surfactants, ²suspending agents, ²emulsifying agents, may be added for oral or parenteral administration.²

[0125] As noted above, suspensions may include oils. Such oils include, but ²are not limited to, ²peanut oil, sesame oil, cottonseed oil, corn oil and olive oil. Suspension ²preparation may also ²contain esters of fatty acids such as ethyl oleate, isopropyl myristate, fatty ²acid glycerides and ²acetylated fatty acid glycerides. Suspension formulations may include ²alcohols, such as, but not ²limited to, ethanol, isopropyl alcohol, hexadecyl alcohol, glycerol and ²propylene glycol. Ethers, ²such as but not limited to, poly(ethyleneglycol), petroleum hydrocarbons such ²as mineral oil and ²petrolatum; and water may also be used in suspension formulations.²

[0126] Injectable dosage forms generally include aqueous suspensions or oil ²suspensions ²which may be prepared using a suitable dispersant or wetting agent and a ²suspending agent. ²Injectable forms may be in solution phase or in the form of a suspension, ²which is prepared with ²a solvent or diluent. Acceptable solvents or vehicles include sterilized ²water, Ringer's solution, ²or an isotonic aqueous saline solution. Alternatively, sterile oils may be ²employed as solvents or²88²<DP=89>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²suspending agents. Typically, the oil or fatty acid is non-volatile, including ²natural or synthetic ²oils, fatty acids, mono-, di- or tri-glycerides.²

[0127] For injection, the pharmaceutical formulation and / or medicament may be ²a powder ²suitable for reconstitution with an appropriate solution as described above. ²Examples of these ²include, but are not limited to, freeze dried, rotary dried or spray dried ²powders, amorphous ²powders, granules, precipitates, or particulates. For injection, the ²formulations may optionally ²contain stabilizers, pH modifiers, surfactants, bioavailability modifiers and ²combinations of ²these.²

[0128] Compounds of the present technology may be administered to the lungs by ²inhalation ²through the nose or mouth. Suitable pharmaceutical formulations for inhalation ²include ²solutions, sprays, dry powders, or aerosols containing any appropriate ²solvents and optionally ²other compounds such as, but not limited to, stabilizers, antimicrobial ²agents, antioxidants, pH ²modifiers, surfactants, bioavailability modifiers and combinations of these. ²The carriers and ²stabilizers vary with the requirements of the particular compound, but ²typically include nonionic ²surfactants (Tweens, Pluronics, or polyethylene glycol), innocuous proteins ²like serum albumin, ²sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, ²salts, sugars or sugar ²alcohols. Aqueous and nonaqueous (e.g., in a fluorocarbon propellant) aerosols ²are typically ²used for delivery of compounds of the present technology by inhalation.²

[0129] Besides those representative dosage forms described above, ²pharmaceutically ²acceptable excipients and carriers are generally known to those skilled in the ²art and are thus ²included in the instant present technology. Such excipients and carriers are ²described, for ²example, in "Remingtons Pharmaceutical Sciences" Mack Pub. Co., New Jersey ²(1991), which ²is incorporated herein by reference. The instant compositions may also ²include, for example, ²micelles or liposomes, or some other encapsulated form.²

[0130] Specific dosages may be adjusted depending on conditions of disease, ²the age, body ²weight, general health conditions, sex, and diet of the subject, dose ²intervals, administration ²routes, excretion rate, and combinations of drugs. Any of the above dosage ²forms containing ²effective amounts are well within the bounds of routine experimentation and ²therefore, well ²within the scope of the instant present technology.²

[0131] Various assays and model systems can be readily employed to determine ²the ²therapeutic effectiveness of the treatment according to the present ²technology.²89²<DP=90>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0132] For the indicated condition, test subjects will exhibit a 10%, 20%, ²30%, 50% or greater ²reduction, up to a 75-90%, or 95% or greater, reduction, in one or more ²symptom(s) caused by, ²or associated with, the disorder in the subject, compared to placebo¨treated ²or other suitable ²control subjects.²

[0133] In another aspect, the present technology provides a method of treating ²cancer by ²administering an effective amount of the targeting composition according to ²Formula II to a ²subject having cancer. Since a cancer cell targeting agent can be selected to ²target any of a wide ²variety of cancers, the cancer considered herein for treatment is not limited. ²The cancer can be ²essentially any type of cancer. For example, antibodies or peptide vectors can ²be produced to ²target any of a wide variety of cancers. The targeting compositions described ²herein are ²typically administered by injection into the bloodstream, but other modes of ²administration, such ²as oral or topical administration, are also considered. In some embodiments, ²the targeting ²composition may be administered locally, at the site where the target cells ²are present, i.e., in a ²specific tissue, organ, or fluid (e.g., blood, cerebrospinal fluid, etc.). Any ²cancer that can be ²targeted through the bloodstream is of particular consideration herein. Some ²examples of ²applicable body parts containing cancer cells include the breasts, lungs, ²stomach, intestines, ²prostate, ovaries, cervix, pancreas, kidney, liver, skin, lymphs, bones, ²bladder, uterus, colon, ²rectum, and brain. The cancer can also include the presence of one or more ²carcinomas, ²sarcomas, lymphomas, blastomas, or teratomas (germ cell tumors). The cancer ²may also be a ²form of leukemia. In some embodiments, the cancer is a triple negative breast ²cancer.²

[0134] As is well known in the art, the dosage of the active ingredient(s) ²generally depends on ²the disorder or condition being treated, the extent of the disorder or ²condition, the method of ²administration, size of the patient, and potential side effects. In different ²embodiments, ²depending on these and other factors, a suitable dosage of the targeting ²composition may be ²precisely, at least, above, up to, or less than, for example, 1 mg, 10 mg, 50 ²mg, 100 mg, 200 mg, ²300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1200 mg, or ²1500 mg, or ²a dosage within a range bounded by any of the foregoing exemplary dosages. ²Furthermore, the ²composition can be administered in the indicated amount by any suitable ²schedule, e.g., once, ²twice, or three times a day or on alternate days for a total treatment time of ²one, two, three, four, ²or five days, or one, two, three, or four weeks, or one, two, three, four, ²five, or six months, or ²within a time frame therebetween. Alternatively, or in addition, the ²composition can be ²administered until a desired change in the disorder or condition is realized, ²or when a ²preventative effect is believed to be provided.²<DP=91>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0135] The examples herein are provided to illustrate advantages of the ²present technology ²and to further assist a person of ordinary skill in the art with preparing or ²using the compounds ²of the present technology or salts, pharmaceutical compositions, derivatives, ²prodrugs, or ²tautomeric forms thereof. The examples herein are also presented in order to ²more fully ²illustrate the preferred aspects of the present technology. The examples ²should in no way be ²construed as limiting the scope of the present technology, as defined by the ²appended claims. ²The examples can include or incorporate any of the variations, aspects or ²embodiments of the ²present technology described above. The variations, aspects or embodiments ²described above ²may also further each include or incorporate the variations of any or all ²other variations, aspects ²or embodiments of the present technology.²EXAMPLES²

[0136] Exemplary Synthetic Procedures and Characterization ²

[0137] Materials and Instrumentation. All solvents and reagents, unless ²otherwise noted, ²were purchased from commercial sources and used as received without further ²purification. ²Solvents noted as "dry" were obtained following storage over 3 A molecular ²sieves. Metal salts ²were purchased from Strem Chemicals (Newburyport, MA) and were of the highest ²purity ²available; Lu(C104)3 was provided as an aqueous solution containing 15.1 wt% ²Lu. The ²bifunctional ligandp-SCN-Bn-DOTA was purchased from Macrocyclics (Plano, TX). ²NMe4OH ²was purchased as a 25 wt% solution in H20 (trace metals basis, Beantown ²Chemical, Hudson, ²NH). Hydrochloric acid (BDH Aristar Plus, VWR, Radnor, PA) and nitric acid ²(Optima, ²ThermoFisher Scientific, Waltham, MA) were of trace metals grade. Both Chelex ²100 (sodium ²form, 50-100 mesh) and human serum used for 225Ac-complex challenge assays ²were purchased ²from Sigma Aldrich (St. Louis, MO). Deionized water (>18 MQ cm) was prepared ²on site using ²either Millipore Direct-Q 3UV or Elga Purelab Flex 2 water purification ²systems.²

[0138] Reactions were monitored by thin-layer chromatography (TLC, Whatman ²UV254 ²aluminum-backed silica gel). The HPLC system used for analysis and ²purification of ²compounds consisted of a CBM-20A communications bus module, an LC-20AP ²(preparative) or ²LC-20AT (analytical) pump, and an SPD-20AV UV / Vis detector monitoring at 270 ²nm ²(Shimadzu, Japan). Analytical chromatography was carried out using an Ultra ²Aqueous C18 ²column, 100 A, 5 p.m, 250 mm x 4.6 mm (Restek, Bellefonte, PA) at a flow rate ²of 1.0 mL / min, ²unless otherwise noted. Purification was performed with an Epic Polar ²preparative column, 120 ²A, 10 p.m, 25 cm x 20 mm (ES Industries, West Berlin, NJ) at a flow rate of 14 ²mL / min, unless²91²<DP=92>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²otherwise noted. Gradient HPLC methods were employed using a binary mobile ²phase that ²contained H20 (A) and either Me0H (B) or ACN (C). HPLC Method A: 10% B (0-5 ²min), 10-²100% B (5-25 min). Method B: 10% C (0-5 min), 10-100% C (5-25 min). Method C: ²10% C ²(0-5 min), 10-100% C (5-40 min). Method D: 10% C (0-5 min), 10-100% C (5-20 ²min). The ²solvent systems contained 0.1% trifluoroacetic acid (TFA), except for Method ²C, in which 0.2% ²TFA was used. NMR spectra were recorded at ambient temperature on Varian Inova ²300 MHz, ²400 MHz, 500 MHz or 600 MHz spectrometers, or on a Bruker AV III HD 500 MHz ²spectrometer equipped with a broadband Prodigy cryoprobe. Chemical shifts are ²reported in ²ppm. 1H and 13C NMR spectra were referenced to the TMS internal standard (0 ²ppm), to the ²residual solvent peak, or to an acetonitrile internal standard (2.06 ppm in ²D20 spectra). 19F ²NMR spectra were referenced to a monofluorobenzene internal standard (-113.15 ²ppm). The ²splitting of proton resonances in the reported 1H spectra is defined as: s = ²singlet, d = doublet, t ²= triplet, q = quartet, m = multiplet, dt = doublet of triplets, td = triplet ²of doublets, and br = ²broad. IR spectroscopy was performed on a KBr pellet of sample using a Nicolet ²Avatar 370 ²DTGS (ThermoFisher Scientific, Waltham, MA). High-resolution mass spectra ²(HRMS) were ²recorded on an Exactive Orbitrap mass spectrometer in positive ESI mode ²(ThermoFisher ²Scientific, Waltham, MA). UV / visible spectra were recorded on a Cary 8454 UV-²Vis (Agilent ²Technologies, Santa Clara, CA) using 1-cm quartz cuvettes, unless otherwise ²noted. Elemental ²analysis (EA) was performed by Atlantic Microlab, Inc. (Norcross, GA).²

[0139] Synthesis and Characterization of Macropa Complexes, Macropa-NCS, and ²Macropa-NHC(S)NHCH3. 1Vs[(6-carboxy-2-pyridil)methy1]-4,13-diaza-18-crown-6 ²(H2macropa=2HC1=4H20)[102,103] was prepared using 1,7,10,16-tetraoxa-4,13-²diazacyclooctadecane (7) that was either purchased from EMD Millipore ²(Darmstadt, Germany) ²or synthesized via literature protocols.

[104] Chelidamic acid monohydrate (1) ²was purchased ²from TCI America (Portland, OR). Dimethyl 4-chloropyridine-2,6-dicarboxylate ²(2),F105] ²dimethyl 4-azidopyridine- 2,6-dicarboxylate (3),

[106] and 6-²chloromethylpyridine-2-carboxylic ²acid methyl ester (8),

[102] were prepared via the indicated literature ²protocols.²92²<DP=93>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0140] Preparation of [La(macropa)J2+.²7 2+² COO HOOC² / ²( N²La3+²\-0 / 0¨²\²To a suspension of H2macropa.2HC1.4H20 (0.0233 g, 0.034 mmol) in 2-propanol ²(0.6 mL) was ²added triethylamine (20 !IL, 0.143 mmol). The pale-gold solution was heated at ²reflux for 25 ²min before a solution of La(C104)3.6H20 (0.0209 g, 0.038 mmol) in 2-propanol ²(0.5 mL) was ²added dropwise. A precipitate formed immediately. The cream suspension was ²stirred at reflux ²for an additional 1.5 h before it was cooled and centrifuged. The supernatant ²was removed, and ²the pellet was washed with 2-propanol (2 >< 1 mL) and then air-dried on filter ²paper to give the ²title complex as a pale-tan solid (0.0177 g) containing 0.64 equiv of 2-²propanol. 1I-1NMR (500 ²MHz, D20, pD 9) 6= 7.87 (t, J= 7.8 Hz, 2H), 7.54 (d, J= 7.8 Hz, 2H), 7.39 (d, ²J = 7.6 Hz, ²2H), 5.21 (d, J = 15.7 Hz, 2H), 4.44 (t, J = 11.6 Hz, 2H), 4.09 (t, J = 11.2 ²Hz, 4H), 4.01 (t, J = ²10.4 Hz, 2H), 3.74 (d, J= 9.9 Hz, 2H), 3.65-3.60 (m, 4H), 3.58-3.47 (m, 4H), ²3.44 (d, J = 10.8 ²Hz, 2H), 2.75 (td, J= 13.1, 2.7 Hz, 2H), 2.56 (d, J = 13.9 Hz, 2H), 2.38 (d, J ²= 14.0 Hz, 2H). ²13C{1H} APT NMR (126 MHz, D20, pD 9) 6= 172.62, 158.70, 150.19, 140.94, ²126.89, ²122.32, 71.88, 70.12, 69.20, 68.05, 60.14, 56.08, 54.01. EA Found: C, 35.16; ²H, 4.73; N, 5.91. ²Calc. for C26H35LaN408.2C104.2H20.0.64iPrOH: C, 35.53; H, 4.71; N, 5.94. IR ²(cm-1): 3443, ²2913, 1630, 1596, 1461, 1370, 1265, 1083, 948, 839, 770, 678, 617, 513. HPLC ²tR = 18.104 ²min (Method A). HRMS (m / z): 669.14289, 335.07519; Calc for [C26H34LaN408]+ and ²²[C26H35LaN408]2+, respectively: 669.14346, 335.07537.²

[0141] Preparation of [Lu(macropa)r.²¨² coo 00C² / ²K\--N Lu3+²93²<DP=94>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²To a suspension H2macropa.2HC1.4H20 (0.0730 g, 0.108 mmol) in 2-propanol (2 ²mL) was ²added triethylamine (61.5 RL, 0.441 mmol). The pale-gold solution was heated ²at reflux for 25 ²min before a solution of aq. Lu(C104)3 (0.1372 g, 0.118 mmol Lu) in 2-propanol ²(1.8 mL) was ²added dropwise. A precipitate formed immediately. After stirring at reflux or ²an additional 1 h, ²the cream suspension was triturated at RT for 20 h and then centrifuged. The ²supernatant was ²removed, and the pellet was washed with 2-propanol (2 x 2 mL) and then air-²dried on filter ²paper to give the title complex as a pale-tan solid (0.0605 g) containing ²residual 2-propanol and ²triethylamine salt. 1H NMR (600 MHz, D20, pD zt 7-8) 6= 7.85 (t, J= 7.7 Hz, ²2H), 7.52 (d, J= ²7.8 Hz, 2H), 7.37 (d, J = 7.6 Hz, 2H), 4.68 (d, J = 16.3 Hz, 2H), 4.56 (td, J ²= 11.2, 1.7 Hz, 2H), ²4.42-4.38 (m, 2H), 4.23-4.19 (m, 6H), 4.07 (d, J= 16.3 Hz, 2H), 3.96-3.87 (m, ²2H), 3.71-3.63 ²(m, 4H), 3.38 (td, J= 10.0, 4.7 Hz, 2H), 3.00 (m, 2H), 2.93 (d, J = 13.1 Hz, ²2H), 2.52 (dt, J = ²14.8, 4.5 Hz, 2H). 13CI1H} APT NMR (126 MHz, D20, pD 7-8) 6= 172.13, 158.67, ²148.98, ²141.81, 127.38, 122.83, 75.33, 73.12, 71.97, 71.70, 64.65, 57.37, 55.08. IR ²(cm-1): 3400, 1639, ²1396, 1274, 1091, 913, 770, 678, 622. HPLC tR = not stable (Method A). FIRMS ²(m / z): ²705.17772; Calc for [C26H34LuN408]+: 705.17788.²

[0142] Preparation of dimethyl 4-aminopyridine-2,6-dicarboxylate (4). ²Me00C NCOOMe²NH2²4²Dimethyl 4-azidopyridine-2,6-dicarboxylate (3, 0.9445 g, 4.0 mmol), 10% Pd / C ²(0.1419 g), and ²DCM:Me0H (1:1, 18 mL) were combined in a round-bottom flask. After purging the ²flask with ²a balloon of H2, the reaction was stirred vigorously at room temperature under ²an H2 atmosphere ²for 46 h. The gray mixture was diluted with DMF (450 mL) and filtered through ²a bed of Celite. ²Following a subsequent filtration through a 0.22 [Em nylon membrane, the ²filtrate was²concentrated at 60 C under reduced pressure and further dried in vacuo to ²obtain 4 as a pale-tan ²solid (0.824 g, 98% yield). 1H NMR (500 MHz, DMSO-d6): 6= 7.36 (s, 2 H), 6.72 ²(s, 2 H), 3.84 ²(s, 6H). 13C{1H} APT NMR (126 MHz, DMSO-d6): 6= 165.51, 156.24, 148.05, ²111.99, 52.29. ²IR (cm-1): 3409, 3339, 3230, 1726, 1639, 1591, 1443, 1265, 996, 939, 787, 630, ²543. HPLC tR ²= 9.369 min (Method B). HRMS (m / z): 211.07213 [M + H]+; Calc: 211.07133.²94²<DP=95>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0143] Preparation of Ethyl 4-amino-6-(hydroxymethyl)picolinate (5).²NH2²To a refluxing suspension of 4 (0.677 g, 3.22 mmol) in absolute Et0H (27 mL) ²was added ²NaBH4 (0.1745 g, 4.61 mmol) portionwise over 1 h to give a pale-yellow ²suspension. The ²reaction was then quenched with acetone (32 mL) and concentrated at 60 C ²under reduced ²pressure to a tan solid. The crude product was dissolved in H20 (60 mL) and ²washed with ethyl ²acetate (4 x 150 mL). The combined organics were dried over sodium sulfate and ²concentrated ²at 40 C under reduced pressure. Further drying in vacuo yielded 5 as a pale-²yellow solid (0.310 ²g, 49% yield). 1H NMR (300 MHz, DMSO-d6): 6= 7.07 (d, J= 2.1 Hz, 1H), 6.78 (m, ²1H), 6.32 ²(s, 2H), 5.30 (t, J= 5.8 Hz, 1H), 4.39 (d, J= 5.6 Hz, 2H), 4.26 (q, J= 7.1 Hz, ²2H), 1.28 (t, J= ²7.1 Hz, 3H). 13C APT NW (126 MHz, DMSO-d6) 6= 165.57, 162.38, 155.68, 147.25, ²108.50, ²107.01, 63.95, 60.61, 14.24. IR (cm-1): 3439, 3217, 2974, 2917, 1717, 1643, ²1600, 1465, 1396, ²1378, 1239, 1135, 1022, 974, 865, 783. HPLC tR = 8.461 min (Method B). HRMS ²(m / z): ²197.09288 [M +1-1]+; Calc: 197.09207.²

[0144] Preparation of Ethyl 4-amino-6-(chloromethyl)picolinate (6).²NH2²6²A mixture of thionyl chloride (2.5 mL) and 5 (0.301 g, 1.53 mmol) was stirred ²in an ice bath for ²1 h, and then at RT for 30 min. The yellow-orange emulsion was concentrated at ²40 C under ²reduced pressure to an oily residue. The residue was neutralized with sat. aq. ²NaHCO3 (12 mL) ²and then extracted with ethyl acetate (75 mL). The organic extract was washed ²with H20 (2 ²mL), dried over sodium sulfate, and concentrated at 40 C under reduced ²pressure. Further ²drying in vacuo gave 6 as an amber wax (0.287 g, 80% yield, corrected for ²residual ethyl ²acetate). 1H NMR (500 MHz, DMSO-d6) 6= 7.18 (d, J= 2.1 Hz, 1H), 6.78 (d, J= ²2.1 Hz, 1H), ²6.62 (br s, 2H), 4.62 (s, 2H), 4.29 (q, J= 7.1 Hz, 2H), 1.30 (t, J= 7.1 Hz, ²3H). 13C{1H} APT²<DP=96>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²NMR (126 MHz, DMSO-d6) 6= 164.75, 156.42, 156.19, 147.17, 109.79, 109.50, ²60.97, 46.47, ²14.15. IR (cm-1): 3452, 3322, 3209, 2978, 2922, 1726, 1639, 1604, 1513, 1465, ²1378, 1248, ²1126, 1026, 983, 861, 783, 752, 700. HPLC tR = 12.364 min (Method B). HRMS ²(m / z): ²215.05903 [M + HIP; Calc: 215.05818.²

[0145] Preparation of Methyl 641,4,10,13-tetraoxa-7,16-diazacyclooctadecan-7-²Amethyl)picolinate (9.2TFA.1H20).²COOMe² / __ \² / -0 0- \²FAN?²<'\----0\²9²To a clear and colorless solution of 1,7,10,16-tetraoxa-4,13-²diazacyclooctadecane (7, 1.9688 g, ²7.5 mmol) and diisopropylethylamine (0.8354 g, 6.5 mmol) in dry ACN (1.075 L) ²at 75 C was ²added dropwise a solution of 6 (0.9255 g, 5.0 mmol) in dry ACN (125 mL) over 2 ²h 40 min. ²The flask was then equipped with a condenser and drying tube, and the slightly-²yellow solution ²was heated at reflux for 42 h. Subsequently, the dark-gold solution containing ²fine, white ²precipitate was concentrated at 60 C under reduced pressure to an amber oil. ²To the crude oil ²was added 10% Me0H / H20 containing 0.1% TFA (10 mL). The slight suspension was ²filtered, ²and the filtrate was purified by preparative HPLC (Method A). Pure fractions ²were combined, ²concentrated at 60 C under reduced pressure, and then lyophilized to give 9 ²(1.6350 g, 50% ²yield) as a pale-orange solid. 1H NMR (500 MHz, DMSO-d6) 6= 8.75 (br s, 2H), ²8.17-8.06 (m, ²2H), 7.83 (dd, J= 7.4, 1.5 Hz, 1H), 4.68 (br s, 2H), 3.91 (s, 3H), 3.85 (br t, ²J= 5.1 Hz, 4H), 3.69 ²(t, J = 5.1 Hz, 4H), 3.59 (br s, 8H), 3.50 (br s, 4H), 3.23 (br t, J= 5.1 Hz, ²4H). 13C{I-H} APT ²NMR (126 MHz, DMSO-d6) 6 164.68, 158.78-157.98 (q, TFA), 151.44, 147.13, ²139.01, 128.63, ²124.87, 120.08-113.01 (q, TFA), 69.33, 69.00, 65.31, 64.60, 56.43, 53.29, ²52.67, 46.32. 1-9F ²NMR (470 MHz, DMSO-d6) 6= -73.84. EA Found: C, 43.88; H, 5.29; N, 6.28. Calc. ²for ²C2oH33N306.2CF3COOH.1H20: C, 43.84; H, 5.67; N, 6.39. HPLC tR = 12.372 min ²(Method B). ²HRMS (m / z): 412.24568 [M + H]P; Calc: 412.24421.²96²<DP=97>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0146] Preparation of Ethyl 4-amino-6-016-06-(methoxycarbonyl)pyridin-2-²yl)methyl)-²1,4,10,13-tetraoxa- 7,16-diazacyclooctadecan-7-yl)methyl)picolinate (10).²C00Me EtO0C²IN / .--0 / \O¨\ NL7-NE12²4 / -1²Into a round-bottom flask equipped with a condenser and drying tube were added ²9 (0.4210 g, ²0.64 mmol), Na2CO3 (0.3400 g, 3.2 mmol), and dry ACN (10 mL). The pale-yellow ²suspension ²was heated to reflux over 15 min, after which 6 (0.1508 g, 0.70 mmol, ²corrected for residual ²ethyl acetate) was added as a slight suspension in dry ACN (3.5 mL). The ²mixture was heated at ²reflux for 44 h and then filtered. The orange filtrate was concentrated at 60 ²C under reduced ²pressure to an orange-brown oil (0.612 g), which was used in the next step ²without further ²purification. HRMS (m / z): 590.32021 [M + H]; Calc: 590.31844.²

[0147] Preparation of 4-Amino-6-416-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-²tetraoxa-7,16-diazacyclooctadecan-7-y1)methyppicolinic acid (11.4TFA).²COOH HOOC²( ¨²IN \O f\r / ²0 iN²Compound 10 (0.612 g) was dissolved in 6 M HC1 (7 mL) and heated at 90 C for ²17 h. The ²orange-brown solution containing slight precipitate was concentrated at 60 C ²under reduced ²pressure to a pale-tan solid. To this solid was added 10% Me0H / H20 containing ²0.1% TFA (3 ²mL). The slight suspension was filtered and the filtrate was purified by ²preparative HPLC using ²Method A. Pure fractions were combined, concentrated at 60 C under reduced ²pressure, and ²then lyophilized to give 11 as an off-white solid (0.2974 g, 46% yield over 2 ²steps). 1H NMR ²(500 MHz, DMSO-d6) 6= 8.13-8.08 (m, 2H), 7.80 (dd, J= 7.3, 1.6 Hz, 1H), 7.64 ²(br s), 7.24 (d, ²J= 2.3 Hz, 1H), 6.76 (d, J= 2.3 Hz, 1H), 4.74 (s, 2H), 4.15 (s, 2H), 3.85 (t, ²J = 5.0 Hz, 4H), ²3.63 (t, J = 5.1 Hz, 4H), 3.57-3.50 (m, 12H), 3.09 (br t, J= 5.2 Hz, 4H). ²13C{1H} NMR (126²97²<DP=98>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²MHz, DMSO-d6) 6 165.96, 163.37, 159.47, 158.78-157.98 (q, TFA), 151.93, ²151.64, 148.25,²144.68, 139.59, 128.43, 124.96, 120.79-113.68 (q, TFA), 109.40, 108.96, 70.03, ²69.89, 67.09, ²65.16, 57.28, 55.85, 54.47, 53.81. 19F NMR (470 MHz, DMSO-d6) 6= ¨74.03. EA ²Found: C, ²40.60; H, 4.29; N, 7.04. Calc. for C26H37N508.4CF3COOH: C, 40.69; H, 4.12; N, ²6.98. IR (cm²-²1): 3387, 3161, 1735, 1670, 1204, 1130, 791, 722. HPLC tR = 11.974 min (Method ²B); 11.546 ²min (Method D). HRMS (m / z): 548.26883 [M + H]; Calc: 548.27149.²

[0148] Preparation of 64(164(6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-²7,16-²diazacyclooctadecan-7- yl)methyl)-4-isothiocyanatopicolinic acid (12, macropa-²NCS).²COON HOOC²\²(r-0 NCS²\²12²macropa-Ncs²A white suspension of 11 (0.1598 g, 0.16 mmol) and Na2CO3 (0.2540 g, 2.4 mmol) ²was heated ²at reflux in acetone (10 mL) for 30 min before the slow addition of CSC12 (305 ²[IL of CSC12, ²85%, Acros Organics). The resulting orange suspension was heated at reflux for ²3 h and then ²concentrated at 30 C under reduced pressure to a pale-orange solid. The solid ²was dissolved ²portionwise in 10% ACN / H20 containing 0.2% TFA (8 mL total), filtered, and ²immediately ²purified by preparative HPLC using Method C.E1 8] Pure fractions were ²combined, concentrated ²at RT under reduced pressure to remove the organic solvent, and then ²lyophilized. Fractions that ²were not able to be concentrated immediately were frozen at ¨80 C. ²Isothiocyanate 12 was ²obtained as a mixture of white and pale-yellow solid (0.0547 g) and was stored ²at ¨80 C in ajar ²of Drierite. Calculations from 1H NMR and 19F NMR spectra of a sample of 12 ²spiked with a ²known concentration of fluorobenzene estimated that 12 was isolated as a tetra-²TFA salt. 1H ²NMR (400 MHz, DMSO-d6) 6=8.17-8.06 (m, 2H), 8.00 (s w / fine splitting, 1H), ²7.84 (d, J= 1.5 ²Hz, 1H), 7.81-7.75 (d w / fine splitting, J= 7.16 Hz, 1H), 4.71 (s, 2H), 4.64 ²(s, 2H), 3.89-3.79 ²(m, 8H), 3.62-3.46 (m, 16H). 19F NMR (470 MHz, DMSO-d6) 6= ¨74.17. IR (cm-1): ²¨3500-²2800, 2083, 2026, 1735, 1670, 1591, 1448, 1183, 1130, 796, 717. HPLC tR = ²15.053 min ²(Method B); 13.885 min (Method D). HRMS (m / z): 590.22600 [M + H]P; Calc: ²590.22791.²98²<DP=99>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²

[0149] Preparation of 6-016-((6-carboxypyridin-2-yl)methyl)-1,4,10,13-tetraoxa-²7,16-²diazacyclooctadecan-7-y1)methyl)-4-(3-methylthioureido)picolinic acid (13, ²macropa-²NHC(S)NHCH3).²COON HOOC S²¨(µ / \ NH²cN / 0 0¨) INJ\²N\-- / ²\-0 0¨ / ²13²macropa-NHC(S)NHCH3²Compound 12 was prepared as described above using 0.0873 g (0.087 mmol) of 11, ²except the ²purification step was omitted. Instead, directly to the crude solid was added ²2 M methylamine ²in THF (4 mL). The tan-orange suspension was stirred at RT for 2 h and then ²concentrated at ²RT under reduced pressure to a pale-peach solid. The solid was dissolved in ²10% ACN / H20 ²containing 0.2% TFA (2 mL), filtered, and purified by preparative HPLC using ²Method C. Pure ²fractions were combined, concentrated at 50 C under reduced pressure to ²remove the organic ²solvent, and then lyophilized. The dark-gold, slightly sticky solid was then ²recrystallized from ²ACN with Et20. The suspension was centrifuged, and the pellet was washed with ²Et20 (2 x 1.5 ²mL) and dried in vacuo to give 13 as a tan powder (0.0166 g, 22% unoptimized ²yield from 11). ²1H NIVIR (600 MHz, DMSO-d6) 6= 10.56 (s, 1H), 8.64 (br s, 1H), 8.26 (s, 1H), ²8.16 (s, 1H), ²8.13-8.02 (m, 2H), 7.81-7.73 (d, J= 7.40 Hz, 1H), 4.74-4.48 (m, 4H), 3.82 (br ²s, 8H), 3.57 (br ²s, 8H), 3.54-3.25 (m, 8 H), 2.97 (d, J= 4.4 Hz, 4H). 13C{1H} NMR (126 MHz, ²DMSO-d6) 6 ²180.71, 165.44, 165.39, 158.77-157.95 (q, TFA), 151.04, 150.96, 149.79, ²147.95, 147.71, ²139.22, 127.76, 124.55, 119.68-112.66 (q, TFA), 116.45, 114.85, 69.36, 64.52, ²64.50, 57.00, ²56.75, 53.42, 53.37, 31.02. 1-9F NMR (470 MHz, DMSO-d6) 6= ¨74.49. EA Found: ²C, 44.66; ²H, 5.36; N, 9.83. Calc. for C28H4oN608S.2CF3COOH.1H20: C, 44.34; H, 5.12; N, ²9.70. FIPLC ²tR = 14.067 min (Method B). HRMS (m / z): 621.26799 [M + H]P; Calc: 621.27011.²

[0150] Preparation of Macropa-(OCH2CH2)-Ph-NCS²A schematic overview of the synthesis of an alternative embodiment of Macropa-²NCS, having ²improved stability is provided in FIG. 3. This compound is evaluated as ²described below, and ²useful in the chelation of radionuclides for their conjunction to antibodies, ²antibody fragments ²(e.g., antigen-binding fragments), and peptides, and their consequent use in ²the manufacture of²99²<DP=100>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²therapeutic compounds and targeted delivery of therapeutic radation. The ²detailed synthesis ²information is provided below.²Os²tagE²A solution of compound 1 (0.725g, 3 mmol), Ph3P (0.802g, 3.1 mmol) in CH2C12 ²(15 mL) was ²cooled to 0 C under N2. NBS (2.180.545g, 3.3 mmol) was added portion wise for ²5 min The ²resulting solution was stirred for 2 hrs at 0 C and concentrated. Resulting ²crude product was ²concentrated and purified by combi-flash (5-10% Et0Ac in hexane) to give ²compound 2 (yield= ²76%).²1414²11,o6²2²To a solution of dimethyl 4-hydroxypyridine-2,6-dicarboxylate (0.253g, ²1.2mmol) and Cs2CO3 ²(0.650g, 2 mmol) in DIVIF (6 mL) was added drop-wise compound 2 (0.299g, 1 ²mmol) in DIVIF (2 ²mL) under a N2 condition. The resulting solution was stirred for 24 hrs at ²room temperature. The ²DMF was removed under reduced pressure and water was added, extracted with ²DCM. Resulting ²crude product was concentrated and purified by combi-flash (5-10% Et0Ac in ²hexane) to give ²compound 3 (yield= 21%).²100²<DP=101>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²64v ?ft²Mil²MI fa²0²Nklai,i, A TM; ca!:²N²4 gH tit4tA²4²Compound 3 (0.215g, 0.5 mmol) was dissolved in DCM: Me0H (2:1, 15 mL) and ²NaBH4 (0.020g, ²0.6mmo1) was added in one portion at room temperature (under a N2 condition). ²The resulting ²solution was stirred at same temperature for 3 hrs. The solvents were removed ²and water was ²added to the resulting residue and extracted into Et0Ac. The organic layer was ²removed under ²reduced pressure and resulting crude product was purified by combi-flash (50-²100% Et0Ac in ²hexane) to give compound 4 (yield= 37%). A solution of compound 4 (0.201g, ²0.5mm01), CBr4 ²(0.198g, 0.6 mmol) and K2CO3 (0.103g, 0.75 mmol) in CH2C12 (25 mL) was cooled ²to 0 C (under ²N2) was added drop-wise a solution of PPh3 (0.157g, 0.6 mmol) in (DCM, 5 mL) ²for 10 min. The ²resulting reaction mixture was stirred for 12 hrs at room temperature. Solvent ²was removed to ²result in a crude reaction mixture, which was purified by combi-flash (Et0Ac ²in hexane) to give ²compound 5 (yield= 70%).²OM²4-²: :NH²0²= N ,.²$²To a clear and colorless solution of 1,7,10,16-tetraoxa- 4,13-²diazacyclooctadecane (1.9688 g, 7.5 ²mmol) and diisopropylethylamine (0.8354 g, 6.5 mmol) in dry ACN (1.075 L) at ²75 C was added ²dropwise a solution of methyl 6-(chloromethyl)picolinate (0.9255 g, 5.0 mmol) ²in dry ACN (125²101²<DP=102>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²mL) over 2 h 40 min. The flask was then equipped with a condenser and drying ²tube, and the ²slightly-yellow solution was heated at reflux for 42 h. Subsequently, the dark-²gold solution ²containing fine, white precipitate was concentrated at 60 C under reduced ²pressure to an amber ²gummy solid, compound 6, which was used in the next step of the synthesis ²without any further ²purification.²____________ / \² / \²o o² NH H CI²o o²NH²N 0²N 0²0 / o DI PEA, ACN o o² / ² / 0²6 _________________________________________________ ft²To a stirred solution of compound 6 (0.205g, 0.5 mmol) and ²diisopropylethylamine (0 129g, 1 ²mmol) in dry ACN (10 mL) was added compound 5 (0.233g g, 0.5 mmol) in dry ACN ²(2 mL). ²The resulting ion solution was stirred at r.t for 12h. Solvent was removed and ²the crude compound ²was purified by combi-flash using Me0H in DCM to yield compound 7.²6w:4M².......²=²= 0² / = ===== =47²= 0²0 7²Compound 7 (0.08g, 0.1 mmol) was dissolved in aq 6M HC1 (5 mL) and stirred at ²room ²temperature for 2h-3h. After completion of the starting material (evidenced by ²LCMS), aq HC1 ²was removed under reduced pressure and the crude reaction mixture, containing ²compound 8 was ²used in the next step of the synthesis without any further purification.²102²<DP=103>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²a.²77² ..................................................... 0²,²0 *²The crude deboc product was dissolved in THIF:1M LiOH (1:1, 5mL) and stirred ²until completion ²of the reaction. The resulting crude product was purified by prep-HPLC giving ²compound 9.²MA²Wq²b (:-²4 )²t $4 / 0 0²L1 / 4....re 1 . awl²014 01,1²0 t²$²0²NEt3 (7.6 mg, 0.076 mmol) was added to a solution of compound 9 (26 mg, 0.038 ²mmol) in (8:2)²acetonitrile and water (1 mL). Next, di-2-pyridyl thionocarbonate (18m g, ²0.076mmo1) was added²at room temperature and stirred vigorously for 1 h. The crude reaction ²solution was directly²purified by HPLC giving compound 10 (macropa-(OCH2CH2)-Ph-NCS).²SCN²= 0² )OH HO² / \ _______________________________________________ / 0 N)²0 ________________________ cil\T _______ 0 )_²N N²0 0²\ _____________________________________________ / ²macropa-(OCH2CH2)-Ph-NCS²103²<DP=104>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0151] X-Ray Diffraction Studies. Single crystals of H2macropa.2HC1=4H20 ²suitable for x-²ray diffraction were grown from a saturated H20: acetone (1:5) solution upon ²standing at room ²temperature. Single crystals of [La(Hmacropa)(H20)]=(C104)2 were grown via ²vapor diffusion ²of THF into an aqueous solution made acidic (pH ¨2) upon addition of the ²complex. Single ²crystals of [Lu(macropa)]=C104.DMF were grown via vapor diffusion of Et20 into ²a DI\TF ²solution of the complex.²

[0152] X-ray diffraction data for H2macropa=2HC1.4H20, [La(Hmacropa)(H20)]= ²(C104)2, and ²[Lu(macropa)]=C104.DMF were collected on a Bruker APEX 2 CCD Kappa ²diffractometer (Mo ²Ka, 2 = 0.71073 A) at 223 K. The structures were solved through intrinsic ²phasing using ²SHELXT11" and refined against F2 on all data by full-matrix least squares with ²SHELXL[11 1 ²following established refinement strategies."] All non-hydrogen atoms were ²refined ²anisotropically. Hydrogen atoms were included in the model at geometrically ²calculated ²positions and refined using a riding model. Hydrogen atoms bound to nitrogen ²and oxygen were ²located in the difference Fourier synthesis and subsequently refined semi-²freely with the help of ²distance restraints. The isotropic displacement parameters of all hydrogen ²atoms were fixed to ²1.2 times the U value of the atoms they are linked to (1.5 times for methyl ²groups). For ²[La(Hmacropa)(H20)]= (C104)2, a partially occupied solvent molecule of water ²was included in ²the unit cell but could not be satisfactorily modeled. Therefore, that solvent ²was treated as a ²diffuse contribution to the overall scattering without using specific atom ²positions by the solvent ²masking function in Olex2.

[112] ²

[0153] La3+ and Lu3+ Titrations with Macropa. The pH of a 10 mM 3-(N-²morpholino)propanesulfonic acid (MOPS) buffer was adjusted to 7.4 using ²aqueous NMe4OH. ²The ionic strength was set at 100 mM using NMe4C1. Stock solutions of ²LaC13=6.8H20 (40 ²mM) and LuC13=6H20 (21 mM) were prepared in 1 mM HC1. A stock solution of ²H2macropa=2HC1.4H20 (8.8 mM) was prepared in MOPS buffer. From these stock ²solutions, ²titration solutions containing macropa (100 M) and either LaC13 or LuC13 were ²prepared in ²MOPS. Each metal ion titration was carried out at RT by adding 5-10 [IL ²aliquots of titrant to a ²cuvette containing 3000 1_, of macropa (100 04) in MOPS. Each sample was ²allowed to ²equilibrate for 5 min following every addition before a spectrum was acquired. ²Complexation of ²the metal ion was monitored by the decrease in absorbance at 268 nm, the Xmax ²of macropa. ²Titrant was added until no further spectral changes were detected.²104²<DP=105>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0154] Kinetic Inertness of La3+ and Lu3+ Complexes of Macropa: Transchelation ²²Challenge. A stock solution of ethylenediaminetetraacetic acid (EDTA, 100 mM) ²was made in ²MOPS buffer (prepared as described above) by adjusting the pH of the initial ²suspension to 6.6 ²using aqueous NMe4OH. A stock solution of diethylenetriaminepentaacetic acid ²(DTPA, 125 ²mM) was prepared in H2O by adjusting the pH to 7.4 as described for EDTA. This ²solution was ²serially diluted with H20 to yield 12.5 mM and 1.25 mM solutions of DTPA.²

[0155] The preformed La3+ and Lu3+ complexes of macropa were challenged with ²EDTA. ²Challenges were initiated by adding an aliquot of solution containing EDTA ²(98.7 mM) and ²macropa (100 [tM) in MOPS buffer to each solution of complex. The final ratios ²of ²M:macropa:EDTA were approximately 1:1:20 (La) and 1:1:10 (Lu). Solutions were ²repeatedly ²analyzed by UV spectroscopy over the course of 21 days for any spectral ²changes. The final pH ²of each solution was between 7.18 and 7.25.²

[0156] The complex formed in situ between La3+ and macropa was more rigorously ²challenged ²with excess DTPA. A solution containing 500 [tM of complex, prepared using the ²LaC13 and ²macropa stock solutions described above, was left to equilibrate for 5 min. ²Subsequently, it was ²portioned into cuvettes and diluted with either 125 mM DTPA, 12.5 mM DTPA, ²1.25 mM ²DTPA, or MOPS to yield solutions containing 1000-, 100-, 10-, or 0-fold excess ²DTPA and 100 ²[NI concentration of macropa. These solutions were repeatedly analyzed by UV ²spectroscopy ²over the course of 21 days for any spectral changes. The final pH of each ²solution was between ²7.11 and 7.42.²

[0157] 225Ac Radiolabeling of Macropa and DOTA. 225AC and 225Ra were produced ²by the ²spallation of uranium carbide, separated downstream from other radionuclides ²by a mass ²separator using the Isotope Separator and Accelerator (ISAC) isotope ²separation on-line (ISOL) ²facility at TRIUMF (Vancouver, BC, Canada), and were collected via literature ²protocols.[103,104] ²225AC was then separated from 225Ra via DGA column[ 105,106] (branched, 50-100 ²p.m, Eichrom ²Technologies LLC) and obtained in 0.05 M HNO3 for use in radiolabeling ²experiments. ²Aluminum-backed TLC plates (silica gel 60, F254, EMD Millipore, Darmstadt, ²Germany) were ²used to analyze 225AC radiolabeling reaction progress. Instant thin layer ²chromatography paper ²impregnated with silica gel (iTLC-SG, Agilent Technologies, Mississauga, ON, ²Canada) was ²used in La' and serum stability challenges. TLC plates were developed and then ²counted on a ²BioScan System 200 imaging scanner equipped with a BioScan Autochanger 1000 ²and WinScan ²software at least 8 h later to allow time for daughter isotopes to decay ²completely, ensuring that²105²<DP=106>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²the radioactive signal measured was generated by parent 225Ac. Quantitative ²radioactivity ², 221²measurements of 225Ac Fr, and 213Bi were determined via gamma-spectroscopy ²using a high-²purity germanium (HPGe) detector (Canberra GR1520, Meriden, CT) calibrated ²using a NIST-²traceable mixed 133Ba. and 152Eu source. Detector dead time was maintained ²below 10% for all ²measurements. Data was analyzed using Genie 2000 software (v3.4, Canberra, ²Meriden, CT). ²

[0158] Concentration Dependence. Various concentrations of macropa and DOTA ²were ²radiolabeled with 225AC3+ to determine the lowest concentration at which >95% ²radiolabeling ²still occurred. Stock solutions of H2macropa.2HC1.4H20 (10-3-10-8M) and H4DOTA ²(10-3, ²10-5, and 10-7M) were prepared in H20. For each radiolabeling reaction, ligand ²(10 [tL) and ²225Ac²(10-26 kBq, 10-30 IlL) were sequentially added to NH40Ac buffer (pH 6, 0.15 M, ²150 ²!IL) to give final ligand concentrations of 5.3 x 10-5-5.9 x 10-1 M for ²macropa and 5.9 x ²5.9 x 10-9M for DOTA. The final pH of all labeling reactions was between 5.5 ²and 6. The ²reaction solutions were maintained at ambient temperature or 80 C. Reaction ²progress was ²monitored at 5 and 30 min by spotting 3-5 pt of the reaction solution onto TLC ²plates. The ²plates were developed with a mobile phase of 0.4 M sodium citrate (pH 4) ²containing 10% ²Me0H and then counted. Under these conditions, [225Ac(macropa)] and ²[225Ac(DOTA)]-²remained at the baseline (RF=0) and any unchelated225Ac (225Ac-citrate) ²migrated with the ²solvent front (RF=1). Radiochemical yields (RCYs) were calculated by ²integrating area under ²the peaks on the radiochromatogram and dividing the counts associated with the ²225Ac-complex ²(RF=0) by the total counts integrated along the length of the TLC plate.²

[0159] Kinetic Inertness of 225AC Complexes of Macropa and DOTA.²

[0160] General. Stock solutions of La(NO3)3 (0.001 M or 0.1 M) were prepared ²in H20. To ²the radiolabeled samples containing macropa (10 tit, of 10-5M stock; 1.0 x 10-²1 moles) or ²DOTA (10 [IL of 10-3M stock; 1.0 x 10-8 moles) and 225Ac (10 [tL, 26 kBq) in ²NH40Ac buffer ²(pH 6, 0.15 M, 150 [EL), a 50-fold mole excess of La3+ was added (54 of 0.001 ²M or 0.1 M ²stock were added to solutions containing macropa and DOTA, respectively). The ²solutions were ²kept at room temperature and analyzed by iTLC at several time points over the ²course of 8 days. ²The iTLC plates were developed using citric acid (0.05 M, pH 5) as the eluent. ²Under these ²conditions, [225Ac(macropa)] and [225Ac(DOTA)]- remained at the baseline ²(RF=0) and any ²unchelated 225AC (225Ac-citrate) migrated with the solvent front (RF=1). ²Percent of complex ²remaining intact was calculated by integrating area under the peaks on the ²radiochromatogram²106²<DP=107>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²and dividing the counts associated with the 225Ac-complex (RF=0) by the total ²counts integrated ²along the length of the iTLC plate.²

[0161] Transmetalation by La3 ,225+. Ac(macropa)r and [225Ac(DOTA)]- were ²prepared using ²10-5 M and 10-3 M stock solutions (10 pL) of macropa and DOTA, respectively, ²to give final ²ligand concentrations of 5.9 x 10-7 M (macropa) and 5.9 x 10-5 M (DOTA). After ²confirming a ²radiochemical yield of >90% by TLC using 0.4 M sodium citrate (pH 4) ²containing 10% Me0H ²as the mobile phase, 160 [IL of human serum (an equal volume based on labeling ²reaction ²volume) were added to each radiolabeled solution. A control solution was also ²prepared in ²which water was substituted for ligand. The solutions were monitored over the ²course of 8 days ²by iTLC. The plates were developed with EDTA (50 mM, pH 5) as the eluent. ²Under these ²conditions, [225Ac(macropa)] and [225Ac(DOTA)]- complexes remained at the ²baseline (RF=0) ²and any 225Ac (225Ac-EDTA) that had been transchelated by serum migrated with ²the solvent ²front (RF=1). Percent of complex remaining intact was calculated.²

[0162] In Vivo Biodistribution of 225AC Complexes of Macropa and DOTA. All ²experiments were approved by the Institutional Animal Care Committee (IACC) of ²the ²University of British Columbia and were performed in accordance with the ²Canadian Council on ²Animal Care Guidelines. A total of 9 female C57BL / 6 mice (6-8 weeks old, 20-25 ²g) were ²used for the biodistribution study of each radiometal complex, n = 3 for each ²time point.²

[0163] Macropa (100 a of a lmg / mL solution in NH40Ac) was diluted with 387 [IL ²of ²NI-140Ac (1 M, pH 7), and an aliquot (203 [tL) of 225Ac(NO3)3 (-157 kBq) was ²then added; the ²pH of this solution was adjusted to 6.5-7 by the addition of 1 M NaOH (210 ²[tL, trace metal ²grade). After 5 min at ambient temperature, the reaction solution was analyzed ²by TLC (0.4 M ²pH 4 sodium citrate as the eluent), which confirmed >95% radiochemical yield. ²The reaction ²was allowed to proceed overnight, and the radiochemical yield was again ²confirmed to be >95% ²the following morning. At this time, mice were anesthetized by 2% isoflurane, ²and ²approximately 100 [IL (10-15 kBq) of the [225Ac(macropa)] complex were ²injected into the tail ²vein of each mouse. After injection, mice were allowed to recover and roam ²freely in their ²cages, and were euthanized by CO2 inhalation at 15 min, 1 h, or 5 h (n = 3 at ²each time point) ²post-injection. Blood was collected by cardiac puncture and placed into an ²appropriate test tube ²for scintillation counting. Tissues collected included heart, liver, kidneys, ²lungs, small intestine, ²large intestine, brain, bladder, spleen, stomach, pancreas, bone, thyroid, ²tail, urine, and feces. ²Tissues were weighed and then counted with a calibrated gamma counter ²(Packard, Cobra II²107²<DP=108>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²model 5002) using three energy windows: 60-120 keV (window A), 180-260 keV ²(window B), ²and 400-480 keV (window C). Counting was performed both immediately after ²sacrifice and ²after 7 days; counts were decay corrected from the time of injection and then ²converted to the ²percentage of injected dose (% ID) per gram of tissue (% ID / g). No differences ²were noted ²between the data; therefore, the biodistributions are reported using the data ²acquired ²immediately using window A.²

[0164] The biodistribution studies of [225Ac(DOTA)] and 225Ac(NO3)3 were ²carried out as ²described above for [225Ac(macropa)]+, with the following modifications. ²[225Ac(DOTA)- was ²prepared by adding 225Ac(NO3)3 (338 [tL, 1.1 MBq) to a solution of DOTA (100 ²ug, 20 mg / mL ²in H20) in NH40Ac (467 uL, 0.15 M, pH 7). The pH of the solution was adjusted ²to 7 using ²NH40Ac (150 uL, 1 M, pH 7) and the solution was heated at 85 C for 45 min. ²RCY > 99% was ²confirmed by TLC as described above. [225Ac(DOTA)]- was diluted with saline to ²a final ²concentration of 0.05 MBq / 100 pL, and 100 uL were injected into each mouse. ²225Ac(NO3)3 ²(-58 pL, 0.4 MBq) was diluted and injected in the same manner as [225Ac(DOTA)]-². One ²mouse that was to be euthanized at the 5 h time point in the [225Ac(DOTA)]- ²study died shortly ²after injection. In the same manner, one mouse that was to be euthanized at ²the 1 h time point in ²the 225Ac(NO3)3 study died.²

[0165] Hydrolysis of Macropa-NCS and p-SCN-Bn-DOTA. To screw-capped vials ²containing approximately 1 mg of macropa-NCS (compound 12, n = 4) orp-SCN-Bn-²DOTA (n ²= 5) was added 1 mL of 0.1 M pH 9.1 NaHCO3 buffer containing 0.154 M NaC1, ²which had ²been passed through a column of pre-equilibrated Chelex. After stirring for 1 ²min, each solution ²was filtered through a 0.2 [tm PES or PTFE membrane. Five pL aliquots were ²removed from ²the vials at various time points over the course of 46-72 h and analyzed by ²HPLC. Method D ²was employed for macropa-NCS. Method B was employed for p-SCN-Bn-DOTA using an ²Epic ²Polar C18 column, 120 A, 10 m, 25 cm x 4.6 mm (ES Industries, West Berlin, ²NJ) at a flow ²rate of 1 mL / min. Between samplings, the vials were stored at room temperature ²(23 1 C) ²away from light. Hydrolysis was considered complete once the peak at 13.8 min ²(corresponding ²to 12) or 18.417 min (corresponding to p-SCN-Bn-DOTA) had disappeared or had ²negligible ²integration. A linear regression performed on the plots of ln peak area versus ²time provided the ²pseudo-first order rate constant (kobs) as the negative slope. The half-life ²(t112) was calculated ²using the equation 6 / 2= 0.693 / kobs. The half-life of each compound is reported ²as the mean + 1 ²standard deviation.²108²<DP=109>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0166] Titration of Macropa-NHC(S)NHCH3 Conjugate with La'. The titration of ²the ²macropa-NHC(S)NHCH3 conjugate (13) with La3+ was carried out at pH 7.4 for ²macropa, ²except that the stock solution of 13 (0.760 mM) was prepared in ACN instead of ²MOPS. The ²amount of ACN in the sample did not exceed 3.3% by volume. A wait time of 3 ²min after the ²addition of each aliquot was found to be sufficient for the sample to reach ²equilibrium before ²spectral acquisition. Complexation of the metal ion was monitored using the ²increase in ²absorbance at 300 nm. The pH of the solution at the end of the titration was ²7.43.²

[0167] Kinetic Inertness of La-Macropa-NHC(S)NHCH3: Transchelation Challenge. ²Solutions of diethylenetriaminepentaacetic acid (DTPA; 125 mM and 12.5 mM) ²were prepared ²in MOPS buffer (pH 7.4). A MOPS solution containing macropa-NHC(S)NHCH3 (126.7 ²p,M, ²16.7% ACN by volume) and LaC13 (126.2 1..EM) was prepared using the stock ²solutions described ²above and was left to equilibrate for 10 min. Subsequently, it was portioned ²into cuvettes and ²diluted with either 125 mM DTPA, 12.5 mM DTPA, or MOPS to yield solutions ²containing ²1000-, 100-, or 0-fold excess DTPA. The final concentration of macropa-²NHC(S)NHCH3 in ²each cuvette was 25.3 [tM. These solutions were repeatedly analyzed by UV ²spectrophotometry ²over the course of 21 days for any spectral changes. The final pH of each ²solution was between ²7.42 and 7.49. The experiment was performed in triplicate.²

[0168] Exemplary Synthesis and Biological Activity of 225Ac-macropa-RPS-070 ²

[0169] Preparation of Di-tert-butyl (((S)-1-(tert-butoxy)-6-(3-(3-²ethynylphenyl)ureido)-1-²oxohexan-2-yl)carbamoy1)-L-glutamate (214).²dim²HN N²H²CO2tBu²0²co,tBu²214²Alkyne 214 was prepared according to published methods'' and isolated as an ²off-white ²powder. 11-1NMIR (500 MHz, CDC13) 6= 7.90 (s, 1H), 7.58 (t, 1H, J= 1.7 Hz), ²7.51 (dd, 1H, Ji ²= 8.2 Hz, J2 = 1.3 Hz), 7.18 (t, 1H, J= 7.9 Hz), 7.05 (d, 1H, J = 7.7 Hz), ²6.38 (d, 1H, J = 7.9 ²Hz), 6.28 (br s, 1H), 5.77 (d, 1H, J= 6.9 Hz), 4.32 (m, 1H), 4.02 (m, 1H), ²3.53 (m, 1H), 3.05 (m, ²1H), 3.00 (s, 1H), 2.39 (m, 2H), 2.07 (m, 1H), 1.88 (m, 1H), 1.74 (m, 1H), ²1.62 (m, 1H), 1.49-²1.37 (m, 4H), 1.41 (s, 18H), 1.37 (s, 9H).²109²<DP=110>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0170] Preparation of 2,5-Dioxopyrrolidin-1-y1 N2-(((9H-fluoren-9-²yl)methoxy)carbony1)-²N6-(tert- butoxycarbony1)-L-lysinate (215).²N-1Boc²0²FmocHN - 'NI I²0 õ,=(²i 1²0 ,*---- / ²215²A suspension of Fmoc-L-Lys(Boc)-OH (5.0 g, 10.7 mmol) and N,Ar-disuccinimidyl ²carbonate ²(2.74 g, 10.7 mmol) in CH2C12 (50 mL) was stirred at room temperature under ²argon. Then ²DIPEA (1.86 mL, 10.7 mmol) was added, and the suspension was stirred ²overnight. The solvent ²was evaporated under reduced pressure and the crude product was purified by ²flash ²chromatography (0-100% Et0Ac in hexane). Lysine 215 was isolated as a white ²powder (2.5 g, ²41%). 1H NMR (500 MHz, CDC13) 6= 7.76 (d, 2H, J = 7.6 Hz), 7.59 (d, 2H, J = ²7.3 Hz), 7.40 ²(t, 2H, J = 7.4 Hz), 7.32 (t, 2H, J = 7.3 Hz), 5.46 (br s, 1H), 4.71 (m, 2H), ²4.45 (m, 2H), 4.23 (t, ²1H, J= 6.6 Hz), 3.14 (br s, 2H), 2.85 (s, 4H), 2.02 (m, 1H), 1.92 (m, 1H), ²1.58 (m, 4H), 1.44 (s, ²9H).²

[0171] Preparation of tert-Butyl N2-(N2-(((9H-fluoren-9-yl)methoxy)carbony1)-²N6-(tert-²butoxycarbony1)-L- lysyl)-N6-((benzyloxy)carbony1)-L-lysinate (216).²NHBoc²l--.².11 H²FmocHN 1,.N.y.....,õ--..,,.NHCbz²o co,tBu²216²A suspension of L-Lys(Z)-0tBu.HC1 (1.49 g, 4.0 mmol) in CH2C12 (15 mL) was ²treated with ²DIPEA (0.87 mL, 5.0 mmol). To the resulting mixture was added a solution of ²lysine 215 (2.2 ²g, 3.9 mmol) in CH2C12 (10 mL), and the reaction was stirred overnight at room ²temperature ²under argon. It was then washed with saturated NaCl solution, and the organic ²layer was dried ²over MgSO4, filtered and concentrated under reduced pressure. The crude ²product was purified ²by flash chromatography (0-100% Et0Ac in hexane), and di-lysine 216 was ²isolated as a white ²powder (2.2 g, 72%). 1H NMR (500 MHz, CDC13) 6= 7.76 (d, 2H, J= 7.5 Hz), 7.59 ²(d, 2H, J= ²7.3 Hz), 7.40 (t, 2H, J = 7.5 Hz), 7.32 (m, 8H), 6.69 (br s, 1H), 5.60 (br s, ²1H), 5.06 (m, 4H),²110²<DP=111>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²4.72 (br s, 1H), 4.43 (m, 1H), 4.38 (m, 1H), 4.21 (m, 1H), 3.14 (m, 4H), 1.85 ²(m, 2H), 1.73 (m, ²2H), 1.50 (m, 4H), 1.46 (s, 9H), 1.44 (s, 9H), 1.39 (m, 4H).²

[0172] Preparation of 2,5-Dioxopyrrolidin-1-y12-(4-iodophenyl)acetate (217).²0²0²217²A solution of 2-(4-iodophenyl)acetic acid (786 mg, 3.0 mmol) and EDC=HC1 (671 ²mg, 3.5 ²mmol) in CH2C12 (20 mL) was stirred for 15 min at room temperature under ²argon. Then N-²hydroxysuccinimide (368 mg, 3.2 mmol) and NEt3 (0.56 mL, 4.0 mmol) were added ²and the ²reaction was stirred for 7 h. It was then washed with saturated NaCl solution, ²and the organic ²layer was dried over MgSO4, filtered and concentrated under reduced pressure. ²The crude ²residue was purified by flash chromatography (0-100% Et0Ac in hexane), and the ²NHS ester ²217 was isolated as a white solid (760 mg, 70%). 1H NMR (500 MHz, CDC13) 6= ²7.69 (d, 2H, J ²= 7.9 Hz), 7.09 (d, 2H, J = 7.9 Hz), 3.88 (s, 2H), 2.83 (s, 4H).²

[0173] Preparation of tert-Butyl N2-(N2-(1-azido-3,6,9,12,15,18-²hexaoxahenicosan-21-²oy1)-N6-(tert-butoxycarbony1)-L-lysyl)-N6-((benzyloxy)carbony1)-L-lysinate ²(218).²NHBoc²0²N NHCbz² / 5²0 CO2tBu²218²To a solution of Fmoc-protected di-lysine 216 (768 mg, 0.97 mmol) in CH2C12 (4 ²mL) was ²added NHEt2 (2.07 mL, 20 mmol). The solution was stirred overnight at room ²temperature. ²The solvents were removed under reduced pressure, and the crude product, a ²yellow oil, was ²used without further purification. To a solution of this oil (183 mg, 0.32 ²mmol) in CH2C12 (3 ²mL) were added successively solutions of NEt3 (57 uL, 0.41 mmol) in CH2C12 (1 ²mL) and ²azido-PEG6-NHS ester (100 mg, 0.21 mmol; Broadpharm, USA) in CH2C12 (1 mL), ²and the ²reaction was stirred overnight at room temperature. It was then diluted with ²CH2C12 and washed ²successively with H20 and saturated NaCl solution. The organic layer was dried ²over MgSO4, ²filtered and concentrated under reduced pressure to give azide 218 as a ²colorless oil (184 mg; ²95%) without need for further purification. Mass (ESI+): 926.4 [M+H]t Calc. ²Mass = 925.54.²111²<DP=112>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0174] Preparation of Di-tert-butyl (((S)-1-(tert-butoxy)-6-(3-(3-(1-09S,12S)-²9-(tert-²butoxycarbony1)-12-(4-((tert-butoxycarbonyl)amino)buty1)-3,11,14-trioxo-1-²phenyl-²2,17,20,23,26,29,32-heptaoxa-4,10,13-triazatetratriacontan-34-y1)-1H-1,2,3-²triazol-4-²yl)phenyl)ureido)-1-oxohexan-2-yl)carbamoy1)-L-glutamate (219).² 0 . \²U H 0²"5²N CO2tBu²u²0 H²CO2tBu NHCbz²0²\IN²1²tBuO2C---' N N 'CO2tBu BocH N²H H²219²A solution of 100 [t.L of 0.5 M CuSO4 and 100 [IL of 1.5 M sodium ascorbate in ²DMF (0.5 mL) ²was mixed for 5 min and was then added to a solution of 218 (184 mg, 0.20 ²mmol) and 214 (132 ²mg, 0.21 mmol) in DMF (2.5 mL). The resulting mixture was stirred at room ²temperature for 45 ²min. It was then concentrated under reduced pressure and the crude residue was ²purified by ²flash chromatography (0-30% Me0H in Et0Ac) to give triazole 219 as an orange ²oil (285 mg; ²87%). Mass (ESI+): 1557.2 [M+H]. Calc. Mass = 1555.90.²

[0175] Preparation of Di-tert-butyl (0S)-1-(tert-butoxy)-6-(3-(3-(1-423S,26S)-²26-(tert-²butoxycarbony1)-23-(4-((tert-butoxycarbonyl)amino)buty1)-33-(4-iodopheny1)-²21,24,32-²trioxo-3,6,9,12,15,18-hexaoxa-22,25,31-triazatritriaconty1)-1H-1,2,3-triazol-4-²²yl)phenyl)ureido)-1-oxohexan-2-yl)carbamoy1)-L-glutamate (220).²0²Ai CO2tBu²HN N²H²-²CO27 Q²tBu 6²N²\ '²0²1\²tBuO2CN N j'CO2tBu 220 BocHN²H H ²Cbz-Protected triazole 219 (285 mg, 0.18 mmol) was dissolved in Me0H (15 mL) ²in a two-neck ²flask. To the solution was added 10% Pd / C (20 mg), and the suspension was ²shaken and the ²flask evacuated. The suspension was then placed under an H2 atmosphere and ²stirred overnight. ²It was filtered through celite, and the filter cake was washed three times ²with Me0H. The ²combined filtrate was concentrated under reduced pressure to give the free ²amine as a colorless ²oil (117 mg; 45%) that was used without further purification. Mass (ESI+): ²1423.8 [M+H]. ²Calc. Mass = 1422.77. To a solution of the amine (117 mg, 82 mop in CH2C12 (4 ²mL) was ²added a solution of DIPEA (23 !IL, 131 mmol) in CH2C12 (1 mL), and the mixture ²was stirred at²112²<DP=113>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479 ²room temperature under argon. Then a solution of 217 (37 mg, 103 ilmol) in ²CH2C12 (2 mL) ²was added, and the reaction was stirred at room temperature for 2 h. It was ²then poured into ²H20 (10 mL) and the layers were separated. The organic layer was dried over ²MgSO4, filtered ²and concentrated under reduced pressure to give the crude product as a ²colorless semi-solid. ²The crude product was purified by prep TLC (10% Me0H in Et0Ac) to give phenyl ²iodide 220 ²as a colorless oil (34 mg; 25%). Mass (ESI+): 1666.6 [M+Hr Calc. Mass = ²1665.80. ²

[0176] Preparation of (((S)-1-Carboxy-5-(3-(3-(14(23S,26S)-26-carboxy-23-(4-(3-²(2-²carboxy-6-016-((6-carboxypyridin-2-yOmethyl)-1,4,10,13-tetraoxa-7,16-²diazacyclooctadecan-7-yl)methyl)pyridin-4-yl)thioureido)buty1)-33-(4-²iodopheny1)-²21,24,32-trioxo-3,6,9,12,15,18-hexaoxa-22,25,31-triazatritriaconty1)-111-1,2,3-²triazol-4-²yl)phenyl)ureido)pentyl)carbamoy1)-L-glutamic acid (221, macropa-RPS-070).²HO2q)_.²C-01--"&"\ii01'²f¨N N²o-)²NH²HN4²P NH ²fO ². o²Ho,c =²0²_J²HN52²N²H²CO2H²1²õ²221²HO2C---'-N-- CO2H macropa-RPS-070²H H -²To a solution of 220 (34 mg, 20 ttmol) in CH2C12 (2 mL) was added TFA (0.5 ²mL), and the ²reaction was stirred at room temperature for 5 h. It was then concentrated ²under reduced ²pressure, and the crude product was diluted with H20 and lyophilized to give ²the free amine as a ²TFA salt. Mass (ESI+): 1342.5 [M+H]t Mass (ESI-): 1340.6 [M-H]. Calc. Mass = ²1341.50. ²To a solution of the amine (9 mg, 6.7 mop in DMF (0.5 mL) was added a ²solution of macropa-²NCS (15 mg, 25.4 [tmol) in DMF (0.5 mL). Then DIPEA (300 ?IL, 1.72 mmol) was ²added and ²the reaction was stirred at room temperature for 2 h. The volatiles were ²removed under reduced ²pressure and the crude product was purified by prep HPLC to give macropa-RPS-²070 (221) as²113²<DP=114>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²a white powder (5.4 mg; 42%). Mass (ESI+): 1932.76 [M+H]. 1931.09 [M+H]. Calc. ²Mass = ²1931.91.²

[0177] Preparation of Radiosynthesis of 225Ac-macropa-RPS-070.²

[0178] General. All reagents were purchased from Sigma Aldrich unless ²otherwise noted, and ²were reagent grade. Hydrochloric acid (HC1) was traceSELECT (>99.999%) for ²trace analysis ²quality. Aluminum-backed silica thin layer chromatography (TLC) plates were ²purchased from ²Sigma Aldrich. Stock solutions of 0.05 M HC1 and 1 M NH40Ac were prepared by ²dilution in ²Milli-Q water.²

[0179] Radiolabeling Procedure. To a solution of225Ac(NO3)3 (Oak Ridge ²National ²Laboratory, USA) in 005 M HC1 (17.9 MBq in 970 [EL) was added 20 [IL of a 1 ²mg / mL ²solution of macropa-RPS-070 in DMSO. The pH was raised to 5-5.5 by addition of ²90 L 1 M ²NH40Ac. The reaction was allowed to stand at room temperature for 20 min with ²periodic ²shaking. Then, 200 [IL of the reaction solution was removed and diluted with ²3.8 mL of normal ²saline (0.9% NaCl in deionized H20; VWR) to give a solution with a ²concentration of 910 ²kBq / mL. An aliquot was removed from the final solution and spotted onto an ²aluminum-backed ²silica TLC plate to determine radiochemical yield An aliquot of the ²225Ac(NO3)3 solution in ²0.05M HC1 was spotted in a parallel lane as a control. The plate was ²immediately run in a 10% ²v / v Me0H / 10mM EDTA mobile phase, and then allowed to stand for 8 h to enable ²radiochemical equilibrium to be reached. The plate was visualized on a Cyclone ²Plus Storage ²Phosphor System (Perkin Elmer) following a 3-min exposure on the phosphor ²screen. The ²radiochemical yield was expressed as a ratio of 225Ac-macropa-RPS-070 to total ²activity and was ²determined to be 98.1%.²

[0180] Biodistribution Studies with 225Ac-macropa-RPS-070.²

[0181] Cell Culture. The PSMA-expressing human prostate cancer cell line, ²LNCaP, was ²obtained from the American Type Culture Collection. Cell culture supplies were ²from ²Invitrogen unless otherwise noted. LNCaP cells were maintained in RPMI-1640 ²medium ²supplemented with 10% fetal bovine serum (Hyclone), 4 mM L-glutamine, 1 mM ²sodium ²pyruvate, 10 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (FIEPES), ²2.5 mg / mL D-²glucose, and 50 pg / mL gentamicin in a humidified incubator at 37 C / 5% CO2. ²Cells were ²removed from flasks for passage or for transfer to 12-well assay plates by ²incubating them with ²0.25% trypsin / ethylenediaminetetraacetic acid (EDTA).²114²<DP=115>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0182] Inoculation of Mice with Xenografts. All animal studies were approved ²by the ²Institutional Animal Care and Use Committee of Weill Cornell Medicine and were ²undertaken ²in accordance with the guidelines set forth by the USPHS Policy on Humane Care ²and Use of ²Laboratory Animals. Animals were housed under standard conditions in approved ²facilities with ²12 h light / dark cycles. Food and water was provided ad libitum throughout the ²course of the ²studies. Hairless male nu / nu mice were purchased from the Jackson Laboratory. ²For ²inoculation in mice, LNCaP cells were suspended at 4 x 107 cells / mL in a 1:1 ²mixture of ²PBS:Matrigel (BD Biosciences). Each mouse was injected in the left flank with ²0.25 mL of the ²cell suspension. Biodistributions were conducted when tumors were in the range ²100-400 mm3.²

[0183] Biodistribution of 225Ac-macropa-RIPS-070 in LNCaP xenograft mice. ²Fifteen ²LNCaP xenograft tumor-bearing mice (5 per time point) were injected ²intravenously with a ²bolus injection of 85-95 kBq and 100 ng (50 pmol) of each ligand. The mice ²were sacrificed by ²cervical dislocation at 4, 24 and 96 h post injection. A blood sample was ²removed, and a full ²biodistribution study was conducted on the following organs (with contents): ²heart, lungs, liver, ²small intestine, large intestine, stomach, spleen, pancreas, kidneys, muscle, ²bone, and tumor. ²Tissues were weighed and counted on a 2470 Wizard Automatic Gamma Counter ²(Perkin ²Elmer). 1% ID / mL samples were counted prior to and following each set of ²tissue samples to ²enable decay correction to be undertaken. Counts were corrected for decay and ²for activity ²injected, and tissue uptake was expressed as percent injected dose per gram (% ²ID / g). Standard ²error measurement was calculated for each data point.²115²<DP=116>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²Table F. Organ distribution of 225Ac-macropa-RPS-070 at t = 4 h, 24 h, and 96 ²h following ²intravenous injection in LNCaP xenograft mice (n = 5 per time point). Values ²expressed as % ²ID / g.²116²<DP=117>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²4h ²1 2 3 4 S Mean SE M²Blood 0.90654 0.55246 ²1.11308 0.8276 0.65638 0.81221 0.0986 ²Heart 0.75759 0.65317 ²0.77395 0.75148 0.6585 031894 0.02604 ²Lungs 0,99558 0,60669 ²1.25979 0.98587 0.88664 0,94691 0.10516 ²Liver 1.62187 1.34632 ²1.74207 1.68077 1.3957 1,55735 0.0788 ²Sala ntestine 0.1998 0.16282 0,3104 ²0.24413 0.17094 0,21762 0,02721 ²Large 0 / testine 136298 0.65162 ²1.27419 0.91656 0.81901 100487 0.13563 ²Stormcn 0,33963 0.2471 ²0.30417 0,4109 0.21221 0,3028 0,03489 ²50een 1.40902 0.70804 ²1.61264 1.10815 0.3756 1.14269 0.16632 ²Pancrea s 0.55487 0.41637 ²035317 0.4675 0,6604 033047 0.01182 ²Kidneys 655884 20.5274 ²108.233 33.654 33.0707 52.2146 15.8618²Muscle 0.68006 0.80579 ²0.72817 0.67666 0.65617 0.70937 0.02684²i B one 1.14361 1.12335 ²1.48731 0.92036 1.15463 1.16685 0.09106²Tumor 6.73177 10.7309 ²23.8367 15.3682 7.50352 12.3342 3.1429 ²24h ²1 2 4 5 Mean 5E0.4 ²Blood 0,34825 0.31324 ²0.22083 0.29453 0.27697 0,29076 0,0211 ²Heart 032256 0.56334 0.4521 ²0.4,914 0.46483 0.49639 0.02052 ²Lungs 0,53778 0.45077 ²0.46083 0,4286 0.44831 0,46526 0,01887 ²Liver 157844 1.47552 ²1.13776 1.14264 1.48473 1.36382 0.09305 ²Smail / ntestine 0.08784 0,09914 ²0.08822 0.09466 04378 0.09473 0.00309 ²Large intestine 0.13296 0.1259 ²0.13252 0.13425 0,13176 0,13148 0,00145 ²Stomch 0.1296 0,12119 0.1119 ²0.14675 0.1..W9 0.13255 0.00773²5p1een 0.62075 0.65764 ²0.62013 0,57685 0,58554 0.61218 0.01443²pancrea s 0.39847 0.39119 ²0.50347 0.33315 0.31944 0.33914 0.03252 ²Kidneys 4.98792 4.25707 ²3.94586 3.66457 4.10348 4.19178 0,22185 ²Muscle 0.61.193 0.5149 ²0.44832 0.78028 0.44579 0.56025 0.06276 ²Bale 1.27255 1.05645 ²0.83943 1.00576 0,69755 0.97635 0,09828 ²Tumor 11.6163 9.26927 ²7.50158 4.41446 8.04683 8.16969 1.17533 ²96h ²2 3 4 5 Mean SEM²Bk3od 0.19042 0.19188 ²0.15206 0,16528 0.23822 0.18757 0,01475 ²ft 0.39939 0.42398 ²0.42861 0.45863 0.45595 0.43331 0.01093 ²Lungs 0.30165 0.50912 ²0,46944 0.37811 0.36979 0.40562 0.03717 ²Liver 0.79406 0.8144 ²0.73301 0.7917 0.79415 0.78546 0.01374 ²Small Mtestne 0.04372 0.0577 ²0,03752 0.04431. 0.04136 0.04492 0.00341²Large intestire 0.04349 0.09663 ²0.04522 0.04198 0.03927 0.05332 0.01087 ²Stomach 0.03442 0,04708 ²0.03448 0.02845 0.02366 0.03362 0.00393 ²Spleen 0.48373 0.394 0.44261 ²0.43481 0.53966 0.45896 0.02469 ²Pancreas 0.442,5 0-333.2 ²013614 0,04347 ²Kidneys 1.30286 1.3239 ²2.00405 1.39866 1.45955 1.4978 0.12958 ²Muscle 0.3022 0.52492 ²0.25089 0.29815 0.2528 0.32579 0.05095²0.86391 086374 033831 1.13223 032042 0,90272 0,05557²Tumr 4,04259 4.07799 ²6.73954 4.58107 434503 4.85724 0.49449 ²117²<DP=118>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0184] Coniugation of Macropa-NCS and p-SCN-Bn DOTA to Trastuzumab. ²

[0185] General. All glassware was washed overnight in 1M HC1. Saline (0.154 M ²NaCl) and ²all buffer solutions were passed through a column of Chelex-100 pre-²equilibrated with the ²appropriate buffer. Trastuzumab (Tmab, Genentech) was purified using a Zeba ²spin desalting ²column (2 mL or 5 mL, 40 MWCO, Thermo Scientific, Waltham, MA) according to ²the ²manufacturer's protocol, with saline as the mobile phase. The concentration of ²purified Tmab ²was calculated via the Beer-Lambert law using Azso and an Ezso of 1.446 mL mg' ²cm-1.

[107] ²Purified Tmab and Tmab conjugates were stored at 4 C.²

[0186] Conjugation of Macropa-NCS to Tmab. A stock solution containing 4.4 ²mg / mL of ²macropa-NCS (12) was prepared in 0.1 M pH 9.1 NaHCO3 buffer containing 0.154 M ²NaCl and ²was stored at -80 C. The stability of 12 during storage was verified by ²analytical HPLC. To a ²portion of Tmab in saline (74 1..iL) were added 12 (52 [IL) and NaHCO3 buffer ²(266 L), so that ²the final concentrations of Tmab and 12 were 5.1 mg / mL and 0.59 mg / mL, ²respectively. ²Macropa-NCS was estimated to be in 16-fold molar excess to Tmab based on a ²molecular ²weight of 1045.76 g / mol for 12 (tetra-TFA salt). The pH of this solution was ²between 8 and 9 ²by litmus paper. The solution was rocked gently at room temperature for 17.5 h ²and then ²purified using a spin column.²

[0187] Conjugation of p-NCS-Bn-DOTA to Tmab. A stock solution containing 3.05 ²mg / mL ²ofp-NCS-Bn-DOTA was prepared in H20 and stored at -80 C. To a portion of Tmab ²in saline ²(66 L) were addedp-NCS-Bn-DOTA (49 [IL) and NaHCO3 buffer (274.5 RL), so that ²the final ²concentrations of Tmab andp-NCS-Bn-DOTA were 5.1 mg / mL and 0.38 mg / mL (16-fold ²molar ²excess of L), respectively. The pH of this solution was between 8 and 9 by ²litmus paper. The ²solution was rocked gently at room temperature for 17.5 h and then purified ²using a spin ²column.²

[0188] Determination of Conjugate Protein Concentration by BCA Assay. The ²concentration of protein in macropa-Tmab and DOTA-Tmab conjugates was ²determined using ²the Pierce BCA Protein Assay kit (Thermo Scientific, Waltham, MA, microplate ²protocol). ²Tmab was employed as the protein standard. A stock solution of purified Tmab ²was diluted ²with saline and the concentration of this solution (1.83 mg / mL) was determined ²using a ²NanoDrop 1000 Spectrophotometer (Thermo Scientific, Waltham, MA). The standard ²curve ²was linear (r2= 0.9966) over the concentration range measured (0-1828 Kg / mL). ²The protein ²concentration of each conjugate was calculated from two independent dilutions, ²each measured²118²<DP=119>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²in triplicate, and the results were averaged to give a protein concentration ²of 4.557 mg / mL for ²macropa-Tmab and 2.839 mg / mL for DOTA-Tmab.²

[0189] Ligand-to-Protein Ratio Analysis by MALDI-ToF. The average number of ²macropa ²or DOTA ligands conjugated to Tmab was determined by MALDI-ToF MS / MS on a ²Bruker ²autoflex speed at the Alberta Proteomics and Mass Spectrometry Facility ²(University of Alberta, ²Canada) using a procedure described elsewhere.[I 81 Purified Tmab and the ²conjugates were ²analyzed in duplicate, and the [M+H]+ mass signals from the chromatograms were ²averaged for ²each compound. The ligand-to-protein (L:P) ratio for each conjugate was ²obtained by ²subtracting the molecular weight of Tmab from the molecular weight of the ²conjugate, and ²subsequently dividing by the mass of the bifunctional ligand.²

[0190] 225Ac Radiolabeling of Tmab Conjugates and Serum Stability of ²Complexes.²10191] General. Instant thin layer chromatography paper impregnated with ²silica gel (iTLC-²SG, Agilent Technologies, Mississauga, ON, Canada) was used to monitor the ²progress of 225Ac ²radiolabeling reactions and to determine serum stability. TLC plates were ²developed as ²described below and then counted on a BioScan System 200 imaging scanner ²equipped with a ²BioScan Autochanger 1000 and WinScan software at least 8 h later to allow time ²for daughter ²isotopes to decay completely, ensuring that the radioactive signal measured ²was generated by ²parent 225Ac.²

[0192] 'Ac Radiolabeling Studies. In a total reaction volume of 200 tL made up ²with ²NH40Ac buffer (pH 6, 0.15 M), 225Ac (10 or 20 kBq, 7-10 RL) was mixed with 25-²100 [tg of ²either macropa-Tmab (5.5-22 pL) or DOTA-Tmab (8.81-35.2 [tL), and the pH was ²adjusted to ²¨5 with NaOH. A control solution was also prepared in which unmodified Tmab ²(25 vg) was ²substituted in place of conjugate. The reaction solutions were maintained at ²ambient ²temperature and analyzed at 5 min, 30 min, 1 h, 2 h, 3 h, and 4 h by spotting ²8 L in triplicate on ²iTLC strips. The strips were developed with a mobile phase of 0.05 M citric ²acid (pH 5). Under ²these conditions, 225Ac-macropa-Tmab and 225Ac-DOTA-Tmab remained at the ²baseline of the ²plate (RF=0) and any unchelated 225AC (225Ac -citrate) migrated with the ²solvent front (RF=1). ²Radiochemical yields (RCYs) were calculated by integrating area under the ²peaks on the ²radiochromatogram and dividing the counts associated with the 225Ac-complex ²(RF=0) by the ²total counts integrated along the length of the TLC plate.²119²<DP=120>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²

[0193] Stability of 'Ae-maeropa-Tmab in Human Serum. A solution of 225Ac-²macropa-²Tmab was prepared using 100 tig of protein. After confirmation by TLC that a ²RCY of >95% ²had been achieved, human serum was thawed to room temperature and added to the ²radiolabeled ²immunoconjugate to give a solution containing 90% serum by volume. The sample ²was ²incubated at 37 C. At various time points over the course of 7 days, aliquots ²(15-30 [iL) were ²removed from the sample and spotted in triplicate onto iTLC strips. The strips ²were developed ²using an EDTA (50 mM, pH 5.2) mobile phase and counted. Under these ²conditions, 225AC-²macropa-Tmab remained at the baseline (RF=0) and any 225Ac (225Ac-EDTA) that ²had been ²transchelated by serum migrated with the solvent front (RF=1). Percent of ²complex remaining ²intact was calculated.²

[0194] As an additional challenge, separate aliquots (39 [iL) were also ²removed from the ²serum sample on days 1 and 7 and mixed with 50 mM DTPA (pH 7, 13 L) to ²challenge off any ²225Ac that was only loosely bound by the radioimmunoconjugate. After ²incubation of this ²solution at 37 C for 15 minutes, an aliquot (30 L) was spotted in triplicate ²on iTLC plates and ²developed using an EDTA (50 mM, pH 5.2) mobile phase. Percent of complex ²remaining intact ²was calculated.²

[0195] In Vivo Biodistribution Studies of 1-225Ac(macropa)1+, [225Pik ²ell"rrsOTA)1-, and ²225AcixTri²

[0196] Table 1. Organ distribution of 225AC complexes following intravenous ²injection in ²mice. Adult C57BL / 6 mice were injected with [225Ac(macropa)r, ,225 Ac(DOTA)]-, ²or²225 , e²(1\103)3 and sacrificed after 15 min, 1 h, or 5 h. Values for each time point ²are given as %²ID / g (n=3) using energy window A (60-120 keV).²Organ 15 min SD 1 h SD 5 h SD²1225Ac(macropa)1+²blood 5.11 2.82 0.40 0.38 0.01 0.01²urine 1378.82 971.53 489.11 26.75 12.78 6.10²feces 0.91 1.18 0.28 0.14 3.46 1.06²heart 2.19 0.60 0.31 0.24 0.10 0.11²liver 2.28 0.41 0.75 0.18 0.39 0.03²kidneys 27.55 7.51 13.36 17.13 0.74 0.06²lungs 5.98 1.81 0.51 0.36 0.01 0.04²120²<DP=121>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²small² 2.64 1.08 1.10 0.47 0.29 0.20²intestines²large²2.40 0.52 0.36 0.10 0.49 0.22²intestines²brain 0.26 0.09 0.12 0.07 0.02 0.02²bladder 46.74 24.65 6.23 7.44 4.25 5.27²spleen 2.52 1.08 0.51 0.19 0.11 0.03²stomach 2.97 0.72 0.41 0.08 0.01 0.06²pancreas 1.46 0.64 0.19 0.16 0.10 0.06²bone²(femur + 2.52 0.34 0.31 0.16 0.05 0.10²joint)²thyroids 28.23 17.90 3.18 2.21 0.10 7.95²tail 8.84 1.56 1.82 1.11 0.14 0.09²1225Ac(DOTA)1-²blood 5.2881 2.9807 0.1144 0.0203 0.0140 0.0024²urine 1467.9186 1073.9229 158.6102 141.1945 1.1612 0.3653²feces 6.2730 8.7284 0.2035 0.2433 5.5318 1.7685²heart 2.3335 0.7337 0.1012 0.0853 0.0664 0.0091²liver 2.2520 0.5051 0.2715 0.1973 0.1010 0.0063²kidneys 27.6566 6.8974 1.4020 0.2124 0.6172 0.0168²lungs 5.7556 1.7234 0.1555 0.0800 0.0390 0.0135²small²2.6370 1.3350 1.7207 2.1165 0.0967 0.0232²intestines²large²2.3348 0.7436 0.1229 0.0551 0.2026 0.1073²intestines²brain 0.2655 0.0598 0.0224 0.0123 0.0213 0.0021²bladder 48.2703 26.4988 4.7351 4.9621 0.3551 0.0335²spleen 2.5905 1.3909 0.0938 0.0322 0.1380 0.0733²stomach 2.7440 0.8312 0.1367 0.1078 0.0852 0.0100²pancreas 1.5090 0.6828 0.0743 0.0752 0.0677 0.0090²121²<DP=122>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²bone²(femur + 2.6298 0.6802 0.4487 0.0586 0.2063 0.0231²joint)²thyroids -5.7725 27.0550 2.3564 2.7015 3.6425 ² 1.8897²tail 8.8606 1.1879 0.8091 0.1272 0.3057 0.0766²225Ac(NO3)3² blood 40.966 6.455 20.8234 0.8102 1.9886 0.5457²urine 5.527 3.460 4.5194 0.4803 4.8267 3.6549²feces 0.240 0.070 0.2189 0.1167 0.9445 0.7998²heart 8.557 2.698 4.4261 1.2771 1.3450 0.2326²liver 22.899 1.788 39.8269 4.5062 59.8156 10.4928²kidneys 10.468 1.897 7.2170 1.5026 4.6910 2.3005²lungs 12.757 2.883 8.2412 1.9189 4.1871 3.8011²small²2.002 0.094 1.5594 0.3191 1.3704 0.4345²intestines²large²1.116 0.145 0.6035 0.4502 0.6479 0.2782²intestines²brain 0.614 0.283 0.2995 0.0893 0.0452 0.0343²bladder 1.477 0.689 0.9047 0.0759 1.4947 2.4402²spleen 22.733 4.962 34.8831 1.6768 62.9614 12.7041²stomach 2.348 0.250 1.6211 0.0147 2.6131 1.4450²pancreas 2.366 0.922 2.1771 0.8907 0.4874 0.4300²bone²(femur + 2.764 0.757 2.4707 0.1198 3.5460 0.6374²joint)²thyroids 4.391 1.511 2.5988 4.9499 -2.7052 2.9758²tail 7.459 5.674 5.7939 1.8506 23.4055 19.5704²

[0197] Table 2. Organ distribution of 225AC complexes following intravenous ²injection in ²mice. Adult C57BL / 6 mice were injected with [225Ac(macropa)], [225Ac(DOTA)], ²or ²225Ac(NO3)3 and sacrificed after 15 min, 1 h, or 5 h. Values for each time ²point are given as % ²ID / g (n=3) using energy window B (180-260 keV).²122²<DP=123>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²Organ 15 min SD 1 h SD 5 h SD²1225Ac(macropa)1²blood 5.23 2.93 0.39 0.38 0.00 0.01²urine 1541.60 1105.98 517.19 11.65 13.51 6.04²feces 1.04 0.92 0.27 0.21 3.49 1.18²heart 2.39 0.80 0.20 0.31 -0.04 0.12²liver 2.17 0.40 0.70 0.16 0.36 0.01²kidneys 27.86 7.39 12.97 17.16 0.78 0.14²lungs 5.83 1.81 0.54 0.25 -0.05 0.14²small² 2.59 1.19 0.94 0.46 0.29 0.21²intestines²large²2.53 0.57 0.22 0.18 0.45 0.27²intestines²brain 0.23 0.06 0.12 0.11 -0.01 0.04²bladder 47.64 25.00 5.92 8.15 3.69 6.69²spleen 2.55 1.54 0.23 0.26 0.09 0.06²stomach 3.29 1.03 0.33 0.26 0.04 0.14²pancreas 1.63 0.73 0.12 0.22 -0.12 0.16²bone²(femur + 2.69 0.63 0.17 0.11 0.02 0.01²joint)²thyroids -2.22 12.06 0.10 5.33 -6.94 8.77²tail 9.39 1.59 1.82 1.04 0.13 0.05²1225Ac(DOTA)1²blood 5.6357 3.2852 0.1127 0.0403 0.0292 0.0172²urine 1635.4394 1233.7980 159.1628 143.0187 3.6967 3.3377²feces 1.0222 0.9859 0.2349 0.2923 3.3534 1.0198²heart 2.7276 0.7955 0.1378 0.1197 0.0879 0.0591²liver 2.1817 0.4921 0.2672 0.1890 0.2712 0.2370²kidneys 28.0858 6.9019 1.2560 0.1319 0.6718 0.1380²lungs 6.0147 1.8416 0.1946 0.1077 0.1289 0.0320²small²2.5009 1.2567 1.8809 2.3424 0.2065 0.1617²intestines²123²<DP=124>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²large² 2.5365 0.7142 0.0813 0.0554 0.2527 0.1980²intestines²brain 0.2735 0.1473 0.0248 0.0120 0.0513 0.0110²bladder 54.4696 32.7034 4.7141 5.1077 0.7521 0.0884²spleen 2.9076 1.5773 0.0825 0.0965 0.0834 0.2219²stomach 2.7311 0.9322 0.1379 0.1390 0.1789 0.0565²pancreas 1.4929 1.2189 0.0746 0.0806 0.1266 0.0354²bone²(femur + 3.0357 0.7199 0.4126 0.0368 0.1478 0.1689²joint)²thyroids 1.6601 7.1867 2.6514 6.1376 16.2357 11.0860²tail 9.4746 1.5429 0.8973 0.0672 0.1634 0.0768²225Ac(NO3)3²blood 41.5628 6.0720 21.4460 1.0862 2.0018 0.5989²urine 5.0951 2.4036 7.0564 2.0984 3.3142 2.6426²feces 0.3857 0.1799 0.3300 0.1741 1.0201 0.9002²heart 8.3605 2.5149 4.5832 1.4669 1.3948 0.3318²liver 23.6091 2.1849 41.0995 5.1387 62.0765 10.0091²kidneys 9.6424 1.6131 6.8770 1.0099 3.8752 1.6179²lungs 12.9714 2.7540 8.4426 1.9117 4.3379 3.9596²small²1.9641 0.1853 1.5192 0.2815 1.2201 0.3708²intestines²large²1.1570 0.1960 0.5629 0.3460 0.6744 0.2893²intestines²brain 0.6536 0.2639 0.3247 0.0633 0.0290 0.0219²bladder 1.6996 0.7289 0.8092 0.2576 1.5234 2.6761²spleen 24.0497 5.3531 37.1540 0.1801 65.9117 13.1934²stomach 2.3704 0.3085 1.5867 0.2853 2.5322 1.4903²pancreas 2.2821 0.9761 2.1579 0.8408 0.4455 0.3936²bone²(femur + 2.7487 0.6608 2.7705 0.0730 3.8533 0.7991²joint)²thyroids 9.6295 8.0396 5.7426 3.0938 -4.6044 2.5708²124²<DP=125>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²tail 8.0722 6.2766 6.4201 2.1693 25.4744 20.7518²

[0198] Table 3. Organ distribution of 225AC complexes following intravenous ²injection in ²mice. Adult C57BL / 6 mice were injected with [225Ac(macropa)], [225Ac(DOTA)], ²or ²225Ac(NO3)3 and sacrificed after 15 min, 1 h, or 5 h. Values for each time ²point are given as % ²ID / g (n=3) using energy window C (400-480 keV).²Organ 15 min SD 1 h SD 5 h SD²1225Ac(macropa)1+²blood 6.49 4.64 0.54 0.55 0.04 0.03²urine 2387.66 1987.77 641.63 49.58 22.27 ²8.14²feces 1.26 2.00 0.69 0.50 5.27 2.17²heart 2.87 1.51 0.23 0.97 0.28 0.84²liver 2.72 0.61 1.08 0.45 0.55 0.08²kidneys 33.46 5.62 17.38 21.12 1.07 0.37²lungs 7.55 3.24 0.84 0.62 0.15 0.14²small² 3.46 2.44 1.62 0.76 0.42 0.28²intestines²large²3.02 1.11 0.79 0.51 0.68 0.17²intestines²brain 0.17 0.10 0.23 0.13 -0.01 0.08²bladder 64.68 45.85 9.00 3.35 8.52 10.72²spleen 3.79 2.96 0.48 1.92 0.43 0.14²stomach 3.45 1.29 0.17 0.77 0.13 0.23²pancreas 3.00 2.21 0.43 1.01 0.13 0.29²bone²(femur + 3.74 1.27 0.70 0.36 0.08 0.16²joint)²thyroids -6.46 66.56 8.34 11.63 19.89 30.96²tail 11.75 0.66 2.57 1.39 0.28 0.10²1225Ac(DOTA)1-²blood 7.2941 4.1461 0.1102 0.0707 - -²urine 2691.0615 1906.4694 177.6788 168.4716 - -²125²<DP=126>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²feces 1.5693 1.8307 0.4091 0.4652 - -²heart 2.5579 2.0110 0.2857 0.2702 - -²liver 2.9046 0.8757 0.2841 0.2157 - -²kidneys 40.4489 10.8186 1.4787 0.7053²lungs 7.3872 1.9528 0.2551 0.1695 - -²small² 3.8916 2.4605 2.0201 2.4443²intestines²large²3.8419 1.8882 0.1381 0.2122 - -²intestines²brain 0.1588 0.0692 0.0380 0.0968 - -²bladder 76.0987 42.8592 6.9149 4.5152 - -²spleen 1.5598 1.6847 0.2228 0.4642 - -²stomach 3.2425 2.1465 0.1720 0.2911 - -²pancreas 1.0290 1.1339 0.1730 0.1437²bone²(femur + 4.4224 1.8431 0.5654 0.2432 - -²joint)²thyroids -109.5394 150.5455 3.5247 36.1530 - -²tail 13.4731 3.2236 1.0280 0.3206²225Ac(NO3)3²blood 42.3521 6.5376 11.3736 15.9719 2.1769 0.7500²urine 19.8282 14.9210 104.9103 130.5319 5.8548 8.2799²feces 0.4896 0.2884 0.1122 0.1587 0.8535 0.2061²heart 9.0992 3.1686 3.3464 4.3204 1.2018 0.1929²liver 24.1147 1.8809 23.6180 33.2545 54.1727 4.7696²kidneys 14.2266 4.1528 6.2070 7.2061 4.2061 1.5123²lungs 14.4797 2.7960 5.2078 7.2810 5.4923 4.6341²small²2.0956 0.0803 3.5548 1.8035 1.2922 0.6032²intestines²large²1.5716 0.8096 0.4366 - 1.0259 0.5032²intestines²brain 0.6755 0.2338 0.4402 0.1057 0.0430 0.0773²bladder 1.9351 2.1420 2.2929 1.3941 3.4975 5.8177²126²<DP=127>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²spleen 25.4263 6.0011 38.1082 62.2357 17.5694²stomach 2.4232 0.3667 2.3350 2.0358 1.6514²pancreas 2.4405 0.5887 1.8508 0.4643 0.3109²bone²(femur + 3.4560 0.9882 2.7213 3.5851 1.4683²joint)²thyroids 3.5934 1.5023 0.0000 -0.4455 3.5100²tail 9.1381 7.4041 9.0877 28.4443 30.7841²

[0199] In Vivo Studies of 225Ac-macropa-Tmab. ²

[0200] At the time points indicated in Table 4 below, an aliquot of complex in ²serum was ²removed and either directly analyzed by radio-TLC or first mixed with excess ²DTPA to remove ²any loosely-bound 225AC. The decay-corrected values shown represent % activity ²associated ²with the complex at RF=0 on the TLC plate after exposure to an EDTA mobile ²phase. Reported ²uncertainties ( 1 SD) were derived from spotting TLC plates in triplicate at ²each time point. ²The % intact complex remaining was not significantly different for samples ²subjected to the ²DTPA challenge versus those that were not (p> 0.05, 2-tail t-test). The ²results demonstrate that ²225AC remains strongly bound by macropa-Tmab in human serum over a 7-day ²period.²Table 4. Complex stability (% intact complex remaining) of 'Ac-macropa-Tmab in ²human ²serum at 37 C.²1 h 1 day 3 days 7 days²Without DTPA Challenge 96.4 + 0.9 99.0 0.5 98.7 + 0.6 99.2 + ²0.4²With DTPA Challenge 91.5 + 12 97.1 + 1.6²

[0201] Characterization of Eighteen-Membered Macrocyclic Ligands for Ion ²Chelation ²

[0202] Radium-223 (223Ra) is the first therapeutic alpha (a)-emitting ²radionuclide to be ²approved for clinical use in cancer patients, and is effective in erradicating ²bone metastases. To ²harness the therapeutic potential of a-particles for soft-tissue metastases, ²the strategy of targeted ²alpha-particle therapy (TAT) has emerged, whereby lethal a-emitting ²radionuclides are ²conjugated to tumor-targeting vectors using bifunctional chelators to ²selectively deliver ²cytotoxic alpha radiation to cancer cells. Actinium-225 (225Ac) was examined ²for use in TAT²127²<DP=128>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²owing to its long 10-day half-life that is compatible with antibody-based ²targeting vectors and 4 ²high-energy a-emissions that are extremely lethal to cells. The 12-membered ²tetraaza ²macrocycle H4DOTA is currently the state of the art for the chelation of the ²225Ac' ion, ²however, the thermodynamic stabilities of complexes of RIDOTA decrease as the ²ionic radius ²of the metal ion increases, indicating that this ligand is not optimal for ²chelation of the of the ²Ac' ion (the largest +3 ion on the periodic table). The macrocyclic complexes ²of the present ²technology provide a signifiant and unexpected improvement over known ²complexes, where the ²present examples (H2macropa and H2macropa-NCS; Scheme 1) illustrate the ²improved 225Ac ²bifunctional chelators according to the present technology.²

[0203] Scheme 1. Structures of H2macropa, H2macropa-NCS ("macropa-NCS"), and ²macropa-(OCH2CH2)-Ph-NC S.²0²OH HO²0 0 __ N²0 0²H2macropa²0²OH HO²( / 1\1 / ___________________ 0 / \O ______ N / NCS²\N²0 0²macropa-NCS²128²<DP=129>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²SON²= 0 0²OH HO²0 ______________________________ / N ___ 0 0²macropa-(OCH2CH2)-Ph-NCS²

[0204] Previous studies have shown that macropa, for which the thermodynamic ²affinity for ²the whole lanthanide series was evaluated, is selective for the larger metal ²ions La', Pb', and ²Am' over the smaller Lu', Ca', and Cm' ions. [24-26] Without wishing to be ²bound by theory ²it was believed that macropa would effectively chelate the large Ac' ion. ²Before assessing its ²Ac-chelation properties, complex formation was evaluated in situ between ²macropa and cold ²La' and Lu' ions. In these studies, La' was used as a non-radioactive ²surrogate for225Ac' ²because it is chemically similar albeit slightly smaller (1.03 A, CN 6). ²Complexation of the ²smaller Lu' ion (0.861 A, CN 6) by macropa was investigated to probe its size-²selectivity. La' ²and Lu3+ titrations confirmed the high affinity of these metal ions for ²macropa at pH 7.4, ²consistent with the previously measured stability constants (log KIAL = 14.99, ²log KLuL = ²8.25).

[24] The kinetic inertness of these complexes formed in situ was ²investigated by ²challenging them with an excess of either ethylenediaminetetraacetic acid ²(EDTA) or ²diethylenetriaminepentaacetic acid (DTPA) chelators that have a higher ²thermodynamic affinity ²than macropa for Lu' and La' ions.

[27] The Lu' ion was transchelated within 1 ²min upon the ²addition of only 10 equiv of EDTA, whereas the La' complex remained intact for ²up to 21 days ²in the presence of 1000 equiv of DTPA. These results demonstrate that, despite ²a strong ²thermodynamic preference for DTPA to transchelate La', the high level of ²kinetic inertness of ²the macropa complex inhibits this process on a detectable time scale.²

[0205] The La' and Lu' complexes of macropa were isolated and their solid-²state structures ²were elucidated by X-ray crystallography (FIGS. IA-1D). The La' and Lu' ions ²reside above²129²<DP=130>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²the 18-membered macrocycle, and the two picolinate arms are positioned on the ²same side of the ²macrocycle. The coordination sphere of the Lu' ion is satisfied by the ten ²donors of macropa ²with both picolinate arms deprotonated; by contrast, the larger La' ion forms ²an 11-coordinate ²complex by the incorporation of an inner-sphere water molecule that penetrates ²the macrocycle. ²The ability of macropa to form stable 11-coordinate complexes is of particular ²significance ²because recent EXAFS studies have demonstrated that Ac' prefers a coordination ²number of 11 ²in aqueous solutions.[29'301²

[0206] Macropa was examined for the chelation of the larger, radioactive ²225Ac' ion and ²compared to DOTA. Both ligands (59 [iM) were incubated with 225Ac (26 kBq) in ²0.15 M ²NH40Ac buffer at pH 5.5-6, and the complexation reaction was monitored by ²radio-TLC after 5 ²min. Remarkably, macropa complexed all the 225A_C after merely 5 min at RT, ²whereas DOTA ²only complexed 10% under these conditions. At 100-fold lower concentration ²(0.59 [iM) of ²macropa, a L:M ratio of only 1800, radiolabeling was still complete at RT in 5 ²min. At this ²concentration, DOTA failed to form a complex with 225AC. Taken together, these ²studies reveal ²macropa to exhibit excellent radiolabeling kinetics at ambient temperature and ²submicromolar ²ligand concentration, conditions under which DOTA fails.²

[0207] The long half-life of 225Ac necessitates its stable complex retention ²in vivo to avoid off-²target damage to normal tissues arising from the release of free 225AC3+. ²Furthermore, the ²stability of 225Ac complexes against transmetalation and transchelation needs ²to be high. To ²determine the kinetic inertness, [225Ac(macropa)] was challeneged with La' ²because of the ²established high affinity of macropa for this metal ion. A 50-fold excess of ²La" with respect to ²ligand concentration was added to 225Ac-radiolabeled solutions of macropa ²(0.59 1,1M) at RT. ²Over 7 days, 98% of the 225AC complex remained intact by radio-TLC, signifying ²that a large ²molar equivalent of La' is unable to displace 225AC3+. The stability of ²[225Ac(macropa)] in ²human serum was also evaluated by radio-TLC and revealed that 225Ac' remains ²complexed by ²macropa for at least 8 days.²

[0208] Evaluation of the Biodistribution of 1225Ac(macropa)1+ Complexes ²

[0209] The in vivo stability [225Ac(macropa)] was examined by comparing its ²biodistribution ²to those of 225Ac(NO3)3 and [225Ac(DOTA)]. C57BL / 6 mice were injected via tail ²vein with ²10-50 kBq of each radiometal complex and were sacrificed after 15 min, 1 h, or ²5 h. The ²amount of 225AC retained in each organ was quantified by gamma counting and ²reported as the ²percent of injected dose per gram of tissue (% ID / g). The results of these ²studies are compiled²130²<DP=131>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²in Tables 1-3. Inadequate stability of an 225Ac complex leading to the loss of ²radioisotope in ²vivo is manifested by the accumulation of 225Ac in the liver, spleen, and bone ²of mice.[11,12,32] ²FIG. 2A demonstrates slow blood clearance and excretion, coupled to large ²accumulation in the ²liver and spleen of the uncomplexed 225Ac(NO3)3. The biodistribution profile ²of²[225 ,225²Ac(macropa)]+ (FIG. 3B) differs markedly from that of 225Ac(NO3)3. ²Ac(macropa)r was²rapidly cleared from mice, with very little activity measured in blood by 1 h ²post injection. ²Most of the injected dose was renally excreted and subsequently detected in ²the urine, ²demonstrating the moderate kidney and bladder uptake of ['Ac(macropa)]+ ²observed in mice at ²15 min and 1 h post injection. Of significance, [225Ac(macropa)] did not ²accumulate in any ²organ over the time course of the study, indicating that the complex does not ²release free 225Ac" ²in vivo. Its biodistribution profile was similar to that of [225Ac(DOTA)]- ²(FIG. 3C), which has ²been previously shown to retain 225Ac" in vivo. [71²

[0210] Synthesis and Characterization of 1225Ac(macropa)1+ TAT Complexes ²

[0211] Due to the inherent stability of the [225Ac(macropa)]+ complexes, ²macropa was ²incorporated into into tumor-targeting constructs. To facilitate its ²conjugation, a reactive ²isothiocyanate functional group was installed onto one of the picolinate arms ²of macropa to give ²the novel bifunctional ligand macropa-NCS (Scheme 1). As illustrated in vide ²supra, macropa-²NCS was synthesized over 8 steps and characterized by conventional techniques. ²For one ²tumor-targeting construct, macropa-NCS was s conjugated to trastuzumab (Tmab), ²an FDA-²approved monoclonal antibody that targets the human epidermal growth factor ²receptor 2 ²(HER2) in breast and other cancers.[331 With a biological half-life of several ²weeks,[34'351 Tmab ²is an ideal vector to shuttle the long-lived 225Ac radionuclide to tumor ²cells. 225Ac-macropa-²Tmab displayed excellent stability in human serum at 37 C; after 7 days, >99% ²of the complex ²remained intact (Table 4). Together, these results highlight the efficacy of ²macropa as a ²chelator for 225Ac in antibody constructs as well as other cancer-targeted ²constructs.²

[0212] REFERENCES:²7. M. R. McDevitt, D. Ma, L. T. Lai, J. Simon, P. Borchardt, R. K. Frank, K. ²Wu, V. ²Pellegrini, M. J. Curcio, M. Miederer, et al., Science 2001, 294, 1537.²11. I. A. Davis, K. A. Glowienka, R. A. Boll, K. A. Deal, M. W. Brechbiel, M. ²Stabin, P. N. ²Bochsler, S. Mirzadeh, S. J. Kennel, Nucl. Med. Biol. 1999, 26, 581.²131²<DP=132>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²12. K. A. Deal, I. A. Davis, S. Mirzadeh, S. J. Kennel, M. W. Brechbiel, I ²Med. Chem. ²1999, 42, 2988.²24. A. Roca-Sabio, M. Mato-Iglesias, D. Esteban-G6mez, E. T6th, A. de Blas, C. ²Platas-²Iglesias, T. Rodriguez-Blas, I Am. Chem. Soc. 2009, 131, 3331.²25. R. Ferreir6s-Martinez, D. Esteban-G6mez, E. T6th, A. de Blas, C. Platas-²Iglesias, T. ²Rodriguez-Blas, Inorg. Chem. 2011, 50, 3772.²26. M. P. Jensen, R. Chiarizia, I. A. Shkrob, J. S. Ulicki, B. D. Spindler, D. ²J. Murphy, M. ²Hossain, A. Roca-Sabio, C. Platas-Iglesias, A. de Blas, et al., Inorg. Chem. ²2014, 53, ²6003.²27. A. E. Martell, R. M. Smith, Critical Stability Constants: Vol. 1, Plenum ²Press, New ²York; London, 1974.²29. M. G. Ferrier, E. R. Batista, J. M. Berg, E. R. Birnbaum, J. N. Cross, J. ²W. Engle, H. S. ²La Pierre, S. A. Kozimor, J. S. Lezama Pacheco, B. W. Stein, et al., Nat. ²Commun. 2016, ²7, 12312.²30. M. G. Ferrier, B. W. Stein, E. R. Batista, J. M. Berg, E. R. Birnbaum, J. ²W. Engle, K. D. ²John, S. A. Kozimor, J. S. Lezama Pacheco, L. N. Redman, ACS Cent. Sci. 2017, ²3, 176.²32. G. J. Beyer, R. Bergmann, K. Schomacker, F. Rosch, G. Schafer, E. V ²Kulikov, A. F. ²Noygorodov, IsoL IsoL Environ. Heal. Stud. 1990, 26, 111.²33. M. M. Moasser, Oncogene 2007, 26, 6469.²34. B. Leyland-Jones, K. Gelmon, J.-P. Ayoub, A. Arnold, S. Verma, R. Dias, P. ²²Ghahramani, I Cl / n. OncoL 2003, 21, 3965.²35. D. Leyeque, L. Gigou, J. P. Bergerat, Curr. Cl / n. PharmacoL 2008, 3, 51.²37. A. P. Kozikowski, F. Nan, P. Conti, J. Zhang, E. Ramadan, T. Bzdega, B. ²Wroblewska, ²J. H. Neale, S. Pshenichkin, J. T. Wroblewski, I Med. Chem. 2001, 44, 298.²38. K. P. Maresca, S. M. Hillier, F. J. Femia, D. Keith, C. Barone, J. L. ²Joyal, C. N. ²Zimmerman, A. P. Kozikowski, J. A. Barrett, W. C. Eckelman, et al., J Med. ²Chem. ²2009, 52, 347.²39. S. M. Hillier, K. P. Maresca, F. J. Femia, J. C. Marquis, C. A. Foss, N. ²Nguyen, C. N. ²Zimmerman, J. A. Barrett, W. C. Eckelman, M. G. Pomper, etal., Cancer Res. ²2009, 69, ²6932.²132²<DP=133>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²40. J. A. Barrett, R. E. Coleman, S. J. Goldsmith, S. Vallabhajosula, N. A. ²Petry, S. Cho, T. ²Armor, J. B. Stubbs, K. P. Maresca, M. G. Stabin, et al., J. Nucl. Med. 2013, ²54, 380.²41. J. Kelly, A. Amor-Coarasa, A. Nikolopoulou, D. Kim, C. Williams Jr., S. ²Ponnala, J. W. ²Babich, Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 647.²42. A. Ghosh, W. D. W. Heston, J. Cell. Biochem. 2004, 91, 528.²43. M. S. Dennis, M. Zhang, Y. Gloria Meng, M. Kadkhodayan, D. Kirchhofer, D. ²Combs, ²L. A. Damico, J. Biol. Chem. 2002, 277, 35035.²44. C. E. Dumelin, S. Trassel, F. Buller, E. Trachsel, F. Bootz, Y. Zhang, L. ²Mannocci, S. C. ²Beck, M. Drumea-Mirancea, M. W. Seeliger, et al., Angew. Chem. Int. Ed. 2008, ²47, ²3196.²102. M. Mato-Iglesias, A. Roca-Sabio, Z. Palinkas, D. Esteban-Gomez, C. ²Platas-²Iglesias, E. T6th, A. de Blas, T. Rodriguez-Blas, Inorg. Chem. 2008, 47, 7840-²7851.²103. A. Roca-Sabio, M. Mato-Iglesias, D. Esteban-G6mez, E. T6th, A. de ²Blas, C. ²Platas-Iglesias, T. Rodriguez-Blas, J. Am. Chem. Soc. 2009, 131, 3331-3341.²104. V. J. Gatto, G. W. Gokel, J. Am. Chem. Soc. 1984, 106, 8240-8244.²105. E. R. Neil, M. A. Fox, R. Pal, L.-0. Palsson, B. A. O'Sullivan, D. ²Parker, Dalton ²Trans. 2015, 44, 14937-14951.²106. Z. E. A. Chamas, X. Guo, J.-L. Canet, A. Gautier, D. Boyer, R. Mahiou, ²Dalton ²Trans. 2010, 39, 7091-7097.²108. D. T. Corson, C. F. Meares, Bioconjug. Chem. 2000, 11, 292-299.²109. G. M. Sheldrick, Acta Crystallogr. Sect. A 2015, 71, 3-8.²110. G. M. Sheldrick, Acta Crystallogr. Sect. A 2008, 64, 112-122.²111. P. Mailer, Crystallogr. Rev. 2009, 15, 57-83.²112. 0. V Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. ²Puschmann, ²Appl. Crystallogr. 2009, 42, 339-341.²113. J. Dilling, R. Kracken, L. Merminga, Eds., ISAC and ARIEL: The TRIUMF ²Radioactive Beam Facilities and the Scientific Program, Springer, Dordrecht, ²Netherlands, 2014.²133²<DP=134>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²114. J. R. Crawford, P. Kunz, H. Yang, P. Schaffer, T. J. Ruth, AppL ²Radial. 'sot. ²2017, 122, 222-228.²115. B. Zielinska, C. Apostolidis, F. Bruchertseifer, A. Morgenstern, ²Solvent Extr. Ion ²Exch. 2007, 25, 339-349.²116. V. Radchenko, J. W. Engle, J. J. Wilson, J. R. Maassen, F. M. Nortier, ²W. A. ²Taylor, E. R. Birnbaum, L. A. Hudston, K. D. John, M. E. Fassbender, I ²Chromatogr. A ²2015, 1380, 55-63.²117. M. P. Miranda-Hernandez, E. R. Valle-Gonzalez, D. Ferreira-Gomez, N. ²0. ²Perez, L. F. Flores-Ortiz, E. Medina-Rivero, Anal. Bioanal. Chem. 2016, 408, ²1523-²1530.²118. E. W. Price, K. J. Edwards, K. E. Carnazza, S. D. Carlin, B. M. ²Zeglis, M. J. ²Adam, C. Orvig, J. S. Lewis, Nucl. Med. Biol. 2016, 43, 566-576.²119. J. Kelly, A. Amor-Coarasa, A. Nikolopoulou, D. Kim, C. Williams, S. ²Ponnala, J. ²W. Babich, Eur. I. NucL Med. MoL Imaging 2017, 44, 647-661.²

[0213] While certain embodiments have been illustrated and described, a person ²with ordinary ²skill in the art, after reading the foregoing specification, can effect ²changes, substitutions of ²equivalents and other types of alterations to the compounds of the present ²technology or salts, ²pharmaceutical compositions, derivatives, prodrugs, metabolites, tautomers or ²racemic ²mixtures thereof as set forth herein. Each aspect and embodiment described ²above can also ²have included or incorporated therewith such variations or aspects as ²disclosed in regard to any ²or all of the other aspects and embodiments.²

[0214] The present technology is also not to be limited in terms of the ²particular aspects ²described herein, which are intended as single illustrations of individual ²aspects of the present ²technology. Many modifications and variations of this present technology can ²be made without ²departing from its spirit and scope, as will be apparent to those skilled in ²the art. Functionally ²equivalent methods within the scope of the present technology, in addition to ²those enumerated ²herein, will be apparent to those skilled in the art from the foregoing ²descriptions. Such ²modifications and variations are intended to fall within the scope of the ²appended claims. It is to ²be understood that this present technology is not limited to particular ²methods, reagents, ²compounds, compositions, labeled compounds or biological systems, which can, ²of course, vary. ²It is also to be understood that the terminology used herein is for the ²purpose of describing ²particular aspects only, and is not intended to be limiting. Thus, it is ²intended that the²134²<DP=135>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²specification be considered as exemplary only with the breadth, scope and ²spirit of the present ²technology indicated only by the appended claims, definitions therein and any ²equivalents ²thereof.²

[0215] The embodiments, illustratively described herein may suitably be ²practiced in the ²absence of any element or elements, limitation or limitations, not ²specifically disclosed herein. ²Thus, for example, the terms "comprising," "including," "containing," etc. ²shall be read ²expansively and without limitation. Additionally, the terms and expressions ²employed herein ²have been used as terms of description and not of limitation, and there is no ²intention in the use ²of such terms and expressions of excluding any equivalents of the features ²shown and described ²or portions thereof, but it is recognized that various modifications are ²possible within the scope ²of the claimed technology. Additionally, the phrase "consisting essentially ²of' will be ²understood to include those elements specifically recited and those additional ²elements that do ²not materially affect the basic and novel characteristics of the claimed ²technology. The phrase ²"consisting of' excludes any element not specified.²

[0216] In addition, where features or aspects of the disclosure are described ²in terms of ²Markush groups, those skilled in the art will recognize that the disclosure is ²also thereby ²described in terms of any individual member or subgroup of members of the ²Markush group. ²Each of the narrower species and subgeneric groupings falling within the ²generic disclosure also ²form part of the invention. This includes the generic description of the ²invention with a proviso ²or negative limitation removing any subject matter from the genus, regardless ²of whether or not ²the excised material is specifically recited herein.²

[0217] As will be understood by one skilled in the art, for any and all ²purposes, particularly in ²terms of providing a written description, all ranges disclosed herein also ²encompass any and all ²possible subranges and combinations of subranges thereof. Any listed range can ²be easily ²recognized as sufficiently describing and enabling the same range being broken ²down into at ²least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting ²example, each range ²discussed herein can be readily broken down into a lower third, middle third ²and upper third, etc. ²As will also be understood by one skilled in the art all language such as "up ²to," "at least," ²"greater than," "less than," and the like, include the number recited and ²refer to ranges which ²can be subsequently broken down into subranges as discussed above. Finally, as ²will be ²understood by one skilled in the art, a range includes each individual member.²

[0218] All publications, patent applications, issued patents, and other ²documents (for example, ²journals, articles and / or textbooks) referred to in this specification are ²herein incorporated by²135²<DP=136>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²reference as if each individual publication, patent application, issued ²patent, or other document ²was specifically and individually indicated to be incorporated by reference in ²its entirety. ²Definitions that are contained in text incorporated by reference are excluded ²to the extent that ²they contradict definitions in this disclosure.²

[0219] The present technology may include, but is not limited to, the features ²and ²combinations of features recited in the following lettered paragraphs, it ²being understood that ²the following paragraphs should not be interpreted as limiting the scope of ²the claims as ²appended hereto or mandating that all such features must necessarily be ²included in such claims:²A. A compound of Formula I²Z3²\²(-0²f-N²Z1²w5 a Z2²(I)²or a pharmaceutically acceptable salt thereof, wherein²Z1 is H or -X1-W2²Z2 is OH or NH-W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl,²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where 14) is 1, 2, 3, 4, ²5, ²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', -²0C(0)R:, -C(0)0R% -C(S)OR', -S021U, -SNOW), -SO2NR'2, -²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS,²NH2, -N=C=N-R% -S02C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl,²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R'²136²<DP=137>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²where Tv is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where ²xis ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, C5-C8 cycloalkenyl, C2-C6 alkynyl, Cs-Cio cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²B. The compound of Paragraph A, wherein the compound is of Formula III² / \²(-0 0²N-\²0 N²0 (III)²or a pharmaceutically acceptable salt thereof.²C. The compound of Paragraph A or Paragraph B, wherein the compound is ²SCN²=0 0²OH HO²) / 1\1 c0²0 0)²or pharmaceutically acceptable salt thereof.²D. The compound of Paragraph A, wherein the compound of Formula I is of ²Formula VI²137²<DP=138>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²(-0²\-0 \N (1\1) __ e²¨ OH²0 \²(VI)²or a pharmaceutically acceptable salt thereof.²E. The compound of Paragraph A, wherein the compound of Formula I is of ²Formula IX²oN²\1=1 \-0 0¨) (1\1) __________ e² _____________________________ OH²W OH²(IX)²or a pharmaceutically acceptable salt thereof.²F. The compound of Paragraph A, wherein the compound of Formula I is of ²Formula XII ²W7²\²(-0²riN²0²¨ OH²0 (XII)²or a pharmaceutically acceptable salt thereof.²G. A compound of Formula IA²Z3²\²C ,²F-N²1\1C¨d¨µ0 / 0²_ ____________________________ OH²zi²w50, _______ Z2²(IA)²138²<DP=139>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²or a pharmaceutically acceptable salt thereof, wherein²MI- is an alpha-emitting radionuclide;²is H or -V-W2²Z2 is OH or NH-W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S,²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl,²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where w is 1, 2, 3, 4, ²5, ²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)7-0R' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²OC(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, - ²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-²NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group,²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),-R' ²where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where ²xis ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, Cs-C8 cycloalkenyl, C2-C6 alkynyl, C8-C10 cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²H. The compound of Paragraph G, wherein MI- is actinium-225 (225Ac3+), radium-²223 (233Ra2+), ²bismuth-213 (213Bi3+), lead-212 (212-rs,nip 2+²and / or 212M4+ terbium-149 (149Tb3+), fermium-²255 (255Fm3+), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 ²(211A-t+), ²astatine-217 (217A-0, or uranium-230.²139²<DP=140>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²I. The compound of Paragraph G or Paragraph H, wherein the compound of Formula ²I is of ²Formula IV²o² / \²0 N²ss0 ______________________ / 1\1 / \ Xl¨W2²HO ¨²0 (IV)²or a pharmaceutically acceptable salt thereof, wherein M2 is an alpha-emitting²radionuclide.²J. The compound of Paragraph I, wherein M2 is actinium-225 (225Ac3)+,, radium-²223 (233Ra2+), ²bismuth-213 (213B=13)+,,²lead-212 (212Pb2+ and / or 212pb4+ss), terbium-149 (149Tb3+), fermium-²255 (255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 ²(2liAt+), ²astatine-217 (217At+), or uranium-230.²K. The compound of Paragraph I, wherein the compound is²SCN²0²OH HO-²-K²N - - - - M - - - N²ss²d 'o²or a pharmaceutically acceptable salt thereof.²L. The compound of Paragraph K, wherein M2 is actinium-225 (225AC 3)+,,²radium-223 (233Ra2+), ²bismuth-213 (213B=3)+,, lead-212 (212Pb2+ and / or 212pb4+), terbium-149 ²(149Tb3+), fermium-²255 (255Fm3+), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 ²(2liAt+), ²astatine-217 (217At+), or uranium-230.²M. The compound of Paragraph G or Paragraph H, wherein the compound of Formula ²IA is of²Formula VIII²140²<DP=141>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²CR,²N 0²\¨d² ________________________________ OH²0 \²(VII)²or a pharmaceutically acceptable salt thereof, wherein M3 is an alpha-emitting²radionuclide.²N. The compound of Paragraph M, wherein M3 is actinium-225 (225AC 3)+µ,²radium-223 (233Ra2+),²bismuth-213 (213B=13)+,,²lead-212 (212Pb2+ and / or 212pb4+), terbium-149 (149Tb3+), fermium-²255 (255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 ²(211A(+),²astatine-217 (217At+), or uranium-230.²0. The compound of Paragraph G or Paragraph H, wherein the compound of Formula ²IA is of²Formula X²rq²,²N 0²\N d 016 ____________________ i<² ¨S_40 OH²\v / 5 OH²(X)²or a pharmaceutically acceptable salt thereof, wherein M4 is an alpha-emitting²radionuclide.²P. The compound of Paragraph 0, wherein M4 is actinium-225 (225A 3-H,²c ) radium-223 (233Ra2+),²bismuth-213 (213B=3)+,µ lead-212 (212Pb2+ and / or 212pb4+), terbium-149 ²(149Tb3+), fermium-²255 (255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 ²(2um), ²astatine-217 (217At+), or uranium-230.²Q. The compound of Paragraph G or Paragraph H, wherein the compound of Formula ²IA is of²Formula XIII²141²<DP=142>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²w7²) _______________ \²rqõ²( ,o² ____________________________ OH²0 (XIII)²or a pharmaceutically acceptable salt thereof, wherein M5 is an alpha-emitting²radionuclide.²R. The compound of Paragraph Q, wherein M5 is actinium-225 (225Ac3+), radium-²223 (233Ra2+),²bismuth-213 (213Bi3+), lead-212 (212-rsrin 2+²and / or 212pl 4)-P\ , terbium-149 (149Tb3+), fermium-²255 (255Fm3+), thorium-227 (227Th²4), ) thorium-226 (226Th 4),²astatine-211 (2liAt+),²astatine-217 (217At+), or uranium-230.²S. A targeting compound of Formula II²Z3²\²(OS P²N N 0²¨c 0 OH²Z1²a Z2²L5²R26²or a pharmaceutically acceptable salt thereof, wherein²IVP is an alpha-emitting radionuclide;²Z3 is H or ¨L3¨²²R22²Z2 is OH or NH¨L4¨²²R24²Z3 is H or ¨L6¨R28;²a is 0 or 1;²X1 is 0, NH, or S;²L3, L4, L5, and L6 are independently at each occurence a bond or a linker ²group; and²R22, R24,²R26, and R28 each independently comprises an antibody, antibody fragment ²(e.g., an antigen-binding fragment), a binding moiety, a binding peptide, a ²binding polypeptide (such as a selective targeting oligopeptide containing up ²to²142²<DP=143>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety ²(such as an oligonucleotide, DNA or RNA vector, or aptamer), or a lectin.²T. The targeting compound of Paragraph S, wherein M' is actinium-225 ²(225Ac3+), radium-223²(233Ra2+), bismuth-213 (213B=13)+,,²lead-212 (212pb2+ and / or 212pb4+), terbium-149 (149Tb3+),²fermium-255 (255Fm3+), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-²211²(2 "At),²astatine-217 (217A0, or uranium-230.²U. The targeting compound of Paragraph S or Paragraph T,wherein R22, R24, R26, ²and R28 each ²independently comprise belimumab, Mogamulizumab, Blinatumomab, Ibritumomab ²tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, ²Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, ²Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, ²Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, ²Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab pendetide, ²Elotuzumab, ²Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ²ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, ²Catumaxomab, Etaracizumab, an antigen-binding fragment of any thereof, a ²prostate ²specific membrane antigen ("PSMA") binding peptide, a somatostatin receptor ²agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²of any ²thereof.²V. The targeting compound of any one of Paragraphs S-U, wherein the targeting ²compound of²Formula II is of Formula V² / \²co,²² ) s\o / 0 __ 1\1 / )¨xl_L3_R22²__________________________ 4-²HO ______________ \²HO²0 (V)²or a pharmaceutically acceptable salt thereof, wherein M2 is an alpha-emitting²radionuclide.²W. The targeting compound of Paragraph V, wherein M2 is actinium-225 ²(225Ac3+), radium-223 ²(233Ra2+), bismuth-213 (213B=13)+\,²lead-212 (212pb2+ and / or 212pb4+), terbium-149 (149Tb3+),²143²<DP=144>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²fermium-255 (255Fm3+), thorium-227 (227Th4+) thorium-226 (226Th 4), astatine-²211²(211At) 4µ,²astatine-217 (217A0, or uranium-230.²X. The targeting compound of any one of Paragraphs S-U, wherein the targeting ²compound of²Formula II is of Formula VIII² / / 9¨\1²,²N 0²0 \²L4-R24²(VIII)²or a pharmaceutically acceptable salt thereof, wherein M3 is an alpha-emitting²radionuclide.²Y. The targeting compound of Paragraph X, wherein M3 is actinium-225 ²(225Ac3+), radium-223²(233Ra2+), bismuth-213 (213B=²1 ) lead-212 (212rTh2+ and / or 212pb4+), terbium-149 (149Tb3+),²fermium-255 (255Fm3+), thorium-227 (227Th4+) thorium-226 (226Th 4), astatine-²211²"At),(2²astatine-217 (217At+), or uranium-230²Z. The targeting compound of any one of Paragraphs S-U, wherein the targeting ²compound of ²Formula II is of Formula XI² / __________________________ ²po ¨ / OH²"\²L5 OH²R26²(XI)²or a pharmaceutically acceptable salt thereof, wherein M4 an alpha-emitting²radionuclide.²AA. The targeting compound of Paragraph Z, wherein M4 is actinium-225 ²(225Ac3+), radium-²223 (233Ra2+), bismuth-213 (213B=²1 ) lead-212 (212Pb2+ and / or 212Pb4+), terbium-149²(149TD 3)+,,²fermium-255 (255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-²211 (211 ,²At ) astatine-217 (217At+), or uranium-230.²144²<DP=145>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²AB. The targeting compound of any one of Paragraphs S-U, wherein the targeting ²compound of ²Formula II is of Formula XIV²R28²L6²\²CRA,²² ____________________________ j<²¨ OH²0 (XIV)²or a pharmaceutically acceptable salt thereof, wherein M5 is an alpha-emitting²radionuclide.²AC. The targeting compound of Paragraph AB, wherein M5 is actinium-225 ²(225Ac3+), radium-²223 (233Ra2+), bismuth-213 (213Bi3+), lead-212 (212Pb2+ and / or 212Pb4+), ²terbium-149²(149T+²D ) fermium-255 (255Fm3+), thorium-227 (227Th 4),²thorium-226 (226Th 4),²astatine-²211 (211 AA .t)-ps,²astatine-217 (217At+), or uranium-230.²AD. A modified antibody, modified antibody fragment, or modified binding ²peptide comprising²a linkage arising from conjugation of a compound of Formula I²Z3²(0²I\T 0--2-0 ____ / 4:)²0 OH²Z2 Z1² a ²(I) or pharmaceutically acceptable salt thereof,²with an antibody, antibody fragment, or binding peptide, wherein²Z1 is H or ¨Xl¨W2²Z2 is OH or NH¨W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl,²alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' where²145²<DP=146>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x ²is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be ²substituted with one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)y-²R' wherey is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2),OR' ²where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', -0C(0)R', -C(0)OR', - ²C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, -P(0)(OR')2, - ²P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR' -NH2, - ²N=C=N-R', -S02C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-²(OCH2CH2)w-R' where Tv is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-²(OCH2CH2)x-OR' where xis 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which ²may optionally be substituted with one or more of halo, -N3, -OR', - ²CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²OC(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SOX, -S02(OR'), -SO2NR'2, ²-P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, - ²NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6²cycloalkyl, C2-C6 alkenyl, C5-C8 cycloalkenyl, C2-C6 alkynyl, Cs-Cto²cycloalkynyl, C5-C6 aryl, heterocyclyl, or heteroaryl²AE. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AD, wherein the antibody comprises belimumab, Mogamulizumab, ²Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, ²Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, ²Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, ²Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, ²Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, ²Capromab pendetide, Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, ²Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, ²Girentuximab, Nimotuzumab, Catumaxomab, or Etaracizumab.²AF. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AD or Paragraph AE, wherein the antibody fragment comprises an ²antigen-²146²<DP=147>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²binding fragment of belimumab, Mogamulizumab, Blinatumomab, Ibritumomab²tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, ²Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, ²Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, ²Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, ²Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab pendetide, ²Elotuzumab, ²Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ²ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab,²Catumaxomab, or Etaracizumab.²AG. The modified antibody, modified antibody fragment, or modified binding ²peptide of any ²one of Paragraphs AD-AF, wherein the binding peptide comprises comprises a ²prostate ²specific membrane antigen ("PSMA") binding peptide, a somatostatin receptor ²agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²thereof²AM. The modified antibody, modified antibody fragment, or modified binding ²peptideof any²one of Paragraphs AD-AG, wherein the compound of Formula I is of Formula III² / \²0 0²o,²)N4²HO _________ ²0 (III)²or a pharmaceutically acceptable salt thereof.²Al. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of Paragraphs AD-AM, wherein the linkage is a thiocyante linkage; wherein the ²thiocyanate linkage arises from conjugation of the compound with the antibody, ²antibody ²fragment, or binding peptide; and wherein the compound is²147²<DP=148>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²SCN²=0 0²\¨OH HO-²-²N Or¨\0¨\ 1\1 / )²\¨N²0)²or pharmaceutically acceptable salt thereof.²AJ. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of Paragraphs AD-AG, wherein the compound of Formula I is of Formula VI²(0²T-N²NH²0 \²(VI)²or a pharmaceutically acceptable salt thereof.²AK. The modified antibody, modified antibody fragment, or modified binding ²peptideof any²one of Paragraphs AD-AG, wherein the compound of Formula I is of Formula IX²1=1 \-0 0¨) (N)² _____________________________ OH²w5 OH²(IX)²or a pharmaceutically acceptable salt thereof.²AL. The modified antibody, modified antibody fragment, or modified binding ²peptideof any²one of Paragraphs AD-AG, wherein the compound of Formula I is of Formula XII²148²<DP=149>²CA 03119467 2021-05-10²WO 2020 / 106886 ²PCT / US2019 / 062479²) \²(0²7-1N²- OH²0 (XII)²or a pharmaceutically acceptable salt thereof.²AM. A modified antibody, modified antibody fragment, or modified binding ²peptide ²comprising a linkage arising from conjugation of a compound of Formula IA²Z3²\²CO\²²N---M1---N²>²C. 0 \-- / - OH² / 'Z2 Z'²W5a' Z2 ²(IA) or a pharmaceutically acceptable salt thereof,²with an antibody, antibody fragment, or binding peptide, wherein²M1 is an alpha-emitting radionuclide,²Z1 is H or -Xl-W2²Z2 is OH or NH-W3²Z3 is H or W7;²aisOorl;²X1 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl,²alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' where ²w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x ²is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be ²substituted with one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)y-²R' wherey is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' ²where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', -0C(0)R', -C(0)OR', - ²C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, -P(0)(OR')2, - ²P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-NH2, - ²N=C=N-R', -S02C1, -C(0)C1, or an epoxide group;²149²<DP=150>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-²(OCH2CH2)w-R' where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-²(OCH2CH2),-OR' where xis 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which ²may optionally be substituted with one or more of halo, -N3, -OR', - ²CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²OC(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, ²-P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, - ²NR'-NH2, -N=C=N-R', -S02C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 alkenyl, C5-C8 cycloalkenyl, C2-C6 alkynyl, C8-Cto²cycloalkynyl, C5-C6 aryl, heterocyclyl, or heteroaryl²AN. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AM, wherein Ml is actinium-225 (225Ac3+), radium-223 (233Ra2+), ²bismuth-²213 (213Bi3+), lead-212 (212Pb2+ and / or 212pb4+), terbium-149 (149Tb3+), ²fermium-255 ²(255Fm3+), thorium-227 (227Th4+) thorium-226 (226Th 4), astatine-211 (211A .-²p\²) astatine-²217 (217At+), or uranium-230.²AO. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AM or Paragraph AN, wherein the antibody comprises belimumab, ²Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, ²Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, ²Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, ²Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, ²Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, ²Capromab pendetide, Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, ²Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, ²Girentuximab, Nimotuzumab, Catumaxomab, or Etaracizumab.²AP. The modified antibody, modified antibody fragment, or modified binding ²peptide of any ²one of Paragraphs AM-AO, wherein the antibody fragment comprises an antigen-²binding ²fragment of belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, ²Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab²150²<DP=151>²CA 03119467 2021-05-10² WO 2020 / 106886 PCT / US2019 / 062479²pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, ²Necitumumab, ²Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, ²Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, ²Avelumab, Durvalumab, Capromab pendetide, Elotuzumab, Denosumab, Ziv-²aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, ²Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, Catumaxomab, or ²Etaracizumab²AQ. The modified antibody, modified antibody fragment, or modified binding ²peptide of any ²one of Paragraphs AM-AP, wherein the binding peptide comprises a prostate ²specific ²membrane antigen ("PSMA") binding peptide, a somatostatin receptor agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²thereof.²AR. The modified antibody, modified antibody fragment, or modified binding ²peptide of any²one of Paragraphs AM-AQ, wherein the compound of Formula I is of Formula IV² / ____________________ \²clõP²N----M2---N² 0 N / ²HO> ___________________ ² 0 0 __ N²HO²0 (IV)²or a pharmaceutically acceptable salt thereof, wherein M2 is an alpha-emitting²radionuclide.²AS. The modified antibody, modified antibody fragment, or modified binding ²peptide of²Paragraph AR, wherein M2 is actinium-225 (225Ac3+), radium-223 (233Ra2+), ²bismuth-213²(213B=13)+,,²lead-212 (212p, 2+²and / or 212pb4+), terbium-149 (149Tb3+), fermium-255²(255Fm3+), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 ) ²astatine-²217 (217At+), or uranium-230.²AT. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AR, wherein the linkage is a thiocyante linkage; wherein the ²thiocyanate ²linkage arises from conjugation of the compound with the antibody, antibody ²fragment, ²or binding peptide; and wherein the compound is²151²<DP=152>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²SCN²= 0 0²OH HO-4(²O / C:²eN ²or a pharmaceutically acceptable salt thereof.²AU. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AT, wherein M2 is actinium-225 (225Ac3+), radium-223 (233Ra2+), ²bismuth-213 ²(2i3B=13)+,,²lead-212 (212Pb2+ and / or 212pb4+), terbium-149 (149Tb3+), fermium-255 ²(255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 (2 AAt) ²+A,²astatine-²217 (217At+), or uranium-230.²AV. The modified antibody, modified antibody fragment, or modified binding ²peptide of any ²one of Paragraphs AM-AQ, wherein the compound of Formula IA is of Formula VIII ²²7¨\²s / ²---N²< <²¨ OH²NH²Or \²(VII)²or a pharmaceutically acceptable salt thereof, wherein M3 is an alpha-emitting²radionuclide.²AW. The modified antibody, modified antibody fragment, or modified binding ²peptide of²Paragraph AV, wherein M3 is actinium-225 (225Ac3+), radium-223 (233Ra2+), ²bismuth-213²(213B=3)+,, lead-212 (212-rsrmi 2+²and / or 212pb4+), terbium-149 (149Tb3+), fermium-255²(255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 (2 1²At ) astatine-²217 (217At+), or uranium-230.²AX. The modified antibody, modified antibody fragment, or modified binding ²peptide of any²one of Paragraphs AM-AQ, wherein the compound of Formula IA is of Formula X²152²<DP=153>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²co,²N----M4---N²¨ OH²W5 OH²(X)²or a pharmaceutically acceptable salt thereof, wherein M4 is an alpha-emitting²radionuclide.²AY. The modified antibody, modified antibody fragment, or modified binding ²peptide of²Paragraph AX, wherein M4 is actinium-225 (225Ac3+), radium-223 (233Ra2+), ²bismuth-213²(213B=3)+,, lead-212 (212P102+ and / or 212p1D4+), terbium-149 (149Tb3+), ²fermium-255²(255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 en A²) astatine-²217 (217At+), or uranium-230.²AZ. The modified antibody, modified antibody fragment, or modified binding ²peptide of any²one of Paragraphs AM-AQ, wherein the compound of Formula IA is of Formula XIII²W7²) \²(O'S²,o²¨ OH²0 (XIII)²or a pharmaceutically acceptable salt thereof, wherein M5 is an alpha-emitting ²²radionuclide.²BA. The modified antibody, modified antibody fragment, or modified binding ²peptide of ²Paragraph AZ, wherein M5 is actinium-225 (225Ac3+), radium-223 (233Ra2+), ²bismuth-213 ²(213B=3)+,\ lead-212 (212P102+ and / or 212pb4+), terbium-149 (149Tb3+), fermium-²255 ²(255Fm3+), thorium-227 (227Th 4), thorium-226 (226Th 4), astatine-211 (2 A²) astatine-²217 (217At+), or uranium-230.²BB. A composition comprising a pharmaceutically acceptable carrier and a ²compound of any ²one of Paragraphs A-R.²153²<DP=154>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²BC. A composition comprising a pharmaceutically acceptable carrier and a ²targeting compound ²of any one of Paragraphs S-AC or comprising a pharmaceutically acceptable ²carrier and ²a modified antibody, modified antibody fragment, or modified binding peptide ²of any ²one of Paragraphs AD-BA.²BD. A pharmaceutical composition useful in targeted radiotherapy of cancer ²and / or mammalian ²tissue overexpressing prostate specific membrane antigen ("PSMA") in a ²subject, ²wherein the pharmaceutical composition comprises a pharmaceutically acceptable ²carrier ²and a compound of any one of Paragraphs S-AC or a modified antibody, modified ²antibody fragment, or modified binding peptide of any one of Paragraphs AD-BA.²BE. The pharmaceutical composition of Paragraph BD, wherein the pharmaceutical ²²composition comprises an effective amount for treating the cancer and / or ²mammalian ²tissue overexpressing PSMA of the compound or an effective amount for treating ²the ²cancer and / or mammalian tissue overexpressing PSMA of the modified antibody, ²modified antibody fragment, or modified binding peptide.²BF. The pharmaceutical composition of Paragraph BD or Paragraph BE, where the ²subject ²suffers from a mammalian tissue expressing a somatostatin receptor, a bombesin ²²receptor, seprase, or a combination of any two or more thereof, and / or ²mammalian tissue ²overexpressing PSMA.²BG. The pharmaceutical composition of any one of Paragraphs BD-BF, wherein the ²subject ²suffers from one or more of a growth hormone producing tumor, a neuroendocrine ²²tumor, a pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a ²small cell ²carcinoma of the lung, gastric cancer tissue, pancreatic cancer tissue, a ²neuroblastoma,²BH. The pharmaceutical composition of any one of Paragraphs BD-BG, wherein the ²subject ²suffers from one or more of a glioma, a breast cancer, an adrenal cortical ²cancer, a ²cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ²ovarian ²carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a ²small cell ²lung cancer, a bladder cancer, a colon cancer, a primary gastric ²adenocarcinoma, a ²primary colorectal adenocarcinoma, a renal cell carcinoma, and a prostate ²cancer.²BI. The pharmaceutical composition of any one of Paragraphs BD-BH, wherein the ²²pharmaceutical composition is formulated for intraveneous administration, ²optionally ²comprising sterilized water, Ringer's solution, or an isotonic aqueous saline ²solution.²154²<DP=155>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²BJ. The pharmaceutical composition of any one of Paragraphs BD-BI, wherein the ²effective ²amount of the compound is from about 0.01 lig to about 10 mg of the compound ²per ²gram of the pharmaceutical composition.²BK. The pharmaceutical composition of any one of Paragraphs BD-BJ, wherein the ²²pharmaceutical composition is provided in an injectable dosage form.²BL. A method of treating a subject, wherein the method comprises administering ²a targeting ²compound of any one of Paragraphs S-AC to the subject or administering a ²modified ²antibody, modified antibody fragment, or modified binding peptide of any one ²of ²Paragraphs AD-BA.²BM. The method of Paragraph BL, wherein the subject suffers from cancer and / or ²mammalian ²tissue overexpressing prostate specific membrane antigen ("PSMA")²BN. The method of Paragraph BM, wherein the method comprises administering an ²effective ²amount for treating the cancer and / or mammalian tissue overexpressing PSMA of ²the ²compound or an effective amount for treating the cancer and / or mammalian ²tissue ²overexpressing PSMA of the modified antibody, modified antibody fragment, or ²modified binding peptide²BO. The method of any one of Paragraphs BL-BN, wherein the subject suffers ²from a ²mammalian tissue expressing a somatostatin receptor, a bombesin receptor, ²seprase, or a ²combination of any two or more thereof and / or mammalian tissue overexpressing ²prostate specific membrane antigen ("PSMA"), when administered to a subject.²BP. The method of any one of Paragraphs BL-BO, wherein the mammalian tissue ²comprises ²one or more of a growth hormone producing tumor, a neuroendocrine tumor, a ²pituitary ²tumor, a vasoactive intestinal peptide-secreting tumor, a small cell carcinoma ²of the lung, ²gastric cancer tissue, pancreatic cancer tissue, a neuroblastoma, and a ²metastatic cancer.²BQ. The method of any one of Paragraphs BL-BP, wherein the subject suffers ²from one or more ²of a glioma, a breast cancer, an adrenal cortical cancer, a cervical ²carcinoma, a vulvar ²carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ²ovarian ²carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder ²cancer, a ²colon cancer, a primary gastric adenocarcinoma, a primary colorectal ²adenocarcinoma, a ²renal cell carcinoma, and a prostate cancer.²155²<DP=156>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²BR. The method of any one of Paragraphs BL-BQ, wherein the administering ²comprises ²parenteral administration.²BS. The method of any one of Paragraphs BL-BR, wherein the ²administeringcomprises ²intraveneous administration.²BT. The method of any one of Paragraphs BL-BS, wherein the effective amount is ²from about ²0.1 itg to about 50 jig per kilogram of subject mass.²BU. A compound comprising a first domain having a blood-protein binding moiety ²with low ²specific affinity for the blood-protein, a second domain having a tumor ²targeting moiety ²with high affinity for a tumor antigen, and a third domain having a chelator.²By. The compound of Paragraph BU, wherein the tumor antigen is PSMA, bombesin, ²²somatostatin receptor, or seprase.²BW. The compound of Paragraph BU or Paragraph By, wherein the blood protein ²binding ²moiety has specific affinity for albumin of about 0.5-50 x 10-6M, and the ²tumor targeting ²moiety has specific affinity for the tumor antigen of about 0.5-50 x 10-9M.²156²<DP=157>²BX. A compound represented by the following structure²0²i..) ²o ²i..) ²o²I ² 1¨²²o ²o² / __ \ HN 0 ²oe² / 1 0 ² c:²(¨ / N N---\ ² HN¨²²C²_______________________________________________________________________________²_________ e 0_ / µ0 21-1²¨ OH²0¨r²OH ² ²0²0²HN 0¨ / ¨²p²S ² 2²HN / ¨Orj²1-, 0¨ / ² ..'²vi ² 2²--4² / -- / ² ,,²,,0²_14N¨r ² ,²Li²0²0¨ / ²AO²HN N .. ---²CO2H ) H Nz--Nr----²0 ² A²1-i²HO2C,----.NAN.-...0O2H²H H ² cp²n.) ²o²1-,²or a pharmaceutically acceptable salt thereof. ² o²;O--, ²o²BY. A composition comprising the compound of Paragraph BX chelating 213Bi3+, ²211At+, 225Ac3+, 152Dy3+, 212Bi3+, 211Bi3+, 217At+, 227Th4+, 226Th4+, N ²4=. ²--4 ²VD²233Ra2+, 212pb2+ , or 212pb4+.²<DP=158>²CA 03119467 2021-05-10²WO 2020 / 106886 PCT / US2019 / 062479²BZ. A method of treating a subject, wherein the method comprises administering ²a composition ²of Paragraph BY to the subject.²CA. The method of Paragraph BZ, wherein the subject suffers from cancer and / or ²mammalian ²tissue overexpressing prostate specific membrane antigen ("PSMA")²CB. The method of Paragraph CA, wherein the method comprises administering an ²effective ²amount for treating the cancer and / or mammalian tissue overexpressing PSMA of ²the ²composition.²CC. The method of any one of Paragraphs BZ-CB, wherein the subject suffers ²from a²mammalian tissue overexpressing prostate specific membrane antigen ("PSMA").²CD. The method of any one of Paragraphs BZ-CC, wherein the mammalian tissue ²comprises ²one or more of a growth hormone producing tumor, a neuroendocrine tumor, a ²pituitary ²tumor, a vasoactive intestinal peptide-secreting tumor, a small cell carcinoma ²of the lung, ²gastric cancer tissue, pancreatic cancer tissue, a neuroblastoma, and a ²metastatic cancer.²CE. The method of any one of Paragraphs BZ-CD, wherein the subject suffers ²from one or ²more of a glioma, a breast cancer, an adrenal cortical cancer, a cervical ²carcinoma, a ²vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a ²metastatic ²ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a ²bladder ²cancer, a colon cancer, a primary gastric adenocarcinoma, a primary colorectal ²²adenocarcinoma, a renal cell carcinoma, and a prostate cancer.²CF. The method of any one of Paragraphs BZ-CE, wherein the administering ²comprises ²parenteral administration.²CG. The method of any one of Paragraphs BZ-CF, wherein the ²administeringcomprises ²intraveneous administration.²CH. The method of any one of Paragraphs BZ-CG, wherein the effective amount is ²from about ²0.1 lig to about 50 jig per kilogram of subject mass.²

[0220] Other embodiments are set forth in the following claims, along with the ²full scope of ²equivalents to which such claims are entitled.²158²

Claims

<DP=1>²What is claimed is:²1. A compound of Formula I²²or a pharmaceutically acceptable salt thereof, wherein²Z' is H or -V-W2²Z2 is OH or NH-W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S,²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl,²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' wherew is 1, 2, 3, 4, 5, ²²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2) -R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, - ²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-²NH2, -N=C=N-R', -502C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' ²where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x ²is ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -502C1, -C(0)C1, or an epoxide group; and²159²<DP=2>²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, C5-C8 cycloalkenyl, C2-C6 alkynyl, Cs-Clo cycloalkynyl, Cs-C6 aryl,²heterocyclyl, or heteroaryl.²2. The compound of claim 1, wherein the compound is of Formula III²²or a pharmaceutically acceptable salt thereof.²3. The compound of claim 1 or claim 2, wherein the compound is²²or pharmaceutically acceptable salt thereof.²4. The compound of claim 1, wherein the compound of Formula I is of Formula VI²²or a pharmaceutically acceptable salt thereof.²5. The compound of claim 1, wherein the compound of Formula I is of Formula IX²160²<DP=3>²²or a pharmaceutically acceptable salt thereof.²6. The compound of claim 1, wherein the compound of Formula I is of Formula ²XII²²or a pharmaceutically acceptable salt thereof.²7. A compound of Formula IA²²or a pharmaceutically acceptable salt thereof, wherein²1\4' is an alpha-emitting radionuclide;²Z" is H or ¨X"¨W2²Z2 is OH or NH¨W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl,²aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2)w-R' where 14, is 1, 2, 3, 4, ²5,²161²<DP=4>²6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2),-OR' where x is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, each of which may optionally be substituted with one or more of halo, -²N3, ²-OR', -CH2CH2-(OCH2CH2)y-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -502R', -502(OR'), -SO2NR'2, - ²P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS,²NH2, -N=C=N-R', -502C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),-R' ²where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x ²is ²1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be substituted ²with ²one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, ²5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, ²8, 9, ²or 10, -SR', -0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -S021V, -502(OR'), - ²SO2NR'2, -P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, - ²NCS, -NR'-NH2, -N=C=N-R', -502C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 ²alkenyl, Cs-C8 cycloalkenyl, C2-C6 alkynyl, C8-C10 cycloalkynyl, C5-C6 aryl, ²heterocyclyl, or heteroaryl.²8. The compound of claim 7, wherein MI- is actinium-225 (225AC3), radium-223 ²(233Ra2+), ²bismuth-213 (213B i3+), lead-212 (212Pb2+ and / or 212Pb4+), terbium-149 (1-²49Tb3+), fermium-²255 (255F1113), thorium-227 (227114+), thorium-226 (226Th4+), astatine-211 ²(211At+), ²astatine-217 (217At+), or uranium-230.²9. The compound of claim 7 or claim 8, wherein the compound of Formula I is of ²Formula IV²²or a pharmaceutically acceptable salt thereof, wherein M2 is an alpha-emitting ²²radionuclide.²162²<DP=5>²10. The compound of claim 9, wherein M2 is actinium-225 (225Ac3)+,µ radium-223 ²(233Ra2), ²bismuth-213 (213B =1 3)+,,²lead-212 (212%2+ and / or 214.134-P), terbium-149 (149Tb 3 ), fermium-²255 (255F1113), thorium-227 (227Th4), thorium-226 (226Th4+), astatine-211 ²(2um), ²astatine-217 (217A0, or uranium-230.²11. The compound of claim 9, wherein the compound is²²or a pharmaceutically acceptable salt thereof.²12. The compound of claim 11, wherein M2 is actinium-225 (225Ac3)+,µ radium-²223 (233Ra2+), ²bismuth-213 (213B =1 3)+µ,²lead-212 (212P+n 2+²and / or 212m4+), terbium-149 (149Tb 3 ), fermium-²255 (255F1113), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 ²(211At+), ²astatine-217 (217At+), or uranium-230.²13. The compound of claim 7 or claim 8, wherein the compound of Formula IA is ²of Formula²VIII²²or a pharmaceutically acceptable salt thereof, wherein M3 is an alpha-emitting²radionuclide.²14. The compound of claim 13, wherein M3 is actinium-225 (225Ac3)+,µ radium-²223 (233Ra2+), ²bismuth-213 (213B =1 3+%²) lead-212 (212m2+ and / or 212m4+), terbium-149 (149Tb 3+), fermium-²255 (255Fril3+), thorium-227 (227Th4), thorium-226 (226Th4+), astatine-211 ²(211At+), ²astatine-217 (217A-0, or uranium-230.²163²<DP=6>²15. The compound of claim 7 or claim 8, wherein the compound of Formula IA is ²of Formula X²²or a pharmaceutically acceptable salt thereof, wherein M4 is an alpha-emitting ²²radionuclide.²16. The compound of claim 15, wherein M4 is actinium-225 (225Ac3-H,²) radium-223 (233Ra2+),²bismuth-213 (213B=13)+\,²lead-212 (212m2+ and / or 212F=b4+), terbium-149 (1-49Tb3+), fermium-²255 (255F1113), thorium-227 (227Th4), thorium-226 (226Th4+), astatine-211 ²(211At+), ²astatine-217 (217At+), or uranium-230.²17. The compound of claim 7 or claim 8, wherein the compound of Formula IA is ²of Formula²XIII²²or a pharmaceutically acceptable salt thereof, wherein M5 is an alpha-emitting²radionuclide.²18. The compound of claim 17, wherein M5 is actinium-225 (225Ac3-H,²) radium-223 (233Ra2+),²bismuth-213 (213B=13)+\,²lead-212 (212m2+ and / or 212pb4+), terbium-149 (1-49Tb3+), fermium-²255 (255F1113), thorium-227 (227Th4), thorium-226 (226Th4+), astatine-211 ²(211At+),²astatine-217 (217At+), or uranium-230.²164²<DP=7>²19. A targeting compound of Formula II²²or a pharmaceutically acceptable salt thereof, wherein²M1 is an alpha-emitting radionuclide;²Z1 is H or ¨L3¨R22²Z2 is OH or NH¨L4¨R24²Z3 is H or ¨L6¨R28;²a 1S 0 or 1;²X1 is 0, NH, or S;²L3, L4, L5, and L6 are independently at each occurence a bond or a linker ²group; and²R22, R24, R26, and²each independently comprises an antibody, antibody fragment²(e.g., an antigen-binding fragment), a binding moiety, a binding peptide, a ²binding polypeptide (such as a selective targeting oligopeptide containing up ²to ²50 amino acids), a binding protein, an enzyme, a nucleobase-containing moiety ²(such as an oligonucleotide, DNA or RNA vector, or aptamer), or a lectin.²20. The targeting compound of claim 19, wherein M1 is actinium-225 (225AC3+), ²radium-223 ²(233Ra2+), bismuth-213 (213Bi3+), lead-212 (212pb2+ and / or 212N4+), terbium-²149 (149Tb3+), ²fermium-255 (255F1T13+), thorium-227 (227Th4)+,, thorium-226 (226Th4)+,, ²astatine-211 ²(211A²t ) astatine-217 (217At+), or uranium-230²21. The targeting compound of claim 19 or claim 20,wherein R22, R24, K-rs 26,²and R28 each²independently comprise belimumab, Mogamulizumab, Blinatumomab, Ibritumomab ²tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ozogamicin, ²Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, Ipilimumab, ²Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, ²Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, ²Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab pendetide, ²Elotuzumab,²165²<DP=8>²Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ²ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, ²Catumaxomab, Etaracizumab, an antigen-binding fragment of any thereof, a ²prostate ²specific membrane antigen ("PSMA") binding peptide, a somatostatin receptor ²agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²of any ²thereof.²22. The targeting compound of any one of claims 19-21, wherein the targeting ²compound of²²or a pharmaceutically acceptable salt thereof, wherein M2 is an alpha-emitting ²²radionuclide.²23. The targeting compound of claim 22, wherein M2 is actinium-225 (225Ac3+), ²radium-223 ²(233Ra2), bismuth-213 (213B=1 3)+µ,²lead-212 (212pb2+ and / or 212N4+), terbium-149 (149Tb3+),²fermium-255 (255Fm3), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-²211 ²(211At) +s,²astatine-217 (217At+), or uranium-230.²24. The targeting compound of any one of claims 19-21, wherein the targeting ²compound of²²or a pharmaceutically acceptable salt thereof, wherein M3 is an alpha-emitting ²²radionuclide.²25. The targeting compound of claim 24, wherein M3 is actinium-225 (225AC3+), ²radium-223 ²(233Ra2), bismuth-213 (213B=1 3+%²) lead-212 (212m2+ and / or 2121:V), terbium-149 (149Tb3),²166²<DP=9>²fermium-255 (255Fm3+), thorium-227 (227Tb4+), thorium-226 (226Tb4+), astatine-²211²(211A -H,²t ) astatine-217 (247At+), or uranium-230.²26. The targeting compound of any one of claims 19-21, wherein the targeting ²compound of²²or a pharmaceutically acceptable salt thereof, wherein M4 an alpha-emitting ²radionuclide.²27. The targeting compound of claim 26, wherein M4 is actinium-225 (225AC3+), ²radium-223 ²(233Ra2), bismuth-213 (213B=1 3)+s,²lead-212 (212pb2+ and / or 212pb4+), terbium-149 (149Tb3-),²fermium-255 (255Fm3+), thorium-227 (227Tb4+), thorium-226 (226Tb4+), astatine-²211 ²(211A,t)+.,²astatine-217 (247At+), or uranium-230.²28. The targeting compound of any one of claims 19-21, wherein the targeting ²compound of²²or a pharmaceutically acceptable salt thereof, wherein M5 is an alpha-emitting ²²radionuclide.²29. The targeting compound of claim 28, wherein M5 is actinium-225 (225AC3+), ²radium-223 ²(233Ra2), bismuth-213 (213B=1 3+%²) lead-212 (212pb2+ and / or 212pb4+), terbium-149 (149Tb3),²167²<DP=10>²fermium-255 (255Fm3+), thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-²211 ²(2nAt+), astatine-217 (217At+), or uranium-230²30. A modified antibody, modified antibody fragment, or modified binding ²peptide comprising ²a linkage arising from conjugation of a compound of Formula I²²or pharmaceutically acceptable salt thereof,²with an antibody, antibody fragment, or binding peptide, wherein²Z' is H or -Xl-W2²Z2 is OH or NH-W3²Z3 is H or W7;²a is 0 or 1;²X3 is 0, NH, or S;²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl,²alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' where ²w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x ²is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be ²substituted with one or more of halo, -N3, -OR', -CH2CH2-(OCH2CH2)y-²R' wherey is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' ²where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', -0C(0)R', -C(0)OR', - ²C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, -P(0)(OR')2, - ²P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-NH2, - ²N=C=N-R', -502C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-²(OCH2CH2)w-R' where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-²(OCH2CH2),-OR' where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which ²may optionally be substituted with one or more of halo, -N3, -OR', - ²CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -²168²<DP=11>²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, ²-P(0)(OR' )2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, - ²NR' -NH2, -N=C=N-R' -SO2C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -N3, C1-C6 alkyl, C3-C6²cycloalkyl, C2-C6 alkenyl, C5-C8 cycloalkenyl, C2-C6 alkynyl, C8-C10²cycloalkynyl, Cs-C6 aryl, heterocyclyl, or heteroaryl²31. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²30, wherein the antibody comprises belimumab, Mogamulizumab, Blinatumomab, ²Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, Inotuzumab ²ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, Daratumumab, ²Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab, Pertuzumab, ²Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, Nivolumab, ²Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, Capromab ²pendetide, Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, Ramucirumab, ²Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, Girentuximab, ²Nimotuzumab, Catumaxomab, or Etaracizumab.²32. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²30 or claim 31, wherein the antibody fragment comprises an antigen-binding ²fragment of ²belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, ²Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, ²Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, ²Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, ²Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, ²Avelumab, Durvalumab, Capromab pendetide, Elotuzumab, Denosumab, Ziv-²aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, ²Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, Catumaxomab, or ²Etaracizumab.²33. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one ²of claims 30-32, wherein the binding peptide comprises comprises a prostate ²specific ²membrane antigen ("PSMA") binding peptide, a somatostatin receptor agonist, a ²bombesin receptor agonist, a seprase binding compound, or a binding fragement ²thereof.²169²<DP=12>²34. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of claims 30-33, wherein the compound of Formula I is of Formula III²²or a pharmaceutically acceptable salt thereof.²35. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of claims 30-34, wherein the linkage is a thiocyante linkage; wherein the ²thiocyanate ²linkage arises from conjugation of the compound with the antibody, antibody ²fragment, ²or binding peptide; and wherein the compound is²²or pharmaceutically acceptable salt thereof.²36. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of claims 30-33, wherein the compound of Formula I is of Formula VI²²or a pharmaceutically acceptable salt thereof.²37. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of claims 30-33, wherein the compound of Formula I is of Formula IX²170²<DP=13>²²or a pharmaceutically acceptable salt thereof.²38. The modified antibody, modified antibody fragment, or modified binding ²peptideof any one ²of claims 30-33, wherein the compound of Formula I is of Formula XII²²or a pharmaceutically acceptable salt thereof.²39. A modified antibody, modified antibody fragment, or modified binding ²peptide comprising ²a linkage arising from conjugation of a compound of Formula IA²²or a pharmaceutically acceptable salt thereof,²with an antibody, antibody fragment, or binding peptide, wherein²1\41 is an alpha-emitting radionuclide,²Z1 is H or ¨X1¨W2²Z2 is OH or NH¨W3²Z3 is H or W7;²a is 0 or 1;²X1 is 0, NH, or S;²171²<DP=14>²W2 and W3 are each independently H, alkyl, cycloalkyl, alkenyl, cycloalkenyl, ²alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-(OCH2CH2),R' where ²w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-(OCH2CH2)x-OR' where x ²is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which may optionally be ²substituted with one or more of halo, -Ni, -OR', -CH2CH2-(OCH2CH2)y-²R' wherey is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -CH2CH2-(OCH2CH2)z-OR' ²where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', -0C(0)R', -C(0)OR', - ²C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, -P(0)(OR')2, - ²P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, -NR'-NH2, - ²N=C=N-R', -502C1, -C(0)C1, or an epoxide group;²W5 and W7 are each independently OH, NH2, SH, alkyl, cycloalkyl, alkenyl, ²cycloalkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, -CH2CH2-²(OCH2CH2)w-R' where w is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or -CH2CH2-²(OCH2CH2),-OR' where x is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, each of which ²may optionally be substituted with one or more of halo, -Ni, -OR', - ²CH2CH2-(OCH2CH2)yx-R' where y is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, - ²CH2CH2-(OCH2CH2)z-OR' where z is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, -SR', - ²0C(0)R', -C(0)OR', -C(S)OR', -S(0)R', -SO2R', -S02(OR'), -SO2NR'2, ²-P(0)(OR')2, -P(0)R'(OR'), -P(0)R'2, -CN, -OCN, -SCN, -NCO, -NCS, - ²NR'-NH2, -N=C=N-R', -SO2C1, -C(0)C1, or an epoxide group; and²R' is independently at each occurance H, halo, -Ni, C1-C6 alkyl, C3-C6 ²cycloalkyl, C2-C6 alkenyl, Cs-Cs cycloalkenyl, C2-C6 alkynyl, Cs-Cio²cycloalkynyl, CS-C6 aryl, heterocyclyl, or heteroaryl.²40. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²39, wherein MI- is actinium-225 (225AC3+), radium-223 (233Ra2+), bismuth-213 ²(213Bi3+), ²lead-212 (212-rsrin 2+²and / or 212Pb4+), terbium-149 (1-49Tb3+), fermium-255 (255Fm3+), ²thorium-227 (227Th4+), thorium-226 (226114+), astatine-211 (211At+), astatine-²217 (217A0, ²or uranium-230.²41. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²39 or claim 40, wherein the antibody comprises belimumab, Mogamulizumab, ²Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, Ofatumumab, Rituximab, ²Inotuzumab ozogamicin, Moxetumomab pasudotox, Brentuximab vedotin, ²Daratumumab, Ipilimumab, Cetuximab, Necitumumab, Panitumumab, Dinutuximab,²172²<DP=15>²Pertuzumab, Trastuzumab, Trastuzumab emtansine, Siltuximab, Cemiplimab, ²Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, Avelumab, Durvalumab, ²Capromab pendetide, Elotuzumab, Denosumab, Ziv-aflibercept, Bevacizumab, ²Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, Alemtuzumab, Cixutumumab, ²Girentuximab, Nimotuzumab, Catumaxomab, or Etaracizumab.²42. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one ²of claims 39-41, wherein the antibody fragment comprises an antigen-binding ²fragment ²of belimumab, Mogamulizumab, Blinatumomab, Ibritumomab tiuxetan, Obinutuzumab, ²²Ofatumumab, Rituximab, Inotuzumab ozogamicin, Moxetumomab pasudotox, ²Brentuximab vedotin, Daratumumab, Ipilimumab, Cetuximab, Necitumumab, ²Panitumumab, Dinutuximab, Pertuzumab, Trastuzumab, Trastuzumab emtansine, ²Siltuximab, Cemiplimab, Nivolumab, Pembrolizumab, Olaratumab, Atezolizumab, ²Avelumab, Durvalumab, Capromab pendetide, Elotuzumab, Denosumab, Ziv-²aflibercept, Bevacizumab, Ramucirumab, Tositumomab, Gemtuzumab ozogamicin, ²Alemtuzumab, Cixutumumab, Girentuximab, Nimotuzumab, Catumaxomab, or ²Etaracizumab.²43. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one ²of claims 39-42, wherein the binding peptide comprises a prostate specific ²membrane ²antigen ("PSMA") binding peptide, a somatostatin receptor agonist, a bombesin ²receptor ²agonist, a seprase binding compound, or a binding fragement thereof.²44. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one ²of claims 39-43, wherein the compound of Formula I is of Formula IV²²or a pharmaceutically acceptable salt thereof, wherein M2 is an alpha-emitting ²²radionuclide.²45. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²44, wherein M2 is actinium-225 (225Ac3+), radium-223 (233Ra2+), bismuth-213 ²(21313i3+),²173²<DP=16>²lead-212 (212Pb2+ and / or 212m4+), terbium-149 (149Tb3+), fermium-255 ²(255F1113+), ²thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 (211At) +.µ,²astatine-217 (217At+),²or uranium-230.²46. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²44, wherein the linkage is a thiocyante linkage; wherein the thiocyanate ²linkage arises ²from conjugation of the compound with the antibody, antibody fragment, or ²binding ²peptide; and wherein the compound is²²or a pharmaceutically acceptable salt thereof.²47. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²46, wherein M2 is actinium-225 (225Ac3)+,µ radium-223 (233Ra2+), bismuth-213 ²(213Bi3+), ²lead-212 (212FD0 2+²and / or 212m4+), terbium-149 (149Tb3+), fermium-255 (255F1113), ²thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 (211A.)+,,²astatine-217 (217A0,²or uranium-230.²48. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one²of claims 39-43, wherein the compound of Formula IA is of Formula VIII²²or a pharmaceutically acceptable salt thereof, wherein M3 is an alpha-emitting²radionuclide.²49. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²48, wherein M3 is actinium-225 (225Ac3)+,µ radium-223 (233Ra2+), bismuth-213 ²(213Bi3+),²174²<DP=17>²lead-212 (212Pb2+ and / or 212m4+), terbium-149 (149Tb3+), fermium-255 ²(255F1113+), ²thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 (211At) +.µ,²astatine-217 (217At+),²or uranium-230.²50. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one²of claims 39-43, wherein the compound of Formula IA is of Formula X²²or a pharmaceutically acceptable salt thereof, wherein M4 is an alpha-emitting²radionuclide.²51. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim ²50, wherein M4 is actinium-225 (225Ac3)+,µ radium-223 (233Ra2+), bismuth-213 ²(213Bi3), ²lead-212 (212piD 2+²and / or 212m4+), terbium-149 (149Tb3+), fermium-255 (255Fm3+), ²thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 (211A.)+µ,²astatine-217 (217A0,²or uranium-230.²52. The modified antibody, modified antibody fragment, or modified binding ²peptide of any one²of claims 39-43, wherein the compound of Formula IA is of Formula XIII²²or a pharmaceutically acceptable salt thereof, wherein M5 is an alpha-emitting²radionuclide.²53. The modified antibody, modified antibody fragment, or modified binding ²peptide of claim²52, wherein M5 is actinium-225 (225Ac3+\²) radiUM-223 (233Ra2+), bismuth-213 (213Bi3+),²lead-212 (2121102+ and / or 212pb4+), terbium-149 (149Tb3+), fermium-255 ²(255F1113+),²175²<DP=18>²thorium-227 (227Th4+), thorium-226 (226Th4+), astatine-211 (211A )²+,x astatine-217 (217A0,²or uranium-230.²54. A composition comprising a pharmaceutically acceptable carrier and a ²compound of any ²one of claims 1-18.²55. A composition comprising a pharmaceutically acceptable carrier and a ²targeting compound ²of any one of claims 19-29 or comprising a pharmaceutically acceptable carrier ²and a ²modified antibody, modified antibody fragment, or modified binding peptide of ²any one ²of claims 30-53.²56. A pharmaceutical composition useful in targeted radiotherapy of cancer ²and / or mammalian ²tissue overexpressing prostate specific membrane antigen ("PSMA") in a ²subject, ²wherein the pharmaceutical composition comprises a pharmaceutically acceptable ²carrier ²and a compound of any one of claims 19-29 or a modified antibody, modified ²antibody ²fragment, or modified binding peptide of any one of claims 30-53.²57. The pharmaceutical composition of claim 56, wherein the pharmaceutical ²composition ²comprises an effective amount for treating the cancer and / or mammalian tissue ²overexpressing PSMA of the compound or an effective amount for treating the ²cancer ²and / or mammalian tissue overexpressing PSMA of the modified antibody, modified ²²antibody fragment, or modified binding peptide.²58. The pharmaceutical composition of claim 56 or claim 57, where the subject ²suffers from a ²mammalian tissue expressing a somatostatin receptor, a bombesin receptor, ²seprase, or a ²combination of any two or more thereof, and / or mammalian tissue overexpressing ²²PSMA.²59. The pharmaceutical composition of any one of claims 56-58, wherein the ²subject suffers ²from one or more of a growth hormone producing tumor, a neuroendocrine tumor, ²a ²pituitary tumor, a vasoactive intestinal peptide-secreting tumor, a small cell ²carcinoma of ²the lung, gastric cancer tissue, pancreatic cancer tissue, a neuroblastoma,²60. The pharmaceutical composition of any one of claims 56-59, wherein the ²subject suffers ²from one or more of a glioma, a breast cancer, an adrenal cortical cancer, a ²cervical ²carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian ²carcinoma, ²a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell ²lung cancer, a²176²<DP=19>²bladder cancer, a colon cancer, a primary gastric adenocarcinoma, a primary ²colorectal ²adenocarcinoma, a renal cell carcinoma, and a prostate cancer.²61. The pharmaceutical composition of any one of claims 56-60, wherein the ²pharmaceutical²composition is formulated for intraveneous administration, optionally ²comprising ²sterilized water, Ringer's solution, or an isotonic aqueous saline solution.²62. The pharmaceutical composition of any one of 57-61, wherein the effective ²amount of the²compound is from about 0.01 lig to about 10 mg of the compound per gram of the ²²pharmaceutical composition.²63. The pharmaceutical composition of any one of claims 56-62, wherein the ²pharmaceutical ²composition is provided in an injectable dosage form.²64. A method of treating a subject, wherein the method comprises administering ²a targeting ²compound of any one of claims 19-29 to the subject or administering a modified ²²antibody, modified antibody fragment, or modified binding peptide of any one ²of claims ²30-53.²65. The method of claim 64, wherein the subject suffers from cancer and / or ²mammalian tissue ²overexpressing prostate specific membrane antigen ("PSMA")²66. The method of claim 65, wherein the method comprises administering an ²effective amount ²for treating the cancer and / or mammalian tissue overexpressing PSMA of the ²compound ²or an effective amount for treating the cancer and / or mammalian tissue ²overexpressing ²PSMA of the modified antibody, modified antibody fragment, or modified binding ²²peptide²67. The method of any one of claims 64-66, wherein the subject suffers from a ²mammalian ²tissue expressing a somatostatin receptor, a bombesin receptor, seprase, or a ²combination ²of any two or more thereof and / or mammalian tissue overexpressing prostate ²specific ²membrane antigen ("PSMA").²68. The method of any one of claims 64-67, wherein the mammalian tissue ²comprises one or ²more of a growth hormone producing tumor, a neuroendocrine tumor, a pituitary ²tumor, ²a vasoactive intestinal peptide-secreting tumor, a small cell carcinoma of the ²lung, ²gastric cancer tissue, pancreatic cancer tissue, a neuroblastoma, and a ²metastatic cancer.²177²<DP=20>²69. The method of any one of claims 64-68, wherein the subject suffers from ²one or more of a ²glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a ²vulvar ²carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ²ovarian ²carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder ²cancer, a ²colon cancer, a primary gastric adenocarcinoma, a primary colorectal ²adenocarcinoma, a ²renal cell carcinoma, and a prostate cancer.²70. The method of any one of claims 64-69, wherein the administering comprises ²parenteral ²administration.²71. The method of any one of claims 64-70, wherein the administering comprises ²intraveneous ²administration.²72. The method of any one of claims 66-71, wherein the effective amount is ²from about 0.1 .mu.g ²to about 50 .mu.g per kilogram of subject mass.²73. A compound comprising a first domain having a blood-protein binding moiety ²with low ²specific affinity for the blood-protein, a second domain having a tumor ²targeting moiety ²with high affinity for a tumor antigen, and a third domain having a chelator.²74. The compound of claim 73, wherein the tumor antigen is PSMA, bombesin, ²somatostatin ²receptor, or seprase.²75. The compound of claim 73, wherein the blood protein binding moiety has ²specific affinity ²for albumin of about 0.5-50 x 10 -6M, and the tumor targeting moiety has ²specific affinity ²for the tumor antigen of about 0.5-50 x 10 -9M.²178²<DP=21>²76 A compound represented by the following structure²I² / __ \ HN² / ²_______________________________________________________________________________²______________________ / 0²HN-²_______________________________________________________________________________²__________________ C²0- / µ0 O21-1²\-0 0) (1\1 __________________________________________________________________ ²e² c_ _,,,,õ OH²- / - ² / -- / ²0²O ² 0- / -²0-r ²HN² s rj²HN / -0²1-, 0- / ²--4²4-IN-r ²0²\-NH 0²0- / ²ra²HNI N ''. -- N-r ² / -²CO2H ) H Nz--K²0 / ²HO2CNANCO2H²H H²or a pharmaceutically acceptable salt thereof.²77. A composition comprising the compound of claim 76 chelating 213Bi3+, ²211m+, 225Ac3+, 152Dy3+, 212Bi3+, 211Bi3+, 217At+, 227m4+, 226m4+, 233Ra2+,²212pb2+ , or 212pb4+.²